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ABSTRACT 
 Malnutrition and muscle loss in hospitalized patients is a significant problem. The 
ability to accurately identify the development of malnutrition and monitor changes in 
muscle at the bedside are essential to optimizing nutrition interventions throughout 
treatment course and hospitalization; however, there is currently a lack of valid bedside 
tools. Furthermore, the provision of adequate protein and amino acids is crucial for 
maintaining muscle and optimizing outcomes in clinical settings. Yet, the methodologies 
used to determine protein needs have significant limitations, and current 
recommendations for dietary protein intake in clinical populations are not supported by 
strong evidence. This dissertation project consists of a series of studies that explore novel 
approaches for evaluating lean tissue and muscle (as core components of nutritional 
status) at the bedside, and determining protein requirements in the clinical setting. 
In the first study, using a large and ethnically-diverse healthy population sample 
(NHANES 1999-2004), it was determined that ethnicity significantly influences the 
values of  phase angle (PA) and impedance ratio (IR), two bioimpedance parameters 
currently being investigated as clinical markers. Based on the findings from this study, 
cut-points for PA and IR corresponding to low muscle mass defined by dual-energy X-
ray absorptiometry (DXA) were established that can potentially serve as reference data 
for future clinical studies investigating the applications of PA and IR as markers of lean 
tissue and/or nutritional status.  
In the second study, it was determined that PA and IR could be used to assess low 
muscularity and predict clinical outcomes in a large sample of critically ill patients. PA 
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and IR were moderately associated with muscle cross-sectional area (CSA) as determined 
by computed tomography (CT). Furthermore, PA and IR appeared to predict low CT-
derived muscle CSA. In summary, PA and IR show promise in being able to aid in the 
identification of low muscularity and poor nutritional status in the ICU setting.  
 In the third and ongoing study, a novel stable amino acid isotope multi-step 
feeding protocol is being employed to determine the protein intake required to prevent 
net protein loss (anabolic threshold) and to evaluate the relationship between protein 
intake and net protein synthesis (anabolic capacity) of individuals with head and neck 
cancer (HNC), following chemoradiation therapy. Moreover, a force-measuring 
ultrasound (US) device is being used to assess changes in muscle quantity and quality due 
to chemoradiation.  
 There is a vital need to develop objective bedside methods capable of assessing 
muscle mass in hospitalized patients. Results from the described studies show the 
potential utility of bioimpedance and US to characterize changes in muscle mass in 
various clinical populations. Furthermore, as clinicians become better equipped at 
detecting changes in muscle, appropriate nutritional intervention is needed to stave off 
the loss of muscle. Amino acid tracer methods that can estimate whole body protein 
synthesis and breakdown are fundamental to the determination of more accurate protein 
and amino acid recommendations in clinical populations in order to improve patient 
outcomes.  
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CHAPTER 1: INTRODUCTION 
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Malnutrition and muscle loss in various clinical populations is a major problem 
that adversely impacts quality of life, functional status, survival, and health-care costs.1–4 
Hospitalized populations are uniquely susceptible to these issues due to prolonged and 
intermittent NPO status, location of various diseases, nutrition-specific effects of 
treatment, and other important factors.5,6 It has been well observed that malnutrition is 
associated with suboptimal outcomes such as reduced quality of life, decreased functional 
status, increased treatment related adverse events, reduced survival, and increased health-
related costs.1,7 
Although there is not a universal consensus on the definition of malnutrition, it is 
accepted that loss of lean tissue, and skeletal muscle mass in particular, is the most 
important defining characteristic.8 Muscle is an essential reservoir of amino acids used by 
the body to support tissue repair and respond to immunologic challenges.9–12 Provision of 
adequate protein to support muscle maintenance and anabolism is thus critical for healing 
during times of stress; however, current protein recommendations are based on limited 
data generated using inaccurate methods.13–17 Furthermore, the ability to monitor changes 
in muscle in response to nutritional interventions has been limited by the lack of valid 
bedside assessment methods. 
This dissertation will address the above concerns through a series of related 
studies. Chapter 2 presents a literature review that will discuss relevant background for 
these concerns. Chapter 3, Chapter 4, and Chapter 5 are publications based on recently 
completed studies that explore the potential utility of various bedside methods to describe 
changes in muscle mass compared to reference methods and how they may be associated 
with patient outcomes. Chapter 6 presents conclusions gathered from the completed, 
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published work of this dissertation project. In addition, future directions are addressed by 
describing the methods from a current ongoing study that applies a novel method that can 
be used to more accurately define protein requirements and a new device that may 
remedy bedside assessment of muscle mass in a stage III and IV HNC.   
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CHAPTER 2: LITERATURE REVIEW, PART I* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Publication Citation (portions of this Literature Review have been published): Teigen 
LM, Kuchnia AJ, Mourtzakis M, et al. The Use of Technology for Estimating Body 
Composition: Strengths and Weaknesses of Common Modalities in a Clinical Setting 
[Epub ahead of print]. Nutr Clin Pract. 2016. doi:10.1177/0884533616676264. 
http://journals.sagepub.com/doi/pdf/10.1177/0884533616676264 
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CLINICAL MALNUTRITION 
Malnutrition is an under-appreciated problem that is typically described as some 
sort of ambiguous state of health resulting from inadequate or excessive intake leading to 
a change in body composition and reduced function.18 It has crippled clinical populations 
for centuries and has been estimated to be prevalent among 13 – 78% of all hospitalized 
patients.19,20 The consequences of malnutrition are not trivial and have been associated 
with poor patient outcomes including increased infections, longer length of hospital stay, 
higher frequency of readmission, and increased mortality.1,21,22 Such poor outcomes 
directly correlate to an estimated 60% increase in hospital costs in affected patients20,23 
and likely contributes to the inability of patients to return to work after a stay in the 
intensive care unit.24 Malnutrition has been suggested to be caused by diffusion of 
responsibility, prolonged NPO status, poor documentation of dietary intake, failure to 
recognize or diagnose those at risk, and failure to provide nutrition support in a timely 
manner.20,25  
Prevalence of malnutrition in vulnerable populations, specifically HNC, has been 
estimated to occur in up to 40 – 67% individuals even before starting treatment.26–29 
Individuals with HNC are uniquely susceptible to nutritional related issues due to the 
location of malignancy, the nutrition-specific effects of treatment in that area, and the 
high likelihood of concurrent chemoradiation therapy.5,6,30–34 There is also a well-
recognized and staggering cycle of anorexia due to an apathetic attitude toward food, 
along with absorption abnormalities, which likely intensify nutritional insufficiencies.6 A 
prospective study of 114 patients with HNC showed that patients with nutritional deficits 
had a 2-year survival of 7.5%. That was compared to patients without deficits, who had a 
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2-year survival of 57%.35 These results highlight the critical role nutrition plays as a 
prognostic indicator in HNC.   
The definition and clinical diagnosis of malnutrition, however, is a challenging 
endeavor. Consensus definitions have been proposed by prominent organizations, but 
diagnostic criteria still varies between institutions.18,36,37 A seemingly universal criterion, 
regardless of institution, is absolute weight change over a specified time-period. The use 
of absolute weight change, however, lacks the ability to meaningfully characterize an 
individual’s nutrition status, primarily due to its inability to identify specific body 
composition changes – lean tissue being central to nutrition status.38 Body composition 
technologies, such as CT, DXA, bioimpedance, and US, may provide a more sensitive 
way to characterize and monitor nutrition status in a clinical setting.39 Body composition 
data can be particularly useful when rounding out other assessment information, 
including handgrip strength and other functional measures. 
 The importance of body composition, specifically skeletal muscle, is reinforced in 
the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral 
Nutrition Consensus Statement.8 The most recent European Society of Enteral and 
Parenteral Nutrition Consensus Statement on diagnostic criteria for malnutrition includes 
a criterion for low fat-free mass index (FFMI) – based on gender-specific cut-offs.37,40 In 
research settings, the most ideal in vivo body composition research uses a number of 
different methods to measure body composition based on a “four-compartment 
model”.41–43 Clinically, however, this is not feasible. Instead, clinicians are forced to rely 
on simpler, easier-to-obtain tissue-level measurements. CT and DXA offer robust 
measures of body composition, and are often used as reference standards against which 
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field techniques (e.g. bioimpedance, US) are validated.11 Bioimpedance and ultrasound 
techniques, although not as well-established as DXA or CT, are more cost-effective and 
accessible, and offer the ability to obtain real-time and repeatable measures at the bedside 
without any radiation exposure. The first portions of this literature review will give a 
general understanding of lean tissue, muscle and the use of CT, DXA, bioimpedance 
techniques, and US as they apply to body composition assessment in clinical settings.   
 
LEAN TISSUE ASSESSMENT 
Lean tissue, with skeletal muscle as its principal constituent, is critical to the 
body’s healthy response to both acute and chronic illnesses.10,11,44 Lean tissue depletion 
has been associated with increased morbidity and mortality,45–48 infections,49 hospital 
length of stay,50,51 and decreased functional capabilities.52 Despite the significance of lean 
tissue (and muscle) loss as a marker of malnutrition and prognosis in chronic and acute 
disease, its estimation is not commonly performed in hospital settings in part due to the 
limited availability of valid bedside methods.11,51 Instead, clinicians often rely on 
subjective physical examination techniques, 36,53,54 alone or as part of the Patient-
Generated Subjective Global Assessment (PG-SGA).55,56 Subjective evaluation of muscle 
mass, however, is potentially error-prone, particularly in obese and edematous states.11 It 
was recently demonstrated that 60% of individuals who were deemed normally nourished 
at admission by SGA were actually sarcopenic (i.e. had low muscle mass) as defined by 
CT.57 Approximately 33% of individuals who were misclassified were overweight or 
obese.57 Clearly, there is a significant and growing need for easily accessible and accurate 
methods for assessing lean tissue in the clinical setting. 
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REFERENCE METHODS FOR ESTIMATING BODY COMPOSITION 
Dual-energy X-ray Absorptiometry 
  DXA began to replace dual-photon absorptiometry (DPA) for estimation of bone 
mineral density in the late 1980s.58 Although DXA is still primarily used to measure bone 
mineral density, it has also been widely employed for body composition estimates. DXA 
relies on principles of x-ray absorptiometry similar to CT, but is associated with a much 
lower radiation dose; as a result, DXA is able to be utilized in a much wider range of 
clinical populations.59–63 In fact, due to the safety and availability of DXA scans, they are 
often used to validate various other body composition-estimating devices and equations – 
including CT.64–68  
DXA, similar to CT, relies on measured changes in x-ray attenuation to estimate 
body composition.69 With DXA scans, however, the energy beam is only passed along 
one-side of the body producing a planar image. DXA imaging relies on attenuation 
measured at two different energy spectra – a “high” and a “low” energy level. The form 
of x-ray beam administration varies, but technological improvements have resulted in a 
progression from a pencil beam to a fan beam, and most recently, to a narrow fan beam.70 
The measured difference in x-ray beam attenuation between the two energy levels is used 
to delineate specific tissues – with increased attenuation occurring with increased tissue 
density. Pixel-based images are generated and, based on algorithms incorporating mass 
attenuation coefficients, allow for the calculation of both mass and volume.43 These 
algorithms can differ among DXA instruments and software. The two energy levels relied 
upon for DXA primarily allow for differentiation of bone mineral and soft tissue. Unique 
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attenuation characteristics of fat and lean soft tissue allow for additional delineation, but 
this is limited to the pixels that do not contain bone. Overall, DXA is capable of 
separating the body into three compartments: bone mineral content, fat and lean soft 
tissue mass. Measurements are able to be obtained at either a whole-body or regional 
level can occur.70–72 
The safety of DXA scans has allowed for the collection of large quantities of 
healthy “normal” body composition data that can be used to generate healthy reference 
values.73,74 In general, DXA tends to be used in stable clinical populations or employed to 
measure long-term changes in body composition associated with aging. One of the most 
notable uses for DXA measures of body composition has been its use in defining 
sarcopenia.75,76 One of the primary features of sarcopenia is the loss of skeletal muscle 
mass, which is difficult to reliably define using subjective methods.77 The ability of DXA 
to safely obtain whole-body imaging on a large, population-based scale has provided the 
data necessary to objectively define sarcopenia.76  
Due to its reliance on x-ray absorptiometry, DXA, similar to CT, has a number of 
technical and physiological limitations that influence attenuation measurements. 
Technological limitations include patient positioning and device and software 
differences.78–81 Physiological limitations include depth and length of the patient, 
hydration status, and timing of the scan in relation to activities of daily living (meal 
timing, bathroom habits, and exercise).71,82,83 Although mild changes in hydration have 
not been demonstrated to influence body composition measurements, disease-associated 
fluid accumulation, such as ascites or edema, have been shown to influence body 
composition measures.82,84 In addition, weight and size limitations of scanners present 
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challenges when scanning individuals with obesity or individuals who are especially tall. 
For example, it may not be possible to adequately separate the limbs within the scanning 
area, thus limiting the ability to define sarcopenia based on DXA-derived appendicular 
lean mass cutpoints.85 It should be noted, however, that some investigators have 
identified methods to accommodate the weight and size limitations of scanners86, and 
larger capacity instruments (e.g. iDXA, GE) that can accommodate heavier and wider 
individuals are now available. 
In summary, DXA imaging technology has proven to be uniquely suited for body 
composition measurement in a wide range of populations. A number of assumptions 
associated with DXA imaging, however, can make interpretation of results challenging. 
Similar to CT scanning it is important to document scanner type and version of software, 
and make every attempt to maintain consistency in device and measuring technician for 
longitudinal measures. In addition, establishment of a standardized protocol, which 
controls for both technical and physiological factors, can minimize error in DXA 
measures. Establishing a collaborative relationship with radiologists and medical 
physicists before utilizing DXA scanning for body composition assessment in your 
patient population is suggested. 
 
Computed Tomography Scans 
CT is another reference technique used since the late 1970s to determine body 
composition in the research setting. CT continues to provide important clinical insights 
on body composition and outcomes.87–89 The primary limitation with the use of 
prospective CT scans for body composition assessment is the high-dose of radiation to 
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which the subject is exposed. Therefore, the application is limited to individuals who 
have had CT scans completed as part of their medical treatment. To date, the majority of 
published research utilizing CT scans for body composition assessment has been 
conducted in cancer populations,90–94 but recent work has extended this to other clinical 
populations.47,95–100 
CT scanners rely on a rotating x-ray beam to produce cross-sectional images of 
the individual being scanned.101 Each of these cross-sectional images has a depth 
associated with it, which is referred to as “slice-thickness”. In order to generate a cross-
sectional image, individual x-ray images—obtained as the x-ray beam rotates—are 
reconstructed, based on algorithms programmed in the device. Each image is composed 
of volumetric units called “voxels”, which are associated with “Hounsfield Units” (HUs). 
The HUs reflect the attenuation the tissue exerts on the x-ray beam during the scan and 
generally reflects the density of that particular tissue. Each voxel is logarithmically 
assigned to a single HU. If there are multiple tissue types in a voxel, the calculated HU 
will reflect an average of the tissues based on the resolution limit of the scanner. In order 
to create the two-dimensional images viewed on the screen following the procedure, the 
HUs of each voxel are used to produce “pixels”. Pixels are square units with pre-
specified dimensions and colors along the gray-scale based on their associated HUs. The 
HUs allow for differentiation of tissue, based on tissue attenuation; the area associated 
with each pixel allows for the calculation of cross-sectional area.  
The two primary software packages utilized for CT analysis in nutrition research 
are ImageJ and Sliceomatic.102 A recent comparison study found no difference in soft-
tissue measurements between the two programs.103 Although both these programs are 
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user friendly, and could be used by clinicians, there are differences in how the scan is 
manipulated to obtain body composition data. It is also important to note that they are not 
the only way to obtain body composition data from CT images. In fact, most radiology 
departments rely on much more advanced software for CT analysis. In general, body 
composition research utilizing CT images relies on single axial image analysis, which is 
purported to reflect whole body tissue distribution.104,105 Although a number of different 
anatomical sites have been used in body composition research, investigators have 
identified the L3 region on CT scans as being particularly reflective of whole-body tissue 
distribution and this has become the most commonly assessed site in the literature.68, 
98,106–108 Current sarcopenia cut-points are based on tissue distribution measurements at 
the L3 vertebra.95  
Most studies that measure body composition with CT analysis attempt to identify 
the prognostic ability of skeletal muscle cross-sectional area, or changes in skeletal 
muscle attenuation values (i.e. HUs) at a single time-point.88, 90–99,108–111 In general, 
skeletal muscle cross-sectional area and muscle attenuation are often demonstrated to 
have strong prognostic values – with lower cross-sectional area or attenuation values 
being associated with worse outcomes. Investigators have standardized skeletal muscle 
cross-sectional area for height by dividing skeletal muscle cross-sectional area (cm2) by 
height in meters squared (m2) to produce what is commonly referred to as a skeletal 
muscle index (SMI) value - similar to BMI. The ability to obtain average HU values for 
tissues of interest on CT images has led researchers to pursue studies assessing tissue 
attenuation values as a surrogate for muscle quality (e.g. a lower average HU value may 
reflect increased fatty infiltration within skeletal muscle).112 A recent study found tissue 
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attenuation to be more prognostic than SMI, which reinforces the potential utility of this 
measure.89  
CT scans are considered by many to provide reference measures of body 
composition72, but, like any indirect assessment method, CT has limitations that are 
important to consider when interpreting results. As stated earlier, the primary limitation 
to the use of CT scans for body composition assessment is the high-dose radiation 
associated with the procedure, which inherently limits its use to individuals needing it for 
diagnostic purposes. In addition, several variables specific to the CT image can introduce 
error and should be taken into consideration. For example, slice thickness and patient 
positioning are two important variables that need to be controlled in order to minimize 
errors in determination of cross-sectional area. Slice thickness (often 3-8 mm) will 
determine the number of slices that exist at the L3 region. The research team of 
Mourtzakis et al. demonstrated that the average height of L3 is nearly 4 cm.68 Therefore, 
multiple slices will exist at the L3 region for each patient and it is important to consider 
that although each slice represents a portion of the L3 region, it does not encompass the 
entire L3. Some studies have attempted to account for the multiple slices obtained at the 
L3 by averaging two adjacent images, but this still fails to ensure that the exact same 
location is assessed in each patient. It is unclear, however, if small changes in the exact 
location of the analyzed slice at the L3 will result in clinically meaningful measurement 
differences.107 Patient positioning can also influence cross-sectional area. Although the 
patient is in a recumbent position during the scan, changes in positioning will influence 
the relaxation state of the muscles in the L3 region, and, subsequently, the cross-sectional 
area. 
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   Some investigators have attempted to utilize average CT HUs as a way to 
evaluate muscle quality, but the validity of this practice is not clear.88,89, 109,110,113 This 
will need to be validated through studies that include muscle biopsies. The major concern 
is that, although HUs predominately reflect tissue attenuation, they are known to be 
influenced by a wide variety of factors (e.g. scanner, tube voltage, edema, patient size 
and shape).114–120 Furthermore, there is no standard definition for HUs.121 Only air and 
water have specific HUs associated with them: -1000 and 0, respectively (in fact, water’s 
HU of 0 is often used to calibrate CT scanners).119 Rather than relying on specific 
attenuation values, tissues are differentiated based on ranges of HUs. The range most 
frequently used for skeletal muscle and adipose are -29 to +150 and -190 to -30, 
respectively; visceral adipose is often defined by a narrower range, -50 to -150. It should 
be noted, however, that a variety of ranges have been used throughout the literature, 
which should be taken into account when interpreting results.105 Although these wide 
ranges accommodate the inherent variation in HUs, tissue measures based on these units 
are likely to include more than just the tissue of interest.  
In summary, CT images offer unique insights on the tissue distribution of the 
body, but rely on a number of assumptions for body composition estimation. The biggest 
assumption is that a single slice represents whole body muscle distribution. To minimize 
error in longitudinal CT measures, the ideal would be to have scans performed using the 
same scanner by the same technician; this is rarely possible in research or clinical 
settings. From a practical standpoint, it is important that technical information such as 
tube voltage, scanner type, and slice thickness are documented given that inconsistencies 
in these variables could impact interpretation. Prospective research using CT, in addition 
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to the aforementioned technical variables, should attempt to control for patient 
positioning by establishing a standard protocol with the imaging department. Although it 
may not be feasible, establishing a collaborative relationship with radiologists and 
medical physicists before attempting to use CT scans to assess body composition is also 
suggested.   
 
BEDSIDE METHODS FOR ASSESSING LEAN TISSUE 
Bioimpedance Analysis  
In a basic sense, bioimpedance involves the application of a small electrical 
current to the body to estimate body water and composition. Because of its relative 
simplicity and accessibility, bioimpedance techniques remain the primary method for 
body composition assessment in clinical settings.122 Bioimpedance techniques have been 
comprehensively reviewed by others123–125; this section will provide an overview of basic 
concepts. 
There are three types of bioimpedance devices available commercially: single- 
and multiple-frequency bioelectrical impedance analysis (SF- and MF-BIA), and 
bioimpedance spectroscopy (BIS).126 Regardless of the device, bioimpedance treats the 
body as an electrical circuit and devices measure changes in voltage across the body.127 
The change in voltage is referred to as impedance, which consists of resistance and 
reactance. Resistance generally refers to the ability of the current to flow through fluid 
and space and reactance reflects the interaction of the current with membrane interfaces 
(i.e. cell membranes).123 Equations that employ these impedance measures are used to 
generate estimates of fluid and other body composition compartments.124    
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Although SF-BIA, MF-BIA, and BIS all rely on the same principle that 
impedance relates to body composition, each approach has different underlying 
assumptions. Different devices allow for whole body or segmental estimates of various 
body compartments. SF-BIA relies on the use of a single frequency, generally 50 kHz, to 
generate impedance data that can be applied to regression-derived prediction equations to 
estimate total body water, fat-free mass, and/or fat mass.128 Due to the use of a single 
frequency, however, SF-BIA is theoretically unable to differentiate between intracellular 
(ICW) and extracellular water (ECW).11 In contrast, MF-BIA involves the application of 
the electric current at a number of defined frequencies (typically two to six) from 5 to 500 
kHz, which theoretically allows for differentiation of ICW and ECW. Impedance data at 
5 kHz can be applied to a regression-derived equation to predict ECW while that from 
higher frequencies can be used to predict total body water; and ICW can be derived by 
subtraction.128 An understanding of both ICW and ECW can be useful when evaluating 
fluid status. The ability to estimate ICW, in particular, is clinically relevant because it 
provides an estimate of body cell mass, which reflects the amount of metabolically active 
tissue.128 Finally, BIS differs fundamentally from SF- and MF-BIA techniques in that it 
involves the utilization of impedance data measured over an entire spectrum of 
frequencies from 5 kHz to 1200 kHz, and utilizes the data from 50 to up to 250 of those 
frequencies.128 Rather than being applied to linear equations, BIS-measured spectral data 
undergo complex modeling based on the classic Cole model129; Cole model terms can 
then by applied to complex algorithms to generate ICW and ECW.123 Similarly, lean 
tissue and fat mass estimates can also be derived in various ways.11,130 Notably, BIS 
techniques have recently shown promise in assessing body composition and mortality 
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risk in people on dialysis,130 and in managing fluid status in dialysis131–136 as well as 
surgery135 and critically illness.134   
Whole body estimates of lean tissue have traditionally utilized single- and multi-
frequency BIA techniques, require the use of population-specific prediction equations 
and are often erroneous in clinical populations due to violation of underlying  
assumptions (e.g. normal body geometry, hydration of FFM, and fluid 
distribution).11,122,123 MF-BIA offers the potential for rapid assessment of lean tissue and 
fluid status with minimal technical expertise required and can also be done at the bedside. 
MF-BIA has been evaluated for its validity in healthy populations,137–139 and some 
clinical populations including HIV,140 hemodialysis,141 and surgery142 and is purported to 
be a method that may be used at the bed-side to monitor changes in fluid distribution as 
well as body composition.122,124 Little has been done in cancer populations and valid, 
cancer-specific prediction equations to predict whole body lean tissue are lacking.143 
Inaccuracies in whole-body lean tissue estimates have led to the investigation of raw BIA 
parameters (e.g. 50 kHz PA and 200/5 kHz IR) as potential markers of nutritional status, 
prognosis, and clinical outcomes in cancer144–147 and other populations.148–158 A number 
of investigators have reported that PA and IR may be useful for assessing nutritional 
status and/or predicting clinical outcomes.159,160 For example, IR has been shown to 
correlate with quadriceps muscle weakness in COPD and disease severity in heart 
failure,158 to predict post-operative edema after major abdominal surgery,156 and to 
predict dry-weight after hemodialysis.11 PA has been reported to predict nutritional status 
and/or post-operative complications161–164 and prognosis in advanced cancer.146,147  
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At this time, bioimpedance offers one of the most convenient clinical tools for 
objective estimates of body composition at the bedside. Regardless of the approach, when 
taking bioimpedance measurements, it is important to implement a standardized 
measurement protocol11,122 and to utilize the same device and equation/algorithm by the 
same technician for longitudinal measures. 
 
Ultrasound 
US imaging, also called sonography, is the measurement of high-frequency sound 
waves as they encounter various underlying tissues, to visualize the body.165,166 The 
production of the image is based on the amplitude of reflected sound waves and the speed 
at which they travel through the body.166 It has been used in medical applications for 
decades and has seen rapid growth in almost all fields of medicine, including bedside 
quantification of various tissues.167 US shares many of the same advantages as 
bioimpedance compared to CT and DXA, including the noninvasive, nondestructive, 
portable nature of the measurements and the ability to be used in real-time at the 
bedside.11,165 
The assessment of body composition by ultrasound is an emerging modality with 
great clinical potential. There has been increasing interest in using US to assess skeletal 
muscle, such as to quantify thickness or cross-sectional area, with intent to further its 
utility in determining the presence and severity of malnutrition.168–170 It has been shown 
to provide reasonable estimates of muscle mass in various clinical populations when 
compared to other reference methods.169,171–175 However, lack of consistency within 
protocol has limited its prognostic value in diagnosing longitudinal muscle loss; primarily 
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due to variability in muscle compression, selection site, and fluid status of the patient.72, 
168,176 
There is currently no clear consensus on an appropriate protocol for assessing 
muscle mass, but some groups have suggested the use of minimal compression with 
minimal deviation of the muscle group being measured.169, 172,173,177 Questioning whether 
edema and increased extracellular fluid affects muscle measurements, recent work has 
evaluated whether maximal compression may more accurately reflect quantity;168 this is a 
significant limitation to the advancement of body composition analysis by US, as 
researchers have clearly demonstrated substantial differences in thickness with the 
application of various forces.178,179 And although mechanical systems have been 
introduced to remedy this concern,172,178,179 a more pragmatic and practical approach may 
be needed to improve the bedside applicability of US. 
Anatomical site selection is also not consistent between researchers. Abe and 
colleagues173 developed a 9-site measurement protocol which was shown to have 
excellent correlation with whole body muscle mass as determined by DXA,174 but again, 
practicality becomes a concern. Protocols measuring fewer sites have been described, in 
comparison to reference methods, with mixed results.168,180 Regardless of which muscle 
groups are assessed, replication of image location on repeat US is essential to accurate 
longitudinal monitoring;169 these limitations continue to persist.    
The rapid expansion of US use within the clinical setting reflects the evolution of 
its diagnostic capabilities181,182 and allows for the assessment of muscle quality.  This is 
important, because skeletal muscle function is not solely determined by quantity.170 
Echogenicity, the characteristic of tissue to reflect ultrasound waves, has been proposed 
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as a sonographic estimate of quality.181 Through grayscale histogram analysis, US has 
been used for years to help identify tissue pathologies typical in children affected by 
Duchenne Muscular Dystrophy167,181 and other various inflammatory myopathies.183,184 
Recent evidence also suggests ultrasound may be a particularly attractive technology to 
objectively assess muscle architecture breakdown and necrosis when compared to muscle 
biopsy,170,181 which has been shown to be reflective of functional status.169 US-based 
determination of muscle quality, however, is limited by transducer anisotropy, or 
transducer orientation, among other factors.178 It is not typical for devices routinely used 
in clinical sonography to control for anisotropy; and this may limit the use of US in 
diagnosing muscle quality.185  
Moreover, US compression-based elastography is a developing area of clinical 
research and allows for the determination of mechanical tissue properties.165 This non-
invasive technique may help elucidate the physiological changes that occur in muscle 
tissue during disease, disuse and treatment course. However, these types of technologies 
are atypical and not available to most clinicians. Such advances in US-based imaging are 
expected to appear in the near future165 and may prove to be useful in determining the 
nutritional status of clinical populations.   
In summary, US imaging is a developing technology that is gaining ground for the 
bedside analysis of body composition in various clinical populations. At this point, 
however, uncertainties about image repeatability, caused by variation in transducer 
surface force, measurement site, anisotropy and protocol practicality, limit its diagnostic 
and monitoring capabilities for nutritional status. Innovative US technologies are being 
created to remedy these concerns, but until they are available to a plethora of researchers, 
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a concerted effort must be made to reach consensus on protocol that is able to provide 
some level of utility in monitoring muscle loss. Caution should be taken with the 
application of this modality, but the future seems promising.   
 
SUMMARY 
A growing appreciation for the clinical relevance of lean tissue has generated a 
need for objective, clinically feasible measurement methods.38 Technologies such as CT, 
DXA, bioimpedance, and US offer clinically viable methods of measuring body 
composition, but a good understanding of each modality’s strengths and weaknesses is 
important for clinicians to have as they interpret measurements in a clinical setting. The 
reader is referred to the full publication by Teigen et al. (2016)186 for full table of 
strengths and weaknesses. Ideally, technologies to estimate body composition will 
ultimately be capable of two types of measures: a single time-point measurement capable 
of contributing to the diagnosis of malnutrition, and repeated measures over time in order 
to monitor changes in body composition – which will function as a surrogate for the 
adequacy of nutrition intervention. The next section will focus on adequate nutrition 
intervention of protein and amino acids to promote lean tissue and muscle maintenance. 
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PROTEIN IN THE HOSPITAL 
Synopsis 
Provision of adequate protein is crucial for optimizing outcomes in hospitalized 
patients. However, the methodologies upon which current recommendations are based 
have limitations and little is known about true requirements in any clinical population. In 
this tutorial, we aim to give clinicians an understanding of how current protein 
recommendations were developed, an appreciation for the limitations of these 
recommendations, and an overview of more sophisticated approaches that can be applied 
to better define protein requirements. A broader perspective of the challenges and 
opportunities in determining clinical protein requirements can help clinicians think 
critically about the individualized nutrition care they provide to their patients with the 
goal of administering adequate protein to optimize outcomes.  
 
Introduction  
Skeletal muscle plays a principal role in the body’s normal response to illness and 
injury.187,188 During times of stress, muscle protein degrades to release amino acids into 
circulation in order to maintain protein synthesis at vital tissues, organs and at other 
locations to regulate inflammatory and immune responses. 187,189,190 The increased rate of 
proteolysis, resulting from enhanced metabolic demand, leads to a net negative protein 
balance and subsequent muscle wasting; this is amplified by severity of illness, organ 
dysfunction, insulin resistance, sepsis, immobility, and lack of adequate nutrition.10, 188,191 
The metabolic cost of this muscle protein breakdown is of great clinical consequence and 
has been shown to be associated with negative patient outcomes in various clinical 
populations.45, 49, 97,188 Despite the significance of muscle wasting, little is known about 
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the amount of amino acid and protein required in clinical settings to preserve muscle 
mass and function. Here, we address the evidence upon which current protein 
recommendations are based, review new methods capable of improving protein 
recommendations, and present potential strategies to help patients achieve existing 
requirements.  
 
Background  
Nitrogen Balance 
Dating back to the early 1900s, the nitrogen balance technique has been used as 
the classical method for determining protein requirements in healthy and clinical 
populations.192–194 Protein requirement in adults has been defined as the minimum 
amount of protein needed to produce nitrogen (N) equilibrium: the balance between N 
(protein) intake and N output.194 Because a N containing amino group is the defining 
structural characteristic of animal protein and N makes up roughly 16% of dietary protein 
(6.25 gm dietary protein for every gm N), N metabolism is often associated with protein 
metabolism.193 Urea is the primary excreted product of N metabolism, the majority being 
excreted in the urine as urinary urea nitrogen (UUN).195,196 N balance is then the net 
difference between the amount of N consumed in the diet and the amount of N excreted 
from all potential sources.197 However, because capturing all sources of N loss is difficult 
and often not feasible,198 the most commonly accepted approach is to add a constant of 4 
gm N to a measured UUN.199 This constant makes the assumption that 2 gm N loss is 
from non-urea urinary N losses (ammonia, creatinine, and uric acid), 1.5 gm N loss is 
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estimated from fecal N losses, and 0.5 gm N loss is estimated from other miscellaneous 
losses.194,200 The N balance equation is as follows:  
 
𝑁 𝐵𝑎𝑙𝑎𝑛𝑐𝑒 = ( 
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑠𝑢𝑚𝑒𝑑 𝑔𝑚𝑠
6.25
) − (𝑈𝑈𝑁 + 4) 
 
At a glance, N balance methodology seems simplistic and uncomplicated. However, the 
complexity in determining protein requirements lies within the interpretation and 
application of such data and continues to spark controversy to this day.194,201 
 
Practical Concerns 
Nitrogen balance methods have provided the foundation for understanding protein 
metabolism and continue to provide important physiological insight used for clinical 
guidance.16,202 However, there are important limitations that make this method 
susceptible to error.187,193,194 An underappreciation of these limitations narrows clinical 
perspective and creates complacency with current nutritional guidelines, often at the 
expense of patient care.  
One major fault of nitrogen balance methodology is that it favors an 
overestimation of N utilization, 16,198 leading to an exaggerated positive balance and thus, 
potentially an underestimation of protein requirements.203,204 Although conceptually 
perspicuous, accounting for the totality of N consumed, metabolized, and excreted is 
difficult. N can inevitably be lost at any step in the process between preparation to 
consumption, from cooking losses to wastage and spillage of food contents;194,205 this 
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concern is partially ameliorated when patients are on full enteral tube feedings. 
Moreover, amino acids that pass through the small bowel may be metabolized by colonic 
bacteria, rendering them largely non-contributive to protein synthesis.206 Further, 
although the majority of N excretion is collected via urine, a failure to capture all other 
routes of excretion and the difficulty quantifying miscellaneous losses may lead to further 
inaccuracies in determining protein utilization; recycling of an unknown amount of 
ammonia N from the colon for reuse in liver has also been shown to convolute an already 
difficult task.207 Taken together, these complexities contribute to a potentially unreliable 
N balance, even under the most meticulous protocols, and results must be interpreted 
with caution.198  
 
Nutritional Adaptation  
Nutritional adaptation has been defined as a process by which a new steady state 
is reached in response to varying levels of intake.208 The ability to adapt to a range of 
protein intakes is advantageous but complicates the N balance method for quantifying 
protein requirements.194 In the face of reduced protein intake, the body first prevents the 
loss of lean mass and maintains N balance by reducing total N excretion, provided intake 
does not fall below a critical level.209 This metabolic adaptation is driven by the severity 
of dietary restriction and reduced amounts of amino acids available for protein synthesis. 
Therefore, in a protein deficient diet the oxidation rate of essential amino acids is 
decreased, which limits urea excretion.210 A reduction in urea cycle enzymes and 
enzymes responsible for transporting N into the urea cycle also contribute to the adaptive 
process.211,212 
27 
 
The most shocking example of this adaptive process was shown by physicians 
studying starvation in the Jewish ghetto in Warsaw, Poland in the early 1940s. Under 
extreme conditions of protein deficiency, physicians noticed a surprising reduction in 
urea excretion in order to maintain N balance.213 Clinically speaking, patients often 
experience prolonged periods of protein energy malnutrition prior to hospitalization but 
may also be unintentionally restricted during admission due to intermittent NPO status. 
To account for such changes in protein intake, N balance experiments must include an 
adaptation period that allows for the urea body pool to completely turnover and achieve a 
new steady state of urea N excretion.205  
Although no consensus has been agreed upon, 1-2 weeks is commonly used as an 
adaptation period to a test diet;198,214,215 other studies of varying protein intakes show non 
steady state urea N excretion up to 28 – 40 days.216 In practice, N balance studies 
typically do not extend beyond a few hours within the clinical setting. Further, it is 
questionable whether there is enough stability to perform a balance study in the hospital. 
Taken together, these factors question whether clinical N balance studies are merely a 
representation of incomplete nutritional adaptation and if they are capable of determining 
protein requirements.194,217  
 
Insulin and Protein Metabolism 
The amount of energy provided in a mixed meal is an important determinant of N 
balance and deserves careful consideration when evaluating protein utilization.218 It has 
long been accepted that energy balance influences N balance and protein requirements, in 
part because protein synthesis and protein breakdown are both energy dependent 
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processes.194,219 Thus, it is nearly impossible to separate the interrelationship between 
dietary energy and protein; when protein (and essential amino acids; EAAs) is adequately 
dosed, the adequacy of dietary energy determines N balance, and when energy is 
adequately dosed, the protein level will determine N balance.220 Consequently, the 
amount of protein needed to achieve N equilibrium increases with inadequate energy 
intake, which calls into question the validity of historic N balance studies that did not 
appropriately control for variations in energy provision.  
Insulin secretion in response to energy intake has been shown to promote 
anabolism by inhibiting protein breakdown.17,205 Moreover, exogenous insulin infusions, 
beyond postabsorptive levels, have also been shown to be sufficient at inhibiting protein 
breakdown in young adults but do not stimulate protein synthesis;191,221 further studies 
have shown that insulin can reduce protein breakdown in a dose-dependent manner.222  
The anti-catabolic role of insulin seems to be partially attributed to its ability to inhibit 
the ubiquitin-proteasome pathway and the lysosomal proteolysis pathway, both of which 
play primary roles in breaking down intracellular proteins in stressed states.219 It is 
postulated that the deficiency of insulin, potentially induced by prolonged periods of 
inadequate energy intake, could result in an enhanced rate of muscle breakdown;219 
insulin resistance caused by severe illness or trauma has also been shown to create a 
catabolic state of muscle depletion.219 This is particularly important when considering the 
individual response to protein supplementation in the context of a mixed meal or tube 
feeding, where underfeeding calories can significantly reduce the insulin response.17  
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Protein Turnover 
Black box is a term often used to describe a complex or unknown transition step 
between input and output.223 Relevant to N balance, the black box is the metabolic fate of 
N between intake and excretion. The lack of clarity within this transition step makes the 
N balance method inherently problematic for measuring anything other than the specific 
net balance of body N.193,194 Thus, it is important to appreciate that the N balance method 
is not a direct measure of whole body protein turnover; it is a direct measure of body N 
from which protein requirements are often estimated. 
Whole body protein turnover describes a dynamic and continuous process of 
simultaneous synthesis and breakdown of all body lean tissues, neither of which can be 
quantified by N balance.17,202 Calculating whole body protein turnover is an informative 
way to determine protein requirements but requires advanced methods that will be 
discussed later. Therefore, if employed to estimate protein needs, N balance study 
findings should be interpreted with an appreciation for what they are capable of directly 
measuring (balance of body N) and what they can only estimate (whole body protein 
turnover).202,224  
 
Protein Requirements 
Current Guidelines 
Regardless of the shortcomings of N balance methodology, it continues to provide 
the basis for protein requirements in healthy and clinical populations and will continue to 
do so until an alternative method is validated and accepted;205,225 such methods are being 
employed in clinical trials.203,226,227 A meta-analysis published in 2003 by Rand, Pellet 
and Young228 forms the foundation of current protein recommendations for healthy adults 
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set forth in a report of a joint WHO/FAO/UNU expert consultation.205 Data from 235 
individuals in 19 N balance studies was gathered to conclude the median (estimated 
average requirement, EAR) and 97.5th percentile safe (recommended dietary allowance, 
RDA) recommendation for good-quality protein was 0.65 and 0.83 gm protein/kg/day, 
respectively;228 these values have been disputed as significantly too low for various 
healthy adult populations.204,229 When investigators reanalyzed the same N balance data 
as Rand et al. using a different, and potentially more appropriate, statistical approach, 
they found an elevated mean and safe protein requirement of 0.91 and 0.99 gm 
protein/kg/day, respectively.204  
Regardless of much dispute, and similar to current guidelines, the protein 
recommendation for metabolically normal hospitalized patients is also 0.8 gm 
protein/kg/day.16 The most common recommendations in various stressed states, 
including critical illness, are 1.2 to 1.5 gm protein/kg/day, but may increase to over 2.0 
gm protein/kg/day in special catabolic cases.230,231 These recommendations, however, are 
grounded in N balance with no consideration given to clinically relevant endpoints, 
which renders them susceptible to both skepticism and criticism.16,232 Higher protein 
intake beyond current guidelines has been shown to safely improve N balance, however, 
this practice does not consider pertinent clinical outcomes.233 In a pediatric study 
evaluating whole body protein turnover in septic adolescents receiving either 1.5 gm 
protein/kg/day or 3.0 gm protein/kg/day, investigators report an improved protein balance 
attributable to increased whole body protein synthesis at the higher protein level;234 
unfortunately, clinical outcome measures were again overlooked. Although it is unknown 
if such high levels are appropriate in adult patient populations, increasing protein beyond 
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1.2 gm protein/kg may improve clinical outcomes based on observational data.235,236 
Intervention studies comparing similar protein levels and measure clinically relevant 
endpoints are desperately needed to support the development of evidence-based 
recommendations.237  
 
Difficulties in Determining a Requirement 
Amino Acid Composition 
Although it is easy to point out flaws in the current protein dosing guidelines, it is 
much more difficult to propose new recommendations capable of maintaining muscle 
mass because of the complexity of an individual’s response to protein intake. There are 
many factors capable of altering the body’s ability to convert dietary protein into cellular 
protein,238 including: protein quality (i.e. dietary protein amino acid composition and 
digestibility), digestion rate, non-protein calorie intake, anabolic resistance, disuse, 
timing of ingestion, and inflammatory status.189,239–242 The sum of these factors make 
defining protein requirements for a homogeneous population very difficult.  
Protein quality refers to a combination of factors, including the balance between 
essential and nonessential amino acids, the digestibility of the protein to provide amino 
acids for absorption, and the availability of the amino acids for protein synthesis.226 The 
predominant belief is that high quality proteins—containing high amounts of EAAs that 
are readily absorbed in the small bowel— consumed in smaller quantities, compared with 
lower quality proteins (i.e. plant proteins), will continue to meet EAA requirements.226 
Recent studies have shown that EAA supplementation, beyond that provided with 
a complete protein source of whey, casein, or soy, is the primary driver of whole body 
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protein turnover;243,244 leucine-enriched EAA supplementation appears to be particularly 
promising in stimulating muscle synthesis.239,245 There is controversy, however, as to the 
degree of importance protein quality has on protein synthesis.239 Some investigators have 
proposed that protein digestion rate and speed of absorption are  important determinants 
of whole body protein turnover, regardless of amino acid composition.246 In order to 
evaluate the importance of digestion rate, researchers characterized amino acid kinetics 
following ingestion of slow and fast digesting proteins with similar amino acid 
profiles.240 They found that fast digesting protein was an independent factor promoting 
protein deposition;240 this is because an increase in the concentration of intracellular 
amino acids facilitates protein synthesis.247 Thus, patients with the same metabolic 
demand may require differing protein amounts depending on the amino acid composition 
of the supplied protein source, the digestibility of the protein, and rate of amino acid 
absorption.  
 
Protein and Calorie Provision in the Hospital 
Hypocaloric feeding, not to be confused with “permissive underfeeding”, is a 
feeding strategy used within the clinical setting to selectively restrict energy with a 
compensatory increase in protein provision.16 The intent is to promote an adequate 
anabolic response while preventing the metabolic complications of overfeeding (e.g. 
hyperglycemia, weight gain, hypercapnia, etc.).197 Defining the appropriate protein 
prescription, however, requires an understanding of the relationship between protein and 
energy intake.  
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Based on N balance studies, increasing energy intake decreases protein needs due 
to the protein-sparing effect of non-protein calories. Similarly, if caloric provision is 
inadequate, protein requirements increase to meet the energy and N demand of the 
body.189,194 Investigating the dynamic relationship between protein and energy with N 
balance, Elwyn and Shaw248–250 showed a rapid rate of N retention with increasing caloric 
intake at fixed protein levels, until calorie requirements reached 50 – 60% of total energy 
expenditure. The provision of additional calories beyond 60% is met with little 
improvements in N retention,251 which supports current caloric guidelines.231 Notably, 
although improvements in N balance ceased with additional energy provisions, any 
potential improvements in clinical outcome were not addressed.  
In contrast to current guidelines, sophisticated methods determining whole body 
protein turnover in critically ill patients have shown that hypocaloric feeding is associated 
with a more negative protein balance than normocaloric feeding.252 Further evaluations 
show the interconnected importance of adequate intake of goal calories and protein on 
mortality.235 Clinically, it is prudent to appreciate the importance of energy needs with 
respect to protein dosing. If caloric restriction (< 80% of measured energy expenditure) 
persists beyond the first 4 days of admission, it should be acknowledged that the current 
protein recommendations may be below that needed to prevent muscle wasting.253  
  Although not discussed in detail, anabolic resistance, immobility, timing of 
ingestion, and inflammatory status are crucial elements that shape protein 
requirements.242,254,255 Individual variations in any of these variables may cause 
substantial differences in amino acid and protein needs, even among individuals of 
similar disease states. Accounting for these variables throughout a hospital stay and over 
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the time-period needed to conduct optimal N balance studies is not feasible. A variety of 
advanced protein kinetic methods, however, have been used to estimate protein 
requirements in shorter time-periods and represent significant advantages over the classic 
N balance technique.227  
 
New Methods  
A number of methods, beyond N balance, have been created to estimate protein 
requirements in both healthy and clinical populations. Focus will be placed on popular 
methods that may be most appropriate in a clinical setting; the reader is referred to 
publications by Wolfe et al. for additional methods.227,256   
 
Whole-Body Protein Synthesis and Breakdown 
The inherent limitations of the N balance technique have prompted the creation of 
alternative methods capable of estimating protein requirements.194 The measurement of 
whole body protein synthesis and breakdown was the first approach to quantify various 
elements of protein metabolism in humans and represents a significant advancement over 
N balance.227 This approach utilizes stable amino acid isotopes to quantify whole body 
net protein balance, using the equation:  
 
𝑁𝑒𝑡 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐵𝑎𝑙𝑎𝑛𝑐𝑒 = 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑆𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 − 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐵𝑟𝑒𝑎𝑘𝑑𝑜𝑤𝑛 
 
Traditionally, anabolic response is equated with muscle protein synthesis, so measuring 
protein synthesis and breakdown in muscle can be very informative.17 However, a more 
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appropriate measure of anabolic response associated with protein intake is quantifying 
the balance between protein breakdown and synthesis at the whole body level.257 This is 
because various high turnover soft tissues, such as the gut, are capable of retaining amino 
acids after a meal.258 In the postabsorptive phase following a meal, these tissues 
redistribute amino acids that fuel protein synthesis in other organs and tissues, such as 
muscle.259 Thus, protein turnover in various soft tissues functions in a  complementary 
capacity to amplify a sustained anabolic response in muscle and may be important when 
determining protein needs.17,259 
The most relevant whole body method for the estimation of protein requirements 
utilizes an infused essential amino acid tracer to calculate protein breakdown and protein 
synthesis. Proposed by Clarke and Bier in 1982,260 labeled phenylalanine (PHE) became 
an ideal tracer due to its limited metabolic fates in the body: incorporation into muscle 
(protein synthesis) and hydroxylation to tyrosine (TYR) – the first committed step in 
PHE oxidation.261 Once infused intravenously (peripherally), the dilution of the labeled 
PHE with unlabeled PHE from muscle (tracee), gives a measure of muscle protein 
breakdown. Knowing the proportional contribution of PHE to the total body amino acid 
pool allows for the estimation of whole body protein breakdown.256,262 Additionally, 
because whole body protein synthesis correlates with muscle protein synthesis, whole 
body protein synthesis can be obtained by deducting total PHE oxidation (from the 
hydroxylation PHE label into TYR, using a simultaneous infusion of labeled TYR) from 
the appearance of the labelled PHE in plasma.227 256 This method can be adapted to assess 
the effect of various levels of protein on whole body protein turnover.263 A recent study 
by Kim et al. (2016)257 estimated net protein balance in healthy young adults given either 
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a moderate (40 gm) or high protein (70 gm) meal. Whole body protein turnover was 
increased in the high protein group due to a greater reduction of protein breakdown.257 A 
similar study in elderly adults corroborated these results showing increased protein 
turnover in a group consuming 1.5 gm protein/kg (2 x RDA) compared with a group 
consuming only 0.8 gm protein/kg (1 x RDA).263 These findings are consistent with other 
studies showing a linear association between protein consumption and whole body 
protein turnover in various clinical populations.264–266 
 
Indispensable Amino Acid Oxidation   
The indicator amino acid oxidation (IAAO) technique is an adapted model of the 
whole body protein turnover approach and has been used to estimate both protein and 
individual amino acid requirements.267 It is based on the concept that when an essential 
(or indispensable) amino acid is deficient in the diet, a limited amount of protein can be 
synthesized by the body.  In this circumstance of deficiency, the body has no choice other 
than to oxidize all other amino acids, including an indicator amino acid isotope tracer 
(typically PHE).268 Consequently, the more deficient the diet in a particular essential 
amino acid, the greater the oxidation of all other amino acids.262 However, with intake 
nearing the requirement of the limiting amino acid, oxidation of the indicator amino acid 
will decrease to a minimum, reflecting incorporation of PHE into protein (i.e. protein 
synthesis).203 Thus, when oxidation of the indicator amino acid is absent or plateaus, 
protein requirements are postulated to be met. Elango and colleagues verified this in 
healthy children by showing that oxidation plateaus or protein requirements are met at 1.3 
to 1.5 gm protein/kg, which is much higher than the N balance determined RDA.269 This 
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method, however, seems well-suited only for the determination of individual amino acid 
requirements270–272 or minimum protein requirements in healthy individuals.227,269 
Clinical applicability of this method to determine protein requirements may be limited 
because the IAAO technique ignores the contribution of protein breakdown to whole 
body protein turnover in response to varying levels of protein intake.227 As described 
above, net protein balance is the sum of synthesis minus breakdown, and solely basing 
protein requirements on protein synthesis ignores half the equation for determining 
anabolic response.17  
The importance of measuring simultaneous protein synthesis and protein 
breakdown is illustrated by  common clinical situations of increased muscle breakdown 
(e.g. cancer and cardiac cachexia, burn injury, wounds, etc.), where protein synthesis, for 
the most part, remains unaffected.273 As stated above, this is due to the ability of the body 
to recycle amino acids from protein breakdown into protein synthesis. As such, the IAAO 
method, although very useful in certain circumstances, may not allow for the 
quantification of the optimal amount of protein needed for healing during disease and 
illness.17,254 
 
Final Thoughts and Considerations for Clinicians 
Regardless of the validity of dosing guidelines, providing adequate protein and 
amino acids is difficult. Hoffer and Bistrian showed that despite the diligent efforts of 
clinicians, the median protein and amino acid intake in critically ill adults ranged from 
0.1 to 0.7 gm protein/kg, which is less than half the most common recommendation of 
1.5 gm protein/kg.16 Consequently, even if new methods to estimate protein requirements 
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reveal the need for an increased level of protein intake during illness, clinicians must 
develop the strategies required to achieve those levels. Often, clinicians are reluctant to 
provide high levels of protein for fear of worsening clinical status. With respect to renal 
function, Dickerson197 makes an important observation that compromising renal function 
with elevated protein intake is inconsequential if a patient is not given sufficient protein 
to survive the insult that led to  hospital admission.197  
Acknowledging the inherent limitations in the current protein guidelines and 
understanding new methods capable of measuring physiological relevant aspects of 
protein metabolism will allow clinicians to better advocate for the well-being of the 
patient. In the future, conducting clinical trials that examine whole body protein turnover 
and are capable of quantifying both protein synthesis and breakdown will help inform 
new protein and amino acid recommendations in clinical populations.227 Such trials must 
consider muscle mass, muscle quality, and clinical endpoints.16,187 
In the meantime, adoption of various practices may help clinicians attempt to meet 
existing protein recommendations in hospitalized patients; these practices must be 
adopted while considering a patient’s clinical status with agreement from all members of 
the healthcare team. The authors suggest clinicians consider the following:   
 Understand the distinction between protein requirement and optimal protein 
intake: requirement has been determined as the minimum amount of protein 
needed to maintain N balance.273 This may be much less than the optimal amount 
of protein needed to maximize protein turnover, maintain muscle, and stave off 
acute or chronic illness.  
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 Adopt a proactive approach to oral and enteral feeding when appropriate: examine 
current protocols as they relate to NPO status. 
 Recognize the importance of nutritional intervention with protein modulars or 
high protein oral supplements early in admission. 
 Consider adopting practices that encourage early utilization of intravenous amino 
acids. 
 Examine the use of piggyback intravenous amino acids with a high ratio of EAAs 
to help promote muscle accretion, without overfeeding calories.16,189  
 Consider an increase in the provision of free amino acids when parenteral 
nutrition is indicated: it has been shown that free amino acids provide 17% less 
substrate needed to make formed protein.16,274 For example, if clinicians are 
aiming for 1.2 – 1.5 gm protein/kg, 1.5 – 1.8 gm protein/kg would be 
administered.274 
 
  While additional research that incorporates whole body and muscle protein 
turnover is needed to elucidate more accurate protein requirements for clinical 
populations, understanding the limitations of current recommendations and the 
methodology behind their inception is essential for clinicians. Although better evidence-
based guidelines are needed, clinicians in the meantime must remain diligent in 
implementing strategies to ensure that patients are at a minimum meeting current protein 
recommendations.  
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CHAPTER SYNOPSIS 
Background: Raw bioimpedance parameters, e.g. 50 kHz phase angle (PA) and 200 
kHz/5 kHz impedance ratio (IR) have been investigated as predictors of nutritional status 
and/or clinical outcomes. However, their validity as prognostic measures depends on the 
availability of appropriate reference data. Using a large and ethnically diverse data set, 
we aimed to determine if ethnicity influences these measures, and provide expanded 
bioimpedance reference data for the US population. 
Methods: The National Health and Nutrition Examination Survey (NHANES) is an 
ongoing compilation of studies conducted by the United States Centers for Disease 
Control and Prevention designed to monitor nutritional status of the US population. The 
NHANES datasets analyzed were from the years1999-2000, 2001-2002, and 2003-2004.  
Results: Multivariate analysis showed that PA and IR differed by BMI, age, gender, and 
ethnicity (n = 6237; R2 = 41.2%, P < 0.0001). Suggested reference cut-points for PA 
stratified by age decade, ethnicity, and gender are provided.  
Conclusion: Ethnicity is an important variable that should be accounted for when 
determining population reference values for PA and IR. We have provided gender, 
ethnicity, and age decade specific reference values from PA for use by future studies in 
US populations. Inter-device differences are likely to be important contributors to 
variability across published population-specific reference data and where possible, should 
be evaluated in future research. Ultimately, further validation with physiologically-
relevant reference measures (e.g. Dual-energy X-ray Absorptiometry) are necessary to 
determine if PA/IR are appropriate bedside tools for the assessment of nutrition status in 
a clinical population. 
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INTRODUCTION 
Malnutrition and lean tissue depletion are associated with a number of adverse 
outcomes in clinical populations, which may include decreased functional capacity, 
increased morbidity and hospital length of stay, substantial healthcare costs, and 
increased mortality.45, 49–51,97 Despite the importance of muscle loss as a key marker of 
malnutrition,8 the ability to accurately assess and monitor lean tissue in clinical settings 
has been limited by the lack of valid bedside methods.11 Single- and multiple-frequency 
bioimpedance techniques have been the most widely studied option, but have been shown 
to be erroneous for whole body estimates in clinical populations, particularly when fluid 
abnormalities and extreme adiposity are present.11 Bioimpedance spectroscopy (BIS) 
modeling approaches have also not been fully realized for whole body lean tissue 
measurement in clinical settings due to similar concerns and limited availability, despite 
promising developments in the management of fluid balance in individuals on 
dialysis.275,276  
There has been growing interest in the use of raw bioimpedance parameters, such 
as phase angle (PA) at 50 kHz and impedance ratio (IR) at 200/5 kHz), as surrogate 
markers of nutritional status and/or clinical outcomes in clinical populations.146, 148,149, 156–
158, 161,162,277,278 The practical application of PA and/or IR measurements to define 
nutritional status requires reference cut-points from a relevant healthy population. Before 
these cut-points can by implemented, however, they will need to be evaluated for their 
sensitivity to identify poor nutritional status and to monitor response to nutritional 
interventions.  
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Several researchers have published reference cut-points for PA derived from large 
healthy population data sets in mostly Caucasian German279–281 and Swiss161 individuals. 
Reference cut-points for PA have also been published from one racially diverse, but 
relatively small, American data set.282  Very little has been done with regard to reference 
cut-points for IR, but some have suggested it may be a more robust measure of lean tissue 
and/or nutritional status.154,156–158  
Most investigators have established PA cut-points, using methods similar to this 
study, based on age, gender and when sample size allows, BMI. Published cut-points, 
however, vary across studies; additional variables such as ethnicity and device-specificity 
may need to be considered. Using BIS data from a large and ethnically-diverse healthy 
population sample (NHANES 1999-2004), we aimed to determine if ethnicity 
significantly influences PA and IR values. Based on these findings, we established cut-
points for PA and IR that could potentially serve as reference data for future clinical 
studies investigating the applications of PA and IR as markers of lean tissue and/or 
nutritional status in diverse US samples. 
 
METHODS 
Dataset 
The National Health and Nutrition Examination Survey (NHANES) is an ongoing 
compilation of studies conducted by the United States Centers for Disease Control and 
Prevention designed to monitor the nutritional status of the United States population. 
NHANES collects a wide variety of measurements, including body composition. The 
NHANES datasets used for this analysis were the 1999-2000, 2001-2002, and 2003-2004 
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datasets, when BIS data were collected using a HYDRA ECW/ICW Bio-Impedance 
Spectrum Analyzer (Hydra Model 4200, Xitron Technologies, Inc., San Diego, 
California). In these years, whole body DXA measurements were conducted using a 
Hologic QDR 4500 A Fan-beam densitometer (Hologic, Inc., Bedford, MA). BIS 
measurements were only conducted on individuals from 8-49 years of age who were not 
pregnant, did not have any amputations (other than fingers and toes), did not have any 
types of metal objects in the body, did not have pacemakers or automatic defibrillators, 
did not have coronary stents or metal suture material in the heart, and weighed less than 
300 pounds. Impedance was measured at 50 frequencies logarithmically spaced from 5 
kHz to 1 mHz. 
This data set was further limited to ages 18-49 years for this analysis. Using 
impedance (Z) data at the 5 KHz and 200 kHz frequencies, the 200/5 kHz impedance 
ratio (IR) was calculated: 
 
𝐼𝑅 = (𝑍 𝑎𝑡 200 𝑘𝐻𝑧)  (𝑍 𝑎𝑡 5 𝑘𝐻𝑧)⁄  
 
Using bioimpedance data at 50 kHz, PA was calculated from the arctangent of the ratio of 
reactance to resistance using the following equation:278 
 
𝑃𝐴 = 𝑎𝑟𝑐𝑡𝑎𝑛𝑔𝑒𝑛𝑡(𝑋 𝑅⁄ ) ×
180°
𝜋⁄  
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Statistical Analysis 
Data were assessed for normality and found to be normally distributed. To 
determine if ethnicity influenced PA and IR measures, a multivariate analysis was 
conducted using a general linear model that included BMI, age, ethnicity, and gender. 
Data were stratified into the following categories: age by decade (18-19, 20-29, 30-39, 
40-49), BMI class (<18.5, 18.5-24.9, 25-29.9, 30-39.9, ≥40), gender (male/female), and 
ethnicity (Hispanic, White, Black, Other). With age, gender, and BMI included in the 
regression model, ethnicity was determined to be a significant predictor of the model. 
Post hoc analysis was conducted to determine which ethnicities differed from one 
another; multiple comparisons were accounted for using Tukey’s procedure correction.    
Mean and standard deviation were calculated for age, weight, height, and BMI, 
stratified by gender and ethnicity. Mean and standard deviation for PA and IR 
measurements, stratified by gender and ethnicity, were also calculated. In addition, 
percentiles of PA were determined for grouped ethnicities (Hispanic/Black, 
White/Other), stratified by age decade and gender. 
Fat-free mass index (FFMI) was generated by dividing DXA derived fat-free 
mass (FFM) by height squared (FFM (kg)/height (meters)2). Stratifying by ethnicity and 
gender, percentiles of DXA FFMI were generated. Within the individuals falling at or 
below the 5th percentile of FFMI, stratified by ethnicity and gender, we identified mean 
PA and IR measures. In the cohort of individuals falling at or above the 25th percentile 
and at or below the 50th percentile of FFMI, stratified by ethnicity and gender, we 
identified mean PA and IR measures. Simple t-tests were conducted to test for differences 
between the 25th – 50th percentile and the ≤ 5th percentile groups.  
46 
 
The cut-points for PA and IR derived from the DXA FFMI data were further 
evaluated by converting to standardized scores (Z-scores).  Using population mean PA 
and IR, stratified by ethnicity and gender, Z-scores were generated by the following 
equation:  
 
𝑍 = (𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑉𝑎𝑙𝑢𝑒 − 𝑀𝑒𝑎𝑛 𝑉𝑎𝑙𝑢𝑒) 𝑆𝐷⁄  
 
The observed values were the mean PA (and IR) values from the DXA ≤ 5th % FFMI 
mean values; and the mean and SD for PA (and IR) were calculated from the overall 
sample, stratified by ethnicity and gender. 
The data analysis was generated using SAS software, version 9.4 of the SAS 
system (Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or 
service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, 
USA). 
 
RESULTS  
 The mean and standard deviation (SD) for age, weight, height, and BMI of the 
6237 NHANES subjects are shown in Table 3.1. Ethnicities were distributed as follows: 
40% white, 23% black, 33% Hispanic, and 4% of another race. There were significant 
differences in age, weight, height, and BMI (p < .0001) between ethnic groups. Gender 
differences were observed in weight, height, and BMI (p < .0001). Overall, mean 
characteristic frequency (Fc) was 43.9 ± 8.2. Fc, measured by the BIS device, represents 
the frequency at which the reactance is maximal. 
47 
 
Table 3. 1: Subject Characteristics 
 
PA and IR values (mean ± SD), stratified by ethnicity and gender, are presented in 
Table 3.2. Crude analysis of PA and IR from all 6237 subjects found significant 
 Race-Ethnicity   
Variables White Black Hispanic Other P-value* 
Men     p < 0.0001 
N 1292 729 1058 156  
Age 
(years) 
32.4 ± 9.7 30.4 ± 10.6 30.3 ± 10.1 28.4 ± 9.2  
Weight 
(kg) 
84.6 ± 16.1 83.0 ±18.6 78.3 ± 15.8 78.2 ± 19.1  
Height 
(cm) 
178.2 ± 6.9 177.5 ± 7.2 170.3 ± 7.1 173.5 ± 7.3  
BMI 
(kg/m2) 
26.6 ± 4.7 26.3 ± 5.6 26.9 ± 4.9 25.8 ± 5.3  
Women     p < 0.0001 
N 1227 685 986 104  
Age 
(years) 
33.1 ± 9.7 31.5 ± 10.6 30.5 ± 10.4 30.5 ± 10.5  
Weight 
(kg) 
72.3 ± 18.5 80.0 ± 20.7 70.2 ± 16.5 63.9 ± 18.4  
Height 
(cm) 
164.3 ± 6.2 163.4 ± 6.2 158.4 ± 6.5 159.8 ± 6.9  
BMI 
(kg/m2) 
27.8 ± 6.7 29.9 ± 7.6 28.0 ± 6.3 24.9 ± 6.3  
All numbers are Mean ± S.D. 
*P-value indicates significant differences in variables between race ethnicity 
Abbreviations:  BMI, body mass index 
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differences between ethnicity (p < .0001). Further multivariate analysis, adding BMI, age, 
and gender to the model, showed that PA and IR continued to significantly differ between 
ethnicities (R2 = 41% and 45 %, respectively; p < .0001). Albeit to a small degree (1 – 
2% change in R2), the model lost power when ethnicity was discarded. A similar change 
in the model was seen when BMI and age were removed. Gender was the most predictive 
variable in the model, describing 32 – 36% of the variance in PA and IR. 
 
Table 3. 2: Mean PA at 50 kHz and IR at 200 kHz/5 kHz by Race and Gender* 
All numbers are Mean ± S.D. 
* Although Age and BMI are not included in the above table, when added to the model, 
race-ethnicity IR values remained significantly different 
PA and IR values generated by the Hydra Model 4200 bioimpedance spectroscopy 
device, Xitron Technologies (San Diego, CA) 
Abbreviations: PA, phase angle; IR, impedance ratio 
 
Suggested reference cut-points for PA, stratified by age decade, ethnicity, and 
gender, are provided in Table 3.3. Mean BMI ± SD are also provided for each cohort. 
BMI was not included in the stratification model due to sample size limitations. 
Additionally, ethnicities were grouped based on post hoc analysis to increase sample size 
of each cohort. The PA cut-points presented are the 5th percentile values.  
 Men        Women 
Race-Ethnicity 
PA (50 kHz) IR (200/5) PA (50 kHz) IR (200/5) 
White 7.36 ± 0.71 0.76 ± 0.02 6.30 ± 0.67 0.79 ± 0.02 
Black 7.55 ± 0.78 0.75 ± 0.02 6.61 ± 0.73 0.78 ± 0.02 
Hispanic 7.58 ± 0.68 0.75 ± 0.02 6.54 ± 0.70 0.78 ± 0.02 
Other 7.37 ± 0.76 0.76 ± 0.02 6.30 ± 0.59 0.79 ±0.02 
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Table 3. 3: Cut-points Defining Low* PA at 50 kHz from NHANES Reference Data. 
Ethnicity 
Age Group 
18-19 y 20-29 y 30-39 y 40-49 y 
Males (n=3,253) 
Hispanic/Black 6.42 6.47 6.68 6.13 
N 441 477 404 465 
Mean BMI 24.4 ± 5.1 26.5 ± 5.2 27.8 ± 4.7 28.1 ± 4.8 
White/Other 6.35 6.30 6.32 6.08 
N 213 423 405 407 
Mean BMI 24.6 ± 4.6 25.8 ± 4.7 27.0 ± 4.6 27.9 ± 4.6 
Females (n=3,002) 
Hispanic/Black 5.43 5.52 5.60 5.37 
N 412 404 370 485 
Mean BMI 26.0 ± 6.6 28.1 ± 6.9 29.7 ± 6.8 30.9 ± 6.4 
White/Other 5.29 5.47 5.38 5.11 
N 172 350 403 406 
Mean BMI 24.9 ± 6.2 26.0 ± 6.5 27.0 ± 6.9 27.4 ± 6.5 
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All numbers are Mean ± S.D. 
*Defined as <5th percentile 
PA values generated by the Hydra Model 4200 bioimpedance spectroscopy device, 
Xitron Technologies (San Diego, CA) 
Abbreviations: BMI, body mass index; PA, phase angle 
 
 The values for FFMI were generated from available DXA and anthropometric 
data. FFMI was found to be significantly correlated with PA and IR measures (r = 0.55 
and - 0.58, respectively; p < 0.0001). Using the <5th percentile and 25th-50th percentile for 
FFMI stratified by ethnicity and gender, the mean PA and IR values were calculated for 
the respective percentiles and are presented in Table 3.4. A comparison of the mean 
values within each gender and ethnicity category were conducted and the mean PA and 
IR values from the <5th percentile compared to the 25th-50th percentile numbers were 
found to be significantly different (p < 0.0013). 
 
Table 3. 4: Comparison of mean PA at 50 kHz and IR at 200 kHz/5 kHz obtained 
from the ≤5th percentile of FFMI and 25th-50th percentile of FFMI. 
 Men Women 
Race-
Ethnicity 
and 
IR/PA  
≤5th % 
of FFMI  
25th-50th 
% of 
FFMI  
P-
value* 
≤5th % 
of FFMI  
25th-50th 
% of 
FFMI  
P-
value* 
White       
IR  0.78 ± 
0.02 
0.76 ± 
0.02 
<0.0001 0.81 ± 
0.02 
0.79 ± 
0.02 
<0.0001 
PA 6.77 ± 
0.76 
7.35 ± 
0.73 
<0.0001 5.79 ± 
0.64 
6.26 ± 
0.63 
<0.0001 
 (n=59) (n=296)  (n=56) (n=283)  
Black       
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IR 0.78 ± 
0.03 
0.75 ± 
0.02 
<0.0001 0.80 ± 
0.02 
0.78 ± 
0.02 
<0.0001 
PA 6.62 ± 
1.02 
7.53 ± 
0.68 
<0.0001 5.92 ± 
0.52 
6.58 ± 
0.66 
<0.0001 
 (n=33) (n=165)  (n=29) (n=147)  
Hispanic       
IR 0.77 ± 
0.02 
0.75 ± 
0.02 
<0.0001 0.80 ± 
0.02 
0.79 ± 
0.02 
<0.0001 
PA 6.97 ± 
0.64 
7.58 ± 
0.70 
<0.0001 5.79 ± 
0.61 
6.48 ± 
0.70 
<0.0001 
 (n=50) (n=250)  (n=47) (n=231)  
Other       
IR 0.79 ± 
0.02 
0.76 ± 
0.02 
<0.0001 0.82 ± 
0.01 
0.79 ± 
0.01 
0.0013 
PA 6.33 ± 
0.56 
7.28 ± 
0.59 
0.0001 5.59 ± 
0.37 
6.48 ± 
0.46 
0.0008 
 (n=8) (n=39)  (n=4) (n=24)  
All numbers are Mean ± S.D. 
*P-values calculated with paired t-tests 
PA and IR values generated by the Hydra Model 4200 bioimpedance spectroscopy 
device, Xitron Technologies (San Diego, CA); FFMI values generated from FFM 
measured by dual-energy X-ray absorptiometry, using a Hologic QDR 4500 A Fan-beam 
densitometer (Hologic, Inc., Bedford, MA) 
Abbreviations: PA, phase angle; IR, impedance ratio; FFMI, fat-free mass index 
 
 Z-scores are provided in Table 3.5. As expected, PA decreases with decreasing 
FFMI, thus there is a negative Z-score; the opposite is true of IR. PA Z-scores range from 
– 0.8 to – 1.4. IR measures ranged from 1.0 – 1.5.  
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Table 3. 5: Standardized scores of population mean PA and IR using the DXA ≤5th 
percentile cut-points from Table 4 as the observed values and the population mean 
and SD, stratified by gender and ethnicity, reported in Table 3.2. 
 Men Women 
Race-Ethnicity 
and IR/PA 
Z-score Z-score 
White   
IR  1.0 1.0 
PA -0.8 -0.8 
Black   
IR  1.5 1.0 
PA -1.2 -1.0 
Hispanic   
IR  1.0 1.0 
PA -0.9 -1.1 
Other   
IR  1.5 1.5 
PA -1.4 -1.2 
𝑍 = (𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑃𝐴 − 𝑀𝑒𝑎𝑛 𝑃𝐴) 𝑆𝐷⁄  
Abbreviations:  PA, phase angle; IR, impedance ratio 
 
 
DISCUSSION 
PA cut-points (defined as < 5th percentile), established using a large ethnically 
diverse dataset, fell between previously published cut-points from other large population 
data.281,282 In addition, PA and IR cut-points, based on physiologically relevant endpoints 
(DXA FFMI), were created. Fc (43.9 ± 8.2) was found to be within the range that has 
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been observed in other healthy populations, which suggests this NHANES data set is a 
representative sample of healthy individuals.11,123   
The application of bioimpedance analysis for the estimation of whole body 
composition has been accepted for the assessment of healthy, non-obese individuals and 
large epidemiologic studies, but has been questioned for its applicability to the clinical 
setting due to its variability at the individual level. Limitations to bioimpedance analyses 
for the assessment of whole body composition in clinical populations have been reviewed 
elsewhere,124, 277,278,282,283 and have led investigators to explore the use of raw 
bioimpedance data in nutrition assessment.277,278   
PA and IR are simple bioimpedance parameters that have been reported to be 
prognostic indicators of disease and nutritional status in a variety of clinical 
populations.146, 149, 157,161,162 Low PA and high IR have been associated with poor 
nutritional status and poor disease outcome.148,149, 157,161 A dearth of available reference 
values, however, has limited research aimed at validating the use of PA and IR in clinical 
settings.  
Normative reference values for PA have been published based on healthy 
American,282 German,277 and Swiss284 populations. Although these investigators used 
similar regression modeling, differences between these published values suggest that 
there are variables other than BMI, age, and gender that affect these raw impedance 
parameters.285 Barbosa-Silva and colleagues282 identified ethnicity as a significant 
predictor with univariate analysis, but not in a multivariate model (with BMI and age). 
We believe, however, that the lack of significance in their multivariate model was due to 
an inadequate sample size. Using a large and ethnically diverse NHANES data set, we 
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were able to demonstrate that PA and IR are significantly different between ethnicity 
when added to a multivariate regression model, which included BMI, age, gender and 
ethnicity. These results suggest that ethnicity influences PA/IR values and should be 
included as a variable in determination of population reference values.  
Various reference techniques  for assessing body composition, such as computed 
tomography, magnetic resonance imaging, and DXA, are frequently used in research 
settings.72 DXA-derived fat-free mass from the NHANES datasets analyzed in this study 
were used to objectively ground our PA and IR cut-points. As expected, PA and IR were 
positively and negatively associated with FFMI, respectively.  This seems to suggest that 
raw bioimpedance parameters may be useful tools in assessing lean tissue286; and more 
specifically, may function as surrogate markers for FFMI in the diagnosis of malnutrition 
- as proposed by the European Society for Parenteral and Enteral Nutrition.37 However, 
this has yet to be determined. 
The use of the 5th percentile for PA values has been determined as a possible cut-
point for malnutrition by other investigators277,282 and was therefore reported in Table 2. 
It should be noted, however, that a specific percentile has not been defined to identify 
malnutrition in clinical populations when using healthy reference values. Therefore, the 
use of z-scores, specifically derived from PA (standardized phase angle), have been 
proposed as a more meaningful way to define malnutrition.163, 279,287,288 More research is 
needed to determine clinically meaningful values for PA and IR z-scores at single time 
points, but the transformation of PA and IR measurements into z-scores seems to offer a 
more meaningful method for quantification of longitudinal changes in nutrition status - 
regardless of the initial value.  
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There are a number of limitations in our study design and presentation of results 
that need to be acknowledged. The results of our study were based on an age and weight 
limited (17<age<50 and less than 300 pounds, respectively) cohort that limits the 
generalizability of the results. In addition, measures were only conducted using one 
bioimpedance device which limits the ability to account for inter-device variability. 
Finally, the reference ranges included in Table 3 are only stratified by gender, age 
decade, and ethnicity. The sample sizes became too small to provide meaningful values 
with additional stratification. Because BMI is an established predictor of PA and IR 
values we provided the means (±SD) for each group in Table 3, but the lack of inclusion 
in our stratification model makes our results incomplete. 
This study is unique for several reasons; it is the first to develop physiologically 
relevant PA and IR cut-points from a large ethnically diverse population data set, using 
reference measures of lean tissue (DXA-derived FFMI) to ground the data. Furthermore, 
these are the first published reference data generated from a BIS device.    
 
CONCLUSION 
 The development of appropriate reference values for PA and IR are essential for 
future research aimed at determining if raw bioimpedance parameters can be used in a 
meaningful way at a clinical level – particularly with regard to the diagnosis and 
treatment of malnutrition. We have demonstrated, using a large and ethnically diverse 
data set, that ethnicity is an important variable that should be accounted for when 
determining population reference values for PA and IR. We have provided reference data, 
which includes ethnicity as a variable, from a large ethnically diverse data set (Table 3 & 
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4). These need to be further evaluated against clinical outcomes data to ascertain their 
sensitivity in identifying malnourished individuals and monitoring response to nutritional 
interventions compared to existing tools.  
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CHAPTER SYNOPSIS 
Background: In critically ill patients, muscle loss is associated with adverse outcomes. 
Raw bioelectrical impedance analysis (BIA) parameters (e.g. phase angle (PA) and 
impedance ratio (IR)) have received attention as potential markers of muscularity, 
nutritional status and clinical outcomes. Our objective was to test whether PA and IR 
could be used to assess low muscularity and predict clinical outcomes.  
Methods: Patients (≥ 18 years) having an abdominal CT scan and admitted to intensive 
care underwent multi-frequency BIA within 72 hours of scan. CT scans were landmarked 
at the 3rd lumbar vertebra and analyzed for skeletal muscle cross-sectional area (CSA). 
CSA ≤ 170cm2 for males and ≤ 110cm2 for females defined low muscularity. The 
relationship between PA (and IR) and CT muscle CSA were evaluated using multivariate 
regression and included adjustments for age, sex, BMI, Charlson comorbidity index, and 
admission type. PA and IR were also evaluated for predicting discharge status using 
DXA-derived cut-points for low fat free mass index. 
Results: Of 171 potentially eligible patients, 71 had BIA and CT Scans within 72 hours. 
Area under the receiver operator characteristic (c-index) curve to predict CT-defined low 
muscularity was 0.67 (p≤0.05) for both PA and IR. With covariates added to logistic 
regression models, PA and IR c-indexes were 0.78 and 0.76 (p<0.05), respectively. Low 
PA and high IR predicted time to live ICU discharge.  
Conclusion: Our study highlights the potential utility of PA and IR as markers to identify 
patients with low muscularity who may benefit from early and rigorous intervention. 
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INTRODUCTION  
 Lean tissue, primarily consisting of skeletal muscle, is central to the body’s 
healthy response to injury and illness.10,11 Muscle wasting often occurs in the setting of 
illness and inflammation due to increased metabolic demands on the body. Critically ill 
patients often experience major losses of lean tissue due to severity of illness and organ 
dysfunction,  prolonged immobility, and malnutrition.3 Loss of this highly metabolic 
tissue is associated with increased morbidity and mortality,45,97 infections,49 and length of 
stay.50  For ICU survivors, muscle atrophy may lead to decreased functional 
capabilities.52  
Despite the prognostic significance of lean tissue loss in acute and chronic 
disease, its estimation is not commonly performed in hospital settings in part due to the 
limited availability of valid objective bedside methods.11,51 Instead, clinicians often rely 
on subjective physical examination techniques,36,54 alone or as part of the Subjective 
Global Assessment (SGA).56 Subjective evaluation of muscle mass, however, is 
potentially error-prone, particularly in obese and edematous states.11,289  
Clearly, there is a significant and growing need for easily accessible and accurate 
methods for assessing lean tissue in the clinical setting. Very few available techniques are 
appropriate for use at the bedside or for repeated measures. Bioimpedance spectroscopy, 
and the more commonly available multifrequency bioelectrical impedance analysis (MF-
BIA) technique offer the potential for easy, rapid, and portable assessment of lean tissue 
and fluid status in the clinical setting. The MF-BIA approach has been evaluated for its 
validity in healthy populations,137,139 and multiple clinical populations.141,290 The MF-BIA 
approach for whole body estimates of lean tissue requires the use of population-specific 
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prediction equations and is predicated upon meeting various underlying  assumptions 
(e.g. normal body geometry, hydration of lean tissue, and fluid distribution), which are 
often violated in critical illness; typically due to fluid shifts and edema present during 
illness and trauma.123  
Inaccuracies in whole-body lean tissue estimates have led to recent interest in the 
use of raw BIA parameters (e.g. 50 kHz phase angle (PA) and 200/5 kHz impedance ratio 
(IR)) as potential markers of nutritional status, disease severity, and outcomes in various 
clinical populations.146, 154–156, 158,290 It has been hypothesized that PA may be related to 
cell membrane integrity;160 and IR may be related to hydration status.11 In order to obtain 
PA, reactance (Xc) and resistance (R) at 50 kHz must be obtained from the BIA device. 
Xc is the resistive force that cell membranes and tissue interfaces have on an electric 
current; R is the inability of an electric current to flow through the body, inversely related 
to the volume of fluid within tissues.160 Subsequently, PA is calculated from the 
arctangent of the ratio of Xc to R at 50 kHz. 
 
𝑃𝐴 = 𝑎𝑟𝑐𝑡𝑎𝑛𝑔𝑒𝑛𝑡 (𝑋𝑐 𝑅⁄ ) × 180° 𝜋⁄   
 
There is growing interest in the use of IR at 200 kHz/5 kHz as a potential marker 
nutritional and clinical status.11  
 
𝐼𝑅 =  
√𝑋𝑐2 + 𝑅2 𝑎𝑡 200 𝑘𝐻𝑧
√𝑋𝑐2 + 𝑅2 𝑎𝑡 5 𝑘𝐻𝑧
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Grounding of these raw bioimpedance parameters by comparison to a reference 
technique such as dual energy X-ray absorptiometry (DXA) or CT, particularly for the 
ability to identify low muscle mass and monitor response to targeted nutrition 
interventions  are necessary steps before they can be accepted as useful tools in any 
clinical population. CT imaging has been shown to be reliable and precise in quantifying 
skeletal muscle mass.291 Moreover, the cross-sectional area (CSA) of skeletal muscle in a 
single transverse CT image at the 3rd lumbar (L3) region has excellent correlation with 
whole body skeletal muscle mass.68,292 However, CT is limited in its bedside 
applicability. MF-BIA generated PA and IR offer the advantages of non-invasiveness, 
portability, and repeatability.  
We are interested to know if PA and IR can be used as surrogate markers of 
muscle mass as measured by abdominal CT scans. Ultimately, as low muscularity is one 
of the key defining criteria to determine malnutrition, we are interested in whether these 
parameters can give insight into the nutritional status and adequacy of nutritional 
intervention throughout hospitalization. Furthermore, we investigated whether PA and IR 
had any prognostic capabilities to predict low CT-derived muscle CSA or clinical 
outcomes, such as ICU and hospital length of stay. Finally, we determined whether the 
creation of reference values (defined by mean PA and IR for healthy individuals falling at 
or below the 5th percentile for fat-free mass index (FFMI; FFM/height) measured by 
DXA in the most recent NHANES) could improve their prediction capabilities of clinical 
outcomes. We hypothesized that PA and IR would have a strong linear association with 
abdominal CT muscle CSA and subsequent strong capabilities in predicting low 
muscularity and live hospital and ICU discharge.  
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METHODS 
Study design 
 This was a prospective, multicenter observational study that was conducted across 
3 ICU’s, including the University of Minnesota Health, Minneapolis-St. Paul, Minnesota; 
VU University Medical Center Amsterdam, Amsterdam, The Netherlands; and Rush 
University Medical Center, Chicago, Illinois. This study was approved by the local and 
institutional Research Ethics Committees. Patients ≥ 18 years of age were included if 
they were admitted to the ICU and had a CT scan of the L3 vertebra performed for 
clinical reasons <24 hours prior to or < 72 hours after admission to the ICU. Moribund 
patients not expected to survive and other vulnerable populations including pregnant 
women, prisoners, and mentally-disabled individuals were excluded.  
 Once enrolled, patients underwent BIA within 72 hours of the initial CT scan. 
Physical data, including age, sex, height and weight was obtained for all patients. All 
patients being bedridden, height was taken by a registered nurse with the patient lying flat 
and weight was calculated using a bed scale; bed items zeroed prior to measurement. 
Clinical data obtained or calculated upon ICU admittance included admission type 
(surgical vs medical), Acute Physiology and Chronic Evaluation (APACHE II) Score (a 
score to assess the severity of disease in the ICU),293 Sequential Organ Failure 
Assessment (SOFA) Score (a score to assess the degree of organ dysfunction in the 
ICU),293  Charlson Comorbidity Index (designed to predict mortality by categorizing 
severity of comorbidities),294 Functional Comorbidity Index (designed to predict physical 
function, not mortality, by categorizing severity of comorbidities),295 number of 
mechanical ventilation days, ICU length of stay, hospital length of stay, ICU mortality 
63 
 
and hospital mortality. Height and weight were used to calculate BMI (kg/m2) for each 
patient, which was further classified into the following categories: underweight (BMI 
<18.5 kg/m2), normal weight (BMI 18.5 to 24.9 kg/m2), overweight (BMI 25 to 29.9 
kg/m2) and obese (BMI >30 kg/m2). 
 
Bioimpedance analysis 
Bioimpedance analysis, in order to acquire PA and IR, was done using a MF-BIA 
QuadScan 4000 (Bodystat LTD, Isle of Man, UK) and was conducted as close as possible 
to a CT scan done for clinical reasons. PA and IR were directly measured by the 
Quadscan 4000. Electrodes were placed in a standard tetrapolar position (on the hands 
and feet), and patients were placed in a recumbent position with arms abducted from the 
body, and legs separated, using rolled blankets as needed to ensure physical separation, as 
described previously.11 MF-BIA was not performed on individuals with pacemakers or 
electronic implantable devices.  For improved interpretation of the PA and IR data, we 
utilized bioimpedance and DXA data from NHANES (1999-2000, 2001-2002, and 2003-
2004) to generate reference cut-points. Data generated from a spectroscopy device 
(Hydra Model 4200, Xitron Technologies, Inc., San Diego, California) and a whole body 
DXA scanner (Hologic QDR 4500 A, Hologic, Inc., Bedford, MA) were available in a 
healthy ethnically-diverse sample of men (n = 149) and  women (n = 137) between the 
ages of 18 and 49 years.  Cut-points were defined by mean PA and IR for individuals 
falling at or below the 5th percentile for DXA-derived FFMI. 
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CT scan analysis 
 PA and IR were compared, separately, to CT-derived muscle CSA of the L3 
region. CT images were sent to the University of Waterloo, Waterloo, ON, Canada for 
analysis of muscle volume. Scans were analyzed using SliceOmatic image analysis 
software (TomoVision, Montreal, QB, Canada – version 4.3). All scans were analyzed by 
trained analysts and reliability measures were performed. The mean coefficient of 
variation for intra- and inter-rater reliability for muscle CSA was 1.0% and 1.9%, 
respectively. Intra- and inter-rater reliability measures completed were similar to the 
coefficients of variation described in the literature.68 Patients were categorized as having 
low muscularity if their skeletal muscle CSA was <110 cm2 for females and <170 cm2 for 
males. These cut-points have been previously established and associated with mortality in 
an ICU population.97 
 
Statistics 
 Descriptive statistics were reported as mean±standard deviation (SD) or median 
and interquartile range (Q1 – Q3). PA and IR were further stratified by age (< and > 65 
years) and gender to compare differences between groups using Student’s t-test. Linear 
regression, with and without consideration of covariates (BMI, age, gender, Charlson 
comorbidity index, and admission type) was performed to assess the ability of PA and IR 
to predict the variability in abdomen CT-derived muscle area. BMI, age, and gender are 
known to affect BIA parameters.282 These and the other two covariates were retained in 
the regression model regardless of their statistical significance in predicting the 
dependent variable. Once patients were classified as having low muscularity (<110 cm2 
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for females and <170 cm2 for males), logistic regression, with and without consideration 
of the same covariates, was performed to assess the capabilities of PA and IR to predict 
CT derived muscle area. Similarly, area under the receiver operating characteristic (ROC) 
curve was performed to assess prognostic capabilities, again taking into account 
covariates as described previously. Finally, Cox regression was performed to determine 
the predictive capabilities of PA and IR, with respect to live ICU and live hospital 
discharge. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, 
NC, USA) and all p-values are two-sided without correction for multiplicity. 
 
RESULTS 
Descriptive characteristics 
 Seventy one out of a total of 171 enrolled had both BIA and readable CT scans for 
comparison and were included for analysis, of whom 62% were male and all fell at or 
below Class I obesity. Overall, patients had a mean age of 57±16 years old and had a 
mean BMI of 29±8 kg/m2. Mean APACHE II score was 16±7 (Table 4.1). According to 
BMI, 39% were classified as normal weight, 31% were overweight, and 30% were class I 
obese. Median ICU and hospital length of stay were 3 (2 – 7) and 10 (6 – 20) days, 
respectively, while ICU and hospital mortality were 4% and 6%, respectively (Table 4.1). 
There was no difference in PA or IR between males and females (p=0.09 and p=0.07, 
respectively). There was a trend toward differences between PA in young versus elderly 
(p=0.05), but no significant differences were seen between IR when stratified by age 
(p=0.09) (Table 4.2). CT scans revealed that 57% of patients had lower than normal 
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muscularity, defined as CSA <110 cm2 for females and <170 cm2 for males. BIA 
occurred within 1.3 days to the CT scan.  
 
Table 4. 1: Patient clinical and physical characteristics. 
Characteristics All patients 
(n=71) 
Age (years) 57±16 (21-87) 
Sex  
Male 44 (62.0%) 
Female 27 (38.0%) 
Height (cm) 172±10 (152-196) 
Usual Weight (kg) 85±24 (51-186) 
BMI (kg/m2) 29± 8 (19-57) 
Normal  28 (39.4%) 
Overweight  22 (31.0%) 
Obesity class I  21 (29.6%) 
APACHE II score 16± 7 ( 3-31) 
SOFA score 5± 4 ( 0-15) 
Charlson comorbidity index 1± 1 ( 0- 5) 
Functional comorbidity index 1± 1 ( 0- 4) 
Admission type  
Medical  54 (76.1%) 
Surgical  17 (23.9%) 
Primary ICU admission  
Cardiovascular/Vascular  17 (23.9%) 
Respiratory  12 (16.9%) 
Gastrointestinal  16 (22.5%) 
Neurologic  2 (2.8%) 
Sepsis  9 (12.7%) 
Trauma  10 (14.1%) 
Metabolic  1 (1.4%) 
Other  4 (5.6%) 
Mechanical ventilation duration 
(days)   
3[ 1 to  6] ( 0-39) 
Intensive care unit length of stay 
(days) 
3[ 2 to  7] ( 1-22) 
Hospital length of stay (days) 10[ 6 to 20] ( 2-72) 
ICU mortality  4 (5.6%) 
Hospital mortality  6 (8.5%) 
Numbers are reported as (n) mean±SD (range) or median [Q1 to Q3] (range) or n (%). 
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BMI = body mass index; APACHE II = acute physiology and chronic health evaluation 
II; SOFA= sequential organ failure assessment; ICU = intensive care unit. 
 
Table 4. 2: Descriptive data of phase angle and impedance ratio stratified by gender 
and age. 
Numbers are reported as mean±SD (n) 
 
 
Phase angle and Impedance ratio 
 Mean PA and IR were 4.34±1.40 and 0.85±0.04, respectively, for all patients. 
Using linear regression, PA alone was able to predict 20% of the variance in CT muscle 
CSA, and 61% of the variance when covariates (age, sex, BMI, Charlson comorbidity 
index, and admission type) were added to the model (Table 4.3 and 4.4). Similarly, IR 
alone was also able to predict 20% of the variance in CT muscle CSA, and 60% of the 
variance when covariates were added. The area under the ROC (c-index) curve to predict 
CT-defined low muscle area was 0.67 for both PA and IR. With covariates added to 
logistic regression models including PA and IR, the c-indexes were 0.78 and 0.76, 
respectively (Figures 1A and 1B). PA and IR were both able to predict live ICU 
discharge (c-index=0.611 and c-index=0.608, p=0.008 and p=0.009, respectively), but 
not live hospital discharge (Table 4.5). When low FFMI cut-points for PA and IR derived 
from NHANES data were used, they were able to predict live ICU discharge with greater 
Measureme
nt 
Mean ± SD 
All 
patients 
(n=71) 
Males 
(n=44) 
 
Females 
(n=27) 
p-
valu
e 
Young 
(<65 
years) 
(n=45) 
 
Elderly 
(≥65 
years) 
(n=26) 
p-
valu
e 
Impedance 
Ratio  
0.85±0.0
4 (69) 
0.85±0.0
4 (42) 
0.86±0.0
5 (27) 
0.07 0.85±0.0
4 (43) 
0.87±0.0
4 (26) 
0.09 
Phase 
Angle  
4.34±1.4
0 (71) 
4.54±1.3
6 (44) 
4.01±1.4
2 (27) 
0.09 4.63±1.4
2 (45) 
3.85±1.2
4 (26) 
0.05 
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certainty (c-index=0.77 and c-index=0.79, p=0.04 and p=0.01, respectively) than that 
found without using low FFMI cut-points (Table 4.5). 
 
Table 4. 3: Linear regression of PA to predict CT-derived muscle area 
Covariates are: age (linear), sex (binary), BMI (linear), Charlson comorbidity index 
(linear) and admission type (binary). NA = not applicable, R2 = % of variance in outcome 
explained by model. RMSE=root mean square error. CT= computed tomography 
 
 
Table 4. 4: Linear regression of IR to predict CT-derived muscle area 
Covariates are: age (linear), sex (binary), BMI (linear), Charlson comorbidity index 
(linear) and admission type (binary). 
NA = not applicable, R2 = % of variance in outcome explained by model. RMSE=root 
mean square error. CT= computed tomography 
 
 
 
 
 
 
 
 
Outcome Predictors R2 Adjuste
d R2 
RMS
E 
p-value 
model 
P-
value 
PA 
CT muscle area 
(cm2) 
PA 0.2
1 
0.20 37.7 <0.000
1 
<0.000
1 
CT muscle area 
(cm2) 
covariates* 0.6
0 
0.57 27.5 <0.000
1 
NA 
CT muscle area 
(cm2) 
covariates+PA 0.6
5 
0.61 26.2 <0.000
1 
0.008 
Outcome Predictors R2 Adjusted 
R2 
RMSE p-value 
model 
P-value 
IR 
CT muscle area 
(cm2) 
IR 0.21 0.20 36.9 <0.0001 <0.0001 
CT muscle area 
(cm2) 
covariates* 0.60 0.57 27.1 <0.0001 NA 
CT muscle area 
(cm2) 
covariates+IR 0.63 0.60 26.1 <0.0001 0.02 
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A      B 
 
Figure 4. 1: (A) Receiver operating characteristic curve for impedance ratio with 
covariates to predict low muscle area. (B) Receiver operating characteristic curve 
for phase angle with covariates to predict low muscle area. Receiver operating 
characteristic curve analysis is used to quantify how accurately medical diagnostic 
tests can discriminate between 2 patient states—in this case, low muscle mass or 
normal muscle mass. Area under the curve or c-index of 0.5 indicates no ability of 
the model to discriminate between low and normal muscle mass, while a c-index of 1 
implies the ability to perfectly discriminate lower and normal muscle mass. 
 
Table 4. 5: Cox regression for the ability of PA and IR to predict relative time to live 
discharge. 
Predictors Outcome c-
index 
of 
model 
p-value 
of PA or 
IR 
PA (continuous) Time to live ICU discharge 0.599 0.028 
PA (continuous) Time to live hospital 
discharge 
0.528 0.49 
PA 
(continuous)+covars* 
Time to live ICU discharge 0.611 0.008 
PA 
(continuous)+covars* 
Time to live hospital 
discharge 
0.599 0.43 
PA<5% cut-point  Time to live ICU discharge 0.774 0.04 
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PA<5% cut-point  Time to live hospital 
discharge 
0.613 0.70 
IR (continuous) Time to live ICU discharge 0.584 0.032 
IR (continuous) Time to live hospital 
discharge 
0.513 0.46 
IR 
(continuous)+covars* 
Time to live ICU discharge 0.608 0.0095 
IR 
(continuous)+covars* 
Time to live hospital 
discharge 
0.587 0.39 
IR<5% cut-point Time to live ICU discharge 0.786 0.01 
IR<5% cut-point Time to live hospital 
discharge 
0.563 0.75 
* covariates in model include sex, age (as linear) and BMI (as linear). 
PA cut-point is 6.75 for men and 5.85 for female 
IR cut-point is 0.78 for men and 0.81 for women 
Abbreviations: PA = phase angle, IR = impedance ratio 
 
 
DISCUSSION  
 We conducted a critical comparison between BIA parameters and CT CSA 
analysis for muscle quantification in ICU patients. In a heterogeneous sample of 71 
critically ill patients, we found that PA and IR accounted for 61% and 60% of the 
variance in CT muscle CSA (p=0.008 and p=0.02), respectively. Prediction of abdominal 
CT muscle CSA was improved when age, sex, BMI, Charlson Comorbidity Index and 
admission type were added to the multivariate regression model. Based on ICU-derived 
gender-specific cut-points from CT analysis,97 57% of patients had low muscularity at 
admission to the ICU, which is similar to that seen in the literature for other ICU-specific 
studies.45,97 ROC curve analysis showed PA and IR had moderate capabilities in 
predicting low CT muscle CSA when controlling for covariates, appropriately diagnosing 
low muscularity 78% and 76% of the time, respectively. Furthermore, when DXA-
derived low FFMI cut-points for PA and IR from an NHANES dataset was applied in a 
logistic model, both were able to significantly predict live ICU discharge 77% and 79% 
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of the time. Prediction of live ICU discharge was improved when applying reference cut-
points from a large dataset.  
   Loss of muscle and functional status are two of the defining criteria to determine 
the presence and severity of malnutrition in the Academy of Nutrition and 
Dietetics/American Society for Parenteral and Enteral Nutrition Consensus definition.54 
PA and IR pose intriguing potential as markers to determine nutritional status and 
monitor nutrition intervention adequacy throughout treatment course. In the context of 
this study, PA performed well and is in agreement with previously published literature.158, 
160,290 When patients with heart failure were classified by severity of disease, a lower PA 
was significantly associated with the severity of disease. Moreover, handgrip strength 
was lower and correlated with PA and severity of disease; similar results were seen with 
IR.158 This points to the potential usefulness of PA and IR in not only predicting disease 
status but also functional status in this population. In individuals undergoing cardiac 
surgery, lower pre-operative PA was associated with undernutrition (as specified by low 
BMI) and prolonged ICU and hospital length of stay.290 This is consistent with the 
findings of our study. Furthermore, a lower PA has been shown to predict post-operative 
complications, nutritional risk, length of stay, and prognosis in various other clinical 
populations, including surgery,163 HIV149 and various cancers.145,146 Although fewer 
studies have been conducted looking at IR, some researchers suggest it may be a more 
robust marker of nutritional status and disease severity.156 It has also been reported to 
identify malnutrition as defined by low total body nitrogen with greater sensitivity (79%) 
than PA (23%).154 Our findings in light of published literature underscore the potential of 
PA and IR as clinical tools and additional clinical evaluation is warranted. 
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Implementation of phase angle and impedance ratio reference cut-points derived 
from NHANES data 
 The practical application of PA and IR measurements as biomarkers to define 
nutritional status requires that reference cut-points from healthy population data be 
established. Several researchers have published reference cut-points for PA in select 
populations including German,277,280  Swiss284 and American;282 very little has been done 
with IR. In order to further establish the use of healthy population cut-points, the 
Continuous NHANES dataset was utilized to produce reference cut-points for PA and IR 
to be applied in this study;296 Grounding BIA parameters in a physiologically relevant 
endpoint, all individuals falling at or below the 5th percentile for FFMI as determined by 
DXA were grouped together. Mean PA and IR values were then found for this group of 
individuals with low muscularity, which subsequently became the reference cut-points 
applied to our critically ill population. Upon inspecting the ability of PA and IR to predict 
live ICU and hospital discharge, we found that when we applied our healthy reference 
cut-points, PA and IR predictive capabilities improved. However, more work is needed to 
establish appropriate cut-points based on age, BMI, gender, and ethnicity from larger, 
more robust datasets comprised of DXA or other reference methods, if raw bioimpedance 
parameters are going to be used in a meaningful way at the clinical level – particularly 
with regard to the identification of malnutrition.  
 
Strengths and limitations 
 The strengths of this study include the use of expert analysis of abdominal muscle 
CSA using CT images in order to evaluate our BIA parameters. Additionally, the multi-
site nature of this collaboration that recruited a heterogeneous ICU population with 
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multiple operators enhances the generalizability of the findings. Admitting diagnoses 
included patients with a plethora of medical and surgical conditions. We believe the 
heterogeneous nature of our population adds strength to the results, as we would expect 
to see even stronger associations and predictive capabilities of PA and IR with a more 
homogeneous sample. Another strength to our study was that we attempted to generate 
physiologically relevant cut-points based on a large U.S. population sample in order to 
better interpret our data. However, it must be noted that the reference data were generated 
by a different bioimpedance device than the device used in our study; inter-device 
differences are potential sources of error but are not well documented. The study was 
limited by its relatively small sample size and the small number of confounding variables 
that were collected at the start of the study for inclusion into statistical modeling. Given 
that a pragmatic approach was taken with the implementation of the BIA protocol, 
logistical challenges in patient positioning and measurement procedures in light of the 
ICU setting likely contributed to the variability in measurements. Furthermore, our final 
sample did not include individuals with Class II and III obesity due to the inability to 
obtain both BIA and CT scans for comparison in these individuals.  
 
CONCLUSIONS 
PA and IR were moderately associated with CT-derived muscle CSA at the L3 
level with covariates added to the model. That is, lower PA and higher IR values were 
associated with lower muscle CSA. Furthermore, PA and IR appeared to predict low CT-
derived muscle CSA. Using a Healthy population dataset, DXA-derived cut-points of low 
FFMI for PA and IR seemed to predict ICU discharge with greater certainty than did PA 
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and IR (with covariates) alone. From a clinical standpoint, the simplicity, non-
invasiveness, and easy repeatability of BIA has substantial appeal as a bedside 
assessment tool, and the idea that a PA below a certain value or an IR above a certain 
value could indicate low muscle mass, poor nutritional status, and/or predict clinical 
outcomes is compelling.  However, it remains to be established if these parameters can be 
effectively used to assess and monitor muscle mass and nutrition status with greater 
sensitivity than other clinically accessible techniques. Successful implementation of PA 
and IR as assessment tools in the ICU will require adherence to standardized 
measurement protocol and utilization of appropriate reference cut-points for these 
parameters. In summary, PA and IR show promise in being able to aide in the 
identification of low muscularity and poor nutritional status in the ICU setting; additional 
research is warranted.  
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INTRODUCTION 
Body composition measures are critical for comprehensive evaluations of 
nutritional status. Body weight, body mass index and change in weight are often used for 
these assessments, however, they cannot distinguish specific tissue compartments from 
muscle. Identifying an objective modality that is readily available for assessing 
muscularity is of critical importance. Given the impact of muscle wasting on clinical 
outcomes, recent research has focused on objective, non-invasive methods to help 
quantitate muscle loss within clinical populations.2 Ultrasound measures of muscle 
thickness at various sites has been shown to correlate well with reference measures of 
total body lean tissue and muscle mass.172, 174,180  As part of the previous study, 
ultrasound measurements of quadriceps muscle layer thickness (QMLT) were measured 
to validate its ability to predict muscle as determined by CT-derived CSA. Results of this 
study have been published. For more detail on study design and methods, the reader is 
referred to the publication by Paris et al. 2017.2 
 
RESULTS 
Physical and clinical characteristics  
Two hundred four patients who had a cross-sectional abdominal CT scan of the 
L3 vertebra for clinical reasons within 24 hours prior or less than 72 hours after ICU 
admission were recruited for further ultrasound analysis. Of the 204 patients recruited, 41 
had a non-analyzable CT scan and 14 had incomplete ultrasound data or it was performed 
greater than 72 hours after initial CT scan, resulting in a total of 149 patients for further 
analysis. A sensitivity analysis was performed and identified no differences between the 
data of the 2 studies; as such, all data were combined. Overall, 42% of patients were 
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female. Patients were 59 ±19 years old, had a BMI of 29 ±8 kg/m2, and had an average 
APACHE II and SOFA Scores of 17 ±8 and 5 ±4. Median ICU and hospital length of 
stay were 3 [2-7] and 8 [5-17] days respectively, while ICU and hospital mortality were 
9% and 11%, respectively. Based on BMI classifications, 68.5% of the population was 
overweight or obese, whereas only 2.7% of the population was underweight.    
   
Mean CT abdominal skeletal muscle CSA was 108.5±24.5 cm2 for females, which 
was significantly different from males 168.4±36.6 cm2 (p<0.001). Approximately 58% 
(59% of females and 57% of males) of patients had low muscularity, despite that only 
2.7% of the population was classified as underweight by BMI. Significant differences 
were found between young (157.4 ±45.6 cm2) and elderly (126.0 ±34.1 cm2) groups 
(p<0.001). However, for QMLT, significant differences were found between males (1.5 
±0.6 cm) and females (1.1 ±0.6 cm) (p<0.001), but not between young (1.4 ±0.7 cm) and 
elderly (1.2 ±0.5 cm) age groups (p=0.57).  
 
QMLT is moderately correlated with abdominal muscle CSA 
On average, QMLT measures were performed 1.1 ±1.0 days after the CT scan. 
Overall, QMLT was moderately (r=0.45, p<0.001) correlated with abdominal skeletal 
muscle CSA. Further sub-analysis examining correlations for young females, older 
females, young males and older males revealed that this correlation was likely driven by 
the largest group - young males (n=55; r=0.51, p<0.001); the remaining groups, young 
females, elderly males and females had non-significant correlations of r=0.13, r=0.24 and 
r=0.26, respectively.   
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Figure 5. 1: Association between CT skeletal muscle cross sectional area and 
ultrasound QMLT with linear regression lines superimposed. Overall regression fit: 
CT skeletal muscle cross sectional area=102.5+31.1 x QMLT. Overall Pearson 
correlation coefficient between CT skeletal muscle cross sectional area and 
Ultrasound QMLT index is 0.45, p<0.0001; L3, 3rd lumbar.    
 
With the addition of age, sex, BMI, Charlson Comorbidity Index and admission 
type (surgical or medical) to the regression model, prediction of abdominal skeletal 
muscle CSA improved to R2=0.61 (r=0.78, p<0.001) (Table 5.1). A multivariate logistic 
regression to predict low muscularity from CT skeletal muscle area demonstrated that 
QMLT alone resulted in a concordance index of c=0.67 (p<0.002), and this improved to 
c=0.77 with the addition of the pre-selected covariates (p<0.001) (Table 5.2).  
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Table 5. 1: Ability of QMLT to predict CT skeletal muscle CSA by linear regression  
 
Outcome Predictors R2 
Adjusted 
R2 RMSE 
p-
value 
model† 
p-value 
QMLT‡ 
CT muscle 
CSA (cm2) QMLT 0.20 0.19 39.1 <0.001 <0.001 
CT muscle 
CSA (cm2) covariates 0.56 0.55 29.3 <0.001 NA 
CT muscle 
CSA (cm2) covariates+QMLT 0.61 0.59 27.8 <0.001 <0.001 
Covariates are: age (linear), sex (binary), BMI (linear), Charlson Comorbidity Index 
(linear) and admission type (binary). All regression models are based on 149 patients 
with complete QMLT within 72 hours of CT. Variance inflation factor for QMLT in 
model with all covariates is 1.2.†P-value of the overall model by the global F-test. ‡P-
value of the QMLT variable. CSA, cross-sectional area; CT, computed tomography; NA, 
not applicable; QMLT, quadriceps muscle layer thickness; RMSE-root mean square 
error. 
 
Table 5. 2: Ability of QMLT to predict low CT skeletal muscle CSA by logistic 
regression  
Outcome 
Low 
MM/n Predictors c 
p-
value 
model† 
p-value 
QMLT‡ 
Low muscle CSA 86/149 QMLT 0.67 <0.002 <0.002 
Low muscle CSA 86/149 covariates 0.72 <0.001 NA 
Low muscle CSA 86/149 covariates+QMLT 0.77 <0.001 <0.005 
Covariates are: age (linear), sex (binary), BMI (linear), Charlson Comorbidity Index 
(linear) and admission type (binary). All regression models are based on 149 patients 
with complete QMLT within 72 hours of CT. Low muscle CSA defined as <170 cm2 for 
males and <110 cm2 for females.97 Variance inflation factor for QMLT in model with all 
covariates is 1.2. †P-value of the overall model by the global F-test. ‡P-value of the 
QMLT variable. CSA, cross-sectional area; CT, computed tomography; c, concordance 
index; NA, not applicable; QMLT, quadriceps muscle layer thickness; RMSE-root mean 
square error. 
 
CONCLUSIONS 
Using BMI classifications, 68% of the patients in this study were overweight or 
obese and only 2.7% were underweight; yet, 58% patients had lower than normal 
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muscularity based on CT imaging. While CT imaging has been an important measure in 
identifying patients with low muscularity, a more practical modality is needed to measure 
muscularity in the ICU. This study was the first to compare muscle quantifications of 
ultrasound with the precise CSA measures of CT analysis. Here, our results suggest that 
with our current protocol, QMLT alone may not accurately predict muscle CSA or 
identify patients with low muscularity. However, ultrasound based QMLT with additional 
predictors including age, BMI, sex, Charlson Comorbidity Index and admission type may 
be valuable in predicting low muscularity in this group of ICU patients, but may not be 
practical or useful in a clinical setting.  
 
 
  
81 
 
 
 
CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
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CONCLUSIONS 
Malnutrition with subsequent muscle loss is devastating to the well-being and 
meaningful longevity of clinical populations. The ability to accurately and objectively 
assess muscle mass throughout treatment course and hospitalization has, however, eluded 
clinicians for centuries. It is imperative to create objective bedside methods that can 
longitudinally evaluate muscle quantity and quality in order to direct nutritional 
interventions and improve patient outcomes. Conjointly to muscle characterization, the 
application of sophisticated tracer methods are sorely needed to more accurately define 
protein and amino acid requirements needed for muscle maintenance.  
Previous investigators have shown the promise of various imaging modalities in 
assessing muscle mass at the bedside including, bioimpedance analysis and ultrasound 
imaging. There is still, however, much that is unknown about the usefulness of these 
techniques at the individual patient level. Differences between technique method, 
equipment type, and measured outcomes continues to complicate progress in this area of 
study and will continue to do so until consensus can be established.  
In order to mitigate lean tissue and muscle loss and to improve patient outcomes, 
many researchers have investigated the need for more advanced methods that can 
accurately determine protein needs during illness and disease. Whole body protein 
synthesis and breakdown are important endpoints that can be measured using new stable 
isotope tracer methodologies. Such physiologically relevant endpoints paint an objective 
picture of protein turnover during times of stress and quantification is needed to 
appropriately dose protein for improved patient outcomes. Investigators are currently 
showing the usefulness of tracer methodology, but more data is needed in order to refine 
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such methods for broader application across clinical populations in order to develop 
strong, evidence-based protein recommendations for all populations.   
 The primary objective of this dissertation was two-fold. First, it was to 
investigate various objective imaging modalities that can be used at the bedside of 
hospitalized patients to quantify loss of muscle in order to inform appropriate nutritional 
interventions. Specifically, raw bioimpedance parameters PA and IR showed an 
improved ability to predict low muscle as determined by CT compared to previous 
subjective methods and correlate with ICU length of stay. Also, it was determined that 
US measures of muscle thickness at the mid-thigh alone does not adequately predict low 
muscle as determined by CT. More research is needed with improved technologies and 
refined protocols supported by global consensus before US can be promoted as an 
adequate modality to measure longitudinal changes in muscle.  
The second objective was to investigate new methods capable of measuring whole 
body protein synthesis and breakdown in order to propose new protein recommendations 
for clinical populations. This objective is currently under investigation in a population of 
stage III and IV HNC undergoing chemoradiation therapy. Further study details can be 
found in the “Future Directions” section of this dissertation.  
In conclusion, the overall goal of this dissertation was to improve the way we 
provide nutrition within the hospital to better care for patients. In order to accomplish this 
goal, muscle imaging and assessment was used as a surrogate of nutritional status. If we 
can accurately monitor changes in muscle quantity and quality, we can then start to tailor 
nutritional intervention by way of optimal amino acid and protein dosing. This will 
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greatly improve functional status and quality of life, while decreasing mortality and 
healthcare costs. Further investigations into these areas remain of paramount importance.        
 
FUTURE DIRECTIONS:  CURRENT STUDY 
Current Project Summary 
Malnutrition and lean tissue loss in individuals with head and neck cancer (HNC) 
is a major problem that adversely impacts quality of life, functional status, survival, and 
health-related costs. Protein requirements in HNC, however, are not well defined.  A 
better understanding of whole-body protein kinetics in individuals with HNC is essential 
to developing meaningful protein recommendations capable of preserving lean mass and 
preventing or slowing the progression of malnutrition. The ability to accurately identify 
the development of malnutrition and monitor changes in lean tissue at the bedside are 
essential to optimizing nutrition interventions throughout cancer treatment; however, 
there is currently a lack of valid bedside tools.  
 
Novel Study Components 
Use of Stable Isotope Tracers for Understanding Protein Turnover  
The provision of adequate protein intake is essential to the preservation of lean 
mass, which is core to the maintenance of nutritional status. In the setting of cancer, 
multiple factors including inflammation and tumor-derived cytokines, drive an increased 
rate of protein breakdown and thus increase dietary protein needs.15, 33,297 Furthermore, 
many of these factors lead to development of cachexia, which is associated with even 
greater protein breakdown, resulting in accelerated muscle loss and reduced anabolic 
capacity.298,299 Protein requirements to promote lean tissue maintenance and anabolism in 
85 
 
cancer patients are not well-defined. Current protein recommendations for non-surgical 
oncology patients range from 1-2 gm/kg/day, but are based on limited evidence and are 
difficult to apply across various cancer populations.13 
Emerging research supports the use of whole body protein kinetics as the best 
choice for defining protein requirements.252,300 This has been demonstrated to be an 
effective method for determining anabolic threshold (i.e. protein intake level required to 
prevent net protein loss and maintain lean tissue mass) and anabolic capacity (i.e. the 
relationship between protein intake and net protein synthesis) in a number of different 
populations.252, 266, 270,301,302  
Whole body protein kinetic studies utilize stable isotope labeled amino acid 
tracers given as a continuous intravenous infusion and/or enteral bolus feeds.303,304 
Infusion of stable isotopically labeled amino acids, termed “tracers”, have the same 
chemical properties as their natural amino acids, termed “tracees.”302,303 Since atomic 
mass is the only differing component between tracers and tracees, they can be safely 
incorporated into the exchangeable body amino acid pool and measured with mass 
spectroscopy.303,305 This relationship is expressed as the tracer-tracee-ratio (TTR).302 
Changes in TTR can provide objective information regarding protein synthesis and 
breakdown and allow for determination of anabolic capacity and anabolic threshold (i.e. 
the protein intake level where protein breakdown equals synthesis).302,303 304 The most 
ideal amino acid tracer combination is an infusion of labeled PHE and TYR.300,303 PHE is 
an essential amino acid that undergoes one of two fates in the body; it is either 
incorporated into protein (synthesis) or oxidized to tyrosine (degradation).300 Therefore, 
whole-body protein turnover can be assessed by measuring changes in the TTR of PHE 
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when a constant infusion of isotopically labeled PHE is provided - as long as oxidation to 
TYR is measured.303   
 
Ultrasound for the Longitudinal Assessment of Muscle Quantity and Quality 
Recently, US has received much attention by clinician researchers for its potential 
application for bedside body composition assessment, due to its ability to quantify muscle 
thickness.51,177 US shares many of the benefits of BIS over CT and DXA, including the 
noninvasive, portable nature of the measurements and ability to be used at the bedside.11 
US devices are widely available in inpatient and outpatient clinical settings, and thus, US 
is an attractive option as a lean tissue assessment method for clinicians.51,306 The primary 
anatomical sites shown to have good capability to reflect whole body muscle mass are the 
quadriceps femoris and biceps brachii.307–310 There is a growing body of validation 
literature of US compared to other body composition techniques171, 174,311; however, it is 
not clear how well US muscle thickness values can be extrapolated to whole body lean 
tissue estimates and technical errors limit the use of US for measuring longitudinal 
changes in lean mass. Furthermore, there is not yet a consensus on the optimal protocol to 
follow when measuring lean tissue, with regard to muscle compressibility, the patient’s 
resting state and hydration status, and lean tissue adipose stranding (i.e. fatty infiltration 
of muscle tissue).11,72 For these reasons, we will evaluate a newly developed force-
measuring US device for measurement of muscle thickness compared to DXA-derived 
LST and FFM and to detect changes in muscle thickness after CRT in individuals with 
HNC. 
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Specific Aims, Hypotheses, and Study Objectives 
Specific Aim 1: To determine the protein intake required to prevent net protein loss 
(anabolic threshold) and to evaluate the relationship between protein intake and net 
protein synthesis (anabolic capacity) of individuals with head and neck cancer, before 
and after chemoradiation therapy, using a novel stable isotope amino tracer multi-step 
feeding protocol.  
Hypothesis 1: Individuals with HNC will have a higher anabolic threshold than has been 
observed previously in healthy older adults (~0.72 gm/kg FFM/day).312 
Hypothesis 2: The anabolic threshold will be higher after CRT compared to pre-
treatment. 
Hypothesis 3: Anabolic capacity in individuals with HNC will be negatively associated 
with inflammation, as indicated by C-reactive protein and inflammatory cytokines. 
Outcome Measures for Hypotheses 1 - 3:  
 Whole body protein breakdown (WbPB) and synthesis (WbPS) 
 Net protein synthesis (i.e. WbPS – WbPB) 
 Anabolic threshold will be determined from linear regression of net protein 
synthesis and protein intake, will be used to identify the anabolic threshold.  
 
Specific Aim 2: To examine several clinically-accessible tools, including force-
measuring ultrasound (US) and bioimpedance for lean tissue assessment at the bedside in 
individuals with HNC. 
88 
 
Hypothesis 4: A novel force-measuring ultrasound device can be used as a surrogate 
marker of lean tissue and detect changes in lean tissue over time. 
Hypothesis 5:  Bioimpedance-derived phase angle, impedance ratio, NHLT, and FFM 
can be used as surrogate markers of lean tissue. 
Outcome Measures for Hypothesis 4: 
 Quadriceps femoris and biceps brachii muscle thickness measured by US 
 Whole body and regional LST measured by DXA 
 Changes in above measurements between Visit 1 and Visit 4 
Outcome Measures for Hypothesis 5: 
 Whole body NHLT by BIS 
 Whole body FFM by BIS 
 50 kHz PA by MF-BIA  
 200/5 kHz IR by MF-BIA 
 Whole body LST by DXA 
 Whole body FFM by DXA 
 Changes in whole body measurements as above between Visit 1 and Visit 4  
 
Specific Aim 3:  To evaluate the validity of bioimpedance to measure changes in fluid 
status compared to dilution techniques 
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Hypothesis 6: Bioimpedance analysis will accurately reflect changes in fluid status as 
measured by dilution methods with acceptable sensitivity (i.e. sensitivity will be > 90%). 
Outcome Measures:  
 Total body water 
 Intra- and extra-cellular fluid 
 
Specific Aim 4: To evaluate the nutrition-focused physical examination approach for 
assessing muscle loss  
Hypothesis 7:  
Presence of muscle loss detected by subjective nutrition-focused physical examination 
will not provide acceptable sensitivity (i.e. sensitivity will be < 90%313) to identify 
individuals with low muscle mass as defined by appendicular skeletal muscle index by 
DXA, according to published cutpoints.11,76 
Outcome Measures: 
 Appendicular skeletal muscle index (sum of arm and leg LST mass divided by 
height in meters squared) 
 Subjective determination of muscle loss (multiple sites including clavicle and 
acromion bone region, temple region, scapular bone region, dorsal hand, calf and 
thigh)36  
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Study Procedures 
In this observational study, 20 individuals with Stage 3-4 HNC will undergo testing at 
four time points:  
 Visit 1: within 1 – 4 weeks prior to beginning CRT – after placement of a central 
venous catheter (CVC) for chemotherapy administration and gastric feeding tube 
 Visit 2: ~3.5 weeks (±1 week) into treatment 
 Visit 3: within 4 weeks (±2 weeks) post final CRT 
 Visit 4: within 3 months (±1 month) post final CRT 
 
Comprehensive testing including the stable isotope multi-step feeding protocol to 
establish the anabolic threshold will occur at Visit 1 and Visit 3 (see Figure 6.1). On 
these two testing days, participants will report to the CTSI Masonic Cancer Research 
Unit at the University of Minnesota at 0700 hours on study day following an overnight 
fast of 8-10 hours. Prior to initiating the stable isotope multi-step feeding protocol, 
participants will undergo height and weight measurements, a DXA scan, and will 
subsequently have necessary peripheral catheters placed. A catheter will be placed in a 
superficial dorsal vein of the hand or lower arm of the contralateral arm to the CVC port 
and serve as the site for arterialized-venous blood sampling using a heating pad as 
previously described.314 The CVC port will serve as a catheter for a 10 ml venous blood 
draw (for subsequent biochemical analysis) before initiation of the stable isotope 
protocol, and will provide the route of continuous tracer infusion throughout the protocol. 
If the participant’s CVC port is removed prior to visit 4, per discretion of physicians, a 
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second peripheral catheter will be placed into an antecubital vein in the opposite arm of 
the peripheral catheter used for blood draws. 
A baseline arterialized-venous blood draw (5 ml) from the peripheral IV will 
occur immediately prior to the start of the continuous tracer infusion, followed by 16 
incremental blood draws (5 ml each) throughout the duration of the tracer infusion 
period. The participant will be placed into a relaxed position based on individual 
preference and the stable isotope multi-step feeding protocol will begin. After 30 minutes 
in the relaxed position, the participant will undergo resting metabolic rate (RMR), 
bioimpedance, and US measurements. Two hours after initiation of the IV tracer infusion, 
the enteral feeding will begin and continue for six hours, in conjunction with the 
continuous IV tracer infusion, until completion of the protocol. During this period, 
dietary intake data, handgrip strength, PG-SGA, and psychosocial measures will be 
completed.  
At Visit 2 and Visit 4, visits will be coordinated with outpatients at Masonic 
Cancer Clinic and Radiation Oncology Clinic. At these visits PG-SGA will be conducted, 
dietary intake data will be collected, and body weight, US, bioimpedance, and handgrip 
strength measurements will be taken.  
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Figure 6. 1: Study Protocol 
 
Stable Isotope Multi-Step Feeding Protocol 
Following the baseline arterialized-venous blood draw, which will be used to 
correct for background enrichment, participants will receive a 7.2 ml IV priming infusion 
of L-[ring-2H5]-phenylalanine and L-[13C9,15N]-tyrosine. Simultaneously, a priming dose 
of 10 – 20 mls of L-[13C6]-allo-isoleucine will be provided enterally via a gastric tube. 
Immediately following the priming doses, an IV continuous stable isotope infusion 
(containing L-[ring-2H5]-phenylalanine, L-[13C9,15N]-tyrosine, and L-[D10-15N]-allo- 
isoleucine) and an oral continuous stable isotope infusion (containing L-[13C6]-allo- 
isoleucine) (Figure 1) will be initiated (T0) and continued over 6 hours to measure 
protein kinetics.  
Incremental arterialized-venous blood draws will occur every 20 minutes during 
the second hour of each two-hour time block during the continuous tracer infusion.  
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The enteral feeding sip regimen will begin at hour 2 (t=2h) and will be provided 
in 20 minute increments until the end of the 6-hour study period. The feedings that occur 
every 20 minutes will be provided via syringe through the participant’s gastric tube. If the 
participant does not have a gastric feeding tube, the participant will consume the enteral 
feedings orally throughout the study period. Each 2 hour volume will be divided by six 
and provided in 20 minute increments, consisting of a Boost nutritional supplement 
mixed  with 120 mg of L-1-[13C]-phenylalanine tracer. Protein intake levels will increase 
incrementally every 2 hours starting at hour 2, and until the end of the 6-hour infusion 
period. The volume of the prepared liquid meal will be adjusted accordingly to match 
required protein levels. The protein levels to be used in this study are based on the 
recently completed study by Dr. Deutz’ team which indicated that the anabolic threshold 
in healthy subjects occurs at 0.03 gm/kg FFM/hr (representing approximately 0.72 gm/kg 
FFM/day).312  
The two protein levels will be:  
Feeding 1, 0.036 gm/kg FFM/hr (approximately 0.87 gm/kg FFM/day or 0.65 gm/kg/day 
total body weight);  
Feeding 2, 0.091 gm/kg FFM/hr (approximately 2.17gm/kg FFM/day or 1.63 gm/kg/day 
total body weight).  
The FFM value used to calculate protein intake will be obtained from the DXA scan that 
will occur shortly after arrival on the morning of the study day. Blood samples collected 
during the enteral feeding period will be taken immediately before the administration of 
each 20-minute incremental feeding.  
 
94 
 
Force-Measuring Ultrasound (US) 
Although previous lean tissue assessment studies support the preliminary use of 
US to detect tissue changes, there is not yet a consensus on the optimal measurement 
protocol to follow when measuring lean tissue, particularly in individuals with acute and 
critical illness, and in individuals with edema and obesity. We will be testing a new US 
device which takes advantage of spatial and force-related variations in the tissue that we 
believe will remedy the current direction of standard US in the diagnosis of muscle loss, 
and thus, malnutrition. The muscle layer thickness (MLT) of the quadriceps femoris and 
biceps brachii muscles will be measured, using the same force of compression for all 
subsequent measurements. At each testing visit, subjects will have multiple ultrasound 
measurements taken on the arm and leg (2 on each leg; one at the midpoint between the 
patella and anterior superior iliac spine, and one at the 2/3rd point between the patella and 
anterior superior iliac spine and 1 on each arm; the anterior surface of the arm, 60% distal 
the acromion process and the lateral epicondyle of the humerus).174 
This device will be used to accurately detect longitudinal changes in lean tissue 
thickness. Intra-rater variability will be evaluated by multiple measurements. Inter-rater 
variability of the device will be tested by having 2 different researchers independently 
measuring the same sites; researchers will be blinded from each others’ evaluations and 
differences will be compared statistically after completion of all data collection. The 
procedure is painless and involves no risk to the patient. If the patient were to have a 
lower/upper extremity injury or pre-existing skeletal deformity to the quadriceps or 
biceps regions, those limbs would not be used for US examination. US measurements 
will be repeated at each study visit.  
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Significance 
This project is innovative in that it addresses two critically important issues faced 
by clinicians caring for individuals with HNC, lack of evidenced based protein 
recommendations and lack of validated bedside tools for assessing lean tissue. 
Importantly, our study will yield insights that are easily transferable to other clinical 
populations susceptible to malnutrition. Specifically, our unique stable isotope multi-step 
feeding protocol will allow us to determine the anabolic threshold and capacity in our 
HNC population, and as such, can be considered a new diagnostic tool for determining 
protein requirements in HNC and other clinical populations. This innovative approach 
has never before been applied to a clinical population and has the potential to improve 
nutritional care by laying the groundwork to ultimately establish both the minimum (for 
lean tissue maintenance) and optimal (for lean tissue anabolism) protein requirements in 
this and other vulnerable populations. Data from the current project will be used to 
support the development of an NIH application to fund a larger, long-term feeding study, 
in order to clearly define the protein requirements necessary to maintain and/or replete 
lean tissue mass in a HNC population. Furthermore, building from the foundation laid by 
the current research project, future research efforts using stable isotope tracers will focus 
on determining protein requirements in other clinical populations. This line of research 
offers to provide a significant breakthrough in clinical nutrition that can benefit all 
clinical populations in the future.  
This project also offers an exceptional opportunity to address the lack of clinically 
accessible tools for lean tissue assessment by evaluating two novel bedside technologies 
for their ability to measure cross-sectional and longitudinal changes throughout treatment 
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course in individuals with HNC. The innovative force-measuring US probe used in this 
study will remedy significant problems associated with standard US and provide the 
foundation for establishing standardized measurement protocols. Furthermore, the 
evaluation of bioimpedance for its ability to measure and monitor changes in lean tissue 
is also highly relevant and will advance our understanding of the optimal utility of this 
technology in the clinical setting. Both US and MF-BIA and BIS devices carry the 
potential to identify malnutrition and serve as effective lean tissue monitoring tools 
during nutritional and other interventions, thus helping clinicians to target lean tissue 
maintenance and/or repletion with resulting reductions in patient morbidity/mortality, 
hospital length of stay, readmissions, and healthcare costs. Ultimately, this study will 
meaningfully address several gaps in clinical care, through the establishment of a 
framework for future translational research aimed at determining protein needs in clinical 
populations and by providing data to support the implementation of improved bedside 
techniques to objectively assess lean tissue changes and further the work aimed at 
defining malnutrition in the clinical setting.315 
 
Acknowledgements 
We would like to thank all of our collaborators who are contributing to the 
analysis of these data, the study would not currently be taking place without your 
expertise.  We would also like to thank all participants and family members who agreed 
to partake in this study. We acknowledge the support (to Carrie Earthman) provided by 
the USDA National Institute of Food and Agriculture and the Minnesota Agricultural 
Experiment Station, Project MIN-18-104, Hatch Funding. We also acknowledge that this 
97 
 
study is funded by the A.S.P.E.N. Rhoads Research Foundation and the Nutricia 
Foundation.  
 
 
 
  
98 
 
REFERENCES 
1.  Correia MITD, Waitzberg DL. The impact of malnutrition on morbidity, mortality, 
length of hospital stay and costs evaluated through a multivariate model analysis. 
Clin Nutr. 2003;22(3):235–239. doi:10.1016/S0261-5614(02)00215-7. 
2.  Paris MT, Mourtzakis M, Day A, et al. Validation of Bedside Ultrasound of 
Muscle Layer Thickness of the Quadriceps in the Critically Ill Patient (VALIDUM 
Study). J Parenter Enter Nutr. 2017;41(2):171–180. 
doi:10.1177/0148607116637852. 
3.  Griffiths RD. Muscle mass, survival, and the elderly ICU patient. Nutrition. 
1996;12(6):456–458. doi:10.1016/S0899-9007(96)00141-4. 
4.  Looijaard WGPM, Dekker IM, Stapel SN, et al. Skeletal muscle quality as 
assessed by CT-derived skeletal muscle density is associated with 6-month 
mortality in mechanically ventilated critically ill patients. Crit Care. 
2016;20(1):386. doi:10.1186/s13054-016-1563-3. 
5.  Chasen MR, Bhargava R. A descriptive review of the factors contributing to 
nutritional compromise in patients with head and neck cancer. Support Care 
Cancer. 2009;17(11):1345–1351. doi:10.1007/s00520-009-0684-5. 
6.  Grobbelaar EJ, Owen S, Torrance A, et al. Nutritional challenges in head and neck 
cancer. Clin Otolaryngol Allied Sci. 2004;29(4):307–313. doi:10.1111/j.1365-
2273.2004.00850.x. 
7.  Neumayer L a, Smout RJ, Horn HG, et al. Early and sufficient feeding reduces 
length of stay and charges in surgical patients. J Surg Res. 2001;95:73–77. 
doi:10.1006/jsre.2000.6047. 
8.  White J V, Guenter P, Jensen G, et al. Consensus statement of the Academy of 
Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: 
characteristics recommended for the identification and documentation of adult 
malnutrition (undernutrition). J Acad Nutr Diet. 2012;112(5):730–8. 
doi:10.1016/j.jand.2012.03.012. 
9.  Hoffer LJ, Bistrian BR. Appropriate protein provision in criticai illness : a 
systematic and narrative review. Am J Clin Nutr. 2012;96:591–600. 
doi:10.3945/ajcn.l. 
10.  Biolo G, Toigo G, Ciocchi B, et al. Metabolic response to injury and sepsis: 
changes in protein metabolism. Nutrition. 1997;13(Suppl):52S–57S. 
doi:10.1016/S0899-9007(97)83044-4. 
11.  Earthman CP. Body Composition Tools for Assessment of Adult Malnutrition at 
the Bedside: A Tutorial on Research Considerations and Clinical Applications. J 
Parenter Enter Nutr. 2015;39(7):787–822. doi:10.1177/0148607115595227. 
99 
 
12.  Tsai S. Importance of Lean Body Mass in the Oncologic Patient. Nutr Clin Pract. 
2012;27(5):593–598. doi:10.1177/0884533612457949. 
13.  Arends J, Bodoky G, Bozzetti F, et al. ESPEN guidelines on enteral nutrition: non-
surgical oncology. Clin Nutr. 2006;25(2):245–259. 
doi:10.1016/j.clnu.2006.01.020. 
14.  Bozzetti F. Re: A.S.P.E.N. clinical guidelines: nutrition support therapy during 
adult anticancer treatment and in hematopoietic cell transplantation. JPEN J 
Parenter Enteral Nutr. 2009;34(4):455; author reply 456. 
doi:10.1177/0148607109341804. 
15.  Dechaphunkul T, Martin L, Alberda C, et al. Malnutrition assessment in patients 
with cancers of the head and neck: A call to action and consensus. Crit Rev Oncol 
Hematol. 2013;88(2):459–476. doi:10.1016/j.critrevonc.2013.06.003. 
16.  Hoffer LJ, Bistrian BR. Appropriate protein provision in critical illness: a 
systematic and narrative review. Am J Clin Nutr. 2012;96(3):591–600. 
doi:10.3945/ajcn.111.032078. 
17.  Deutz NE, Wolfe RR. Is there a maximal anabolic response to protein intake with 
a meal? Clin Nutr. 2013;32(2):309–313. doi:10.1038/jid.2014.371. 
18.  Soeters PB, Reijven PLM, van Bokhorst-de van der Schueren M a E, et al. A 
rational approach to nutritional assessment. Clin Nutr. 2008;27(5):706–16. 
doi:10.1016/j.clnu.2008.07.009. 
19.  Soeters PB, Schols AMWJ. Advances in understanding and assessing malnutrition. 
Curr Opin Clin Nutr Metab Care. 2009;12(5):487–94. 
doi:10.1097/MCO.0b013e32832da243. 
20.  Kubrak C, Jensen L. Malnutrition in acute care patients: A narrative review. Int J 
Nurs Stud. 2007;44(6):1036–1054. doi:10.1016/j.ijnurstu.2006.07.015. 
21.  Lim SL, Ong KCB, Chan YH, et al. Malnutrition and its impact on cost of 
hospitalization, length of stay, readmission and 3-year mortality. Clin Nutr. 
2012;31(3):345–350. doi:10.1016/j.clnu.2011.11.001. 
22.  Corkins MR, Guenter P, DiMaria-Ghalili RA, et al. Malnutrition diagnoses in 
hospitalized patients: United States, 2010. JPEN J Parenter Enteral Nutr. 
2014;38(2):186–95. doi:10.1177/0148607113512154. 
23.  Braunschweig C, Gomez S, Sheean PM. Impact of declines in nutritional status on 
outcomes in adult patients hospitalized for more than 7 days. J Am Diet Assoc. 
2000;100(11):1316-1322-1324. doi:10.1016/S0002-8223(00)00373-4. 
24.  Bams J, Miranda D. Outcome and costs of intensive care. Intensive Care Med. 
1985;11:234–240. Available at: 
http://www.springerlink.com/index/R6H31756P1U6VG42.pdf. 
100 
 
25.  Malone A, Hamilton C. The Academy of Nutrition and Dietetics/The American 
Society for Parenteral and Enteral Nutrition Consensus Malnutrition 
Characteristics: Application in Practice. Nutr Clin Pract. 2013;28(6):639–650. 
doi:10.1177/0884533613508435. 
26.  Mulasi U, Vock D, Kuchnia AJ, et al. Malnutrition Identified by the Academy of 
Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition 
Consensus Criteria and Other Bedside Tools is Highly Prevalent in a Sample of 
Individuals Undergoing Treatment for Head and Neck Ca. Accept Publ JPEN J 
Parenter Enter Nutr. 2016. doi:10.1177/0148607116672264. 
27.  Locher JL, Bonner J a, Carroll WR, et al. Prophylactic percutaneous endoscopic 
gastrostomy tube placement in treatment of head and neck cancer: a 
comprehensive review and call for evidence-based medicine. JPEN J Parenter 
Enteral Nutr. 2011;35(3):365–374. doi:10.1177/0148607110377097. 
28.  Ravasco P. Nutritional support in head and neck cancer: how and why? Anticancer 
Drugs. 2011;22(7):639–646. doi:10.1097/CAD.0b013e328345b4c5. 
29.  Jager-Wittenaar H, Dijkstra P, Vissink A, et al. Critical weight loss in head and 
neck cancer--prevalence and risk factors at diagnosis: an explorative study. 
Support Care Cancer. 2007;15(9):1045–1050. doi:10.1007/s00520-006-0212-9. 
30.  Newman L a, Vieira F, Schwiezer V, et al. Eating and weight changes following 
chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol 
Head Neck Surg. 1998;124(5):589–592. 
31.  Gorenc M, Kozjek NR, Strojan P. Malnutrition and cachexia in patients with head 
and neck cancer treated with (chemo)radiotherapy. Reports Pract Oncol 
Radiother. 2015;20(4):249–258. doi:10.1016/j.rpor.2015.03.001. 
32.  Langius J, Doornaert P, Spreeuwenberg M, et al. Radiotherapy on the neck nodes 
predicts severe weight loss in patients with early stage laryngeal cancer. Radiother 
Oncol. 2010;97(1):80–85. doi:10.1016/j.radonc.2010.02.017. 
33.  Van Cutsem E, Arends J. The causes and consequences of cancer-associated 
malnutrition. Eur J Oncol Nurs. 2005;9(SUPPL. 2). 
doi:10.1016/j.ejon.2005.09.007. 
34.  Capra S, Ferguson M, Ried K. Cancer : Impact of Nutrition Intervention Outcome 
— Nutrition Issues for Patients. Nutrition. 2001:769–772. 
35.  Brookes G. Nutritional status - a prognostic indicator in head and neck cancer. 
Otolaryngol Neck Surg. 1985;93(1):69–74. 
36.  Malone A, Hamilton C. The Academy of Nutrition and Dietetics/ the American 
Society for Parenteral and Enteral Nutrition consensus malnutrition characteristics: 
application in practice. Nutr Clin Pract. 2013;28(6):639–650. 
doi:10.1177/0884533613508435. 
101 
 
37.  Cederholm T, Bosaeus I, Barazzoni R, et al. Diagnostic criteria for malnutrition - 
An ESPEN Consensus Statement. Clin Nutr. 2015;34(3):335–340. 
doi:10.1016/j.clnu.2015.03.001. 
38.  Earthman CP, Wolfe RR, Heymsfield SB. Dudrick Research Symposium 2015--
Lean Tissue and Protein in Health and Disease: Key Targets and Assessment 
Strategies. J Parenter Enter Nutr. 2015. doi:10.1177/0148607115619599. 
39.  Thibault R, Genton L, Pichard C. Body composition: Why, when and for who? 
Clin Nutr. 2012;31(4):435–447. doi:10.1016/j.clnu.2011.12.011. 
40.  Schutz Y, Kyle UUG, Pichard C. Fat-free mass index and fat mass index 
percentiles in Caucasians aged 18-98 y. Int J Obes Relat Metab Disord. 
2002;26(7):953–60. doi:10.1038/sj.ijo.0802037. 
41.  Pourhassan M, Schautz B, Braun W, et al. Impact of body-composition 
methodology on the composition of weight loss and weight gain. Eur J Clin Nutr. 
2013;67(5):446–54. doi:10.1038/ejcn.2013.35. 
42.  LaForgia J, Dollman J, Dale MJ, et al. Validation of DXA body composition 
estimates in obese men and women. Obesity (Silver Spring). 2009;17(4):821–826. 
doi:10.1038/oby.2008.595. 
43.  Ellis KJ. Human body composition: in vivo methods. Physiol Rev. 
2000;80(2):649–680. doi:10.1007/978-1-4899-1268-8. 
44.  Hoffer JL, Bistrian BR. Appropriate protein provision in critical illness : a 
systematic and narrative review. Am J Clin Nutr. 2012;96:591–600. 
doi:10.3945/ajcn.111.032078.1. 
45.  Moisey LL, Mourtzakis M, Cotton B a, et al. Skeletal muscle predicts ventilator-
free days, ICU-free days, and mortality in elderly ICU patients. Crit Care. 
2013;17(5):R206. doi:10.1186/cc12901. 
46.  Yamada Y, Schoeller D a, Nakamura E, et al. Extracellular water may mask actual 
muscle atrophy during aging. journals Gerontol. 2010;65(5):510–6. 
doi:10.1093/gerona/glq001. 
47.  Montano–Loza AJ, Meza–Junco J, Prado CMM, et al. Muscle wasting is 
associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 
2012;10(2):166–173. doi:10.1016/j.cgh.2011.08.028. 
48.  Parsons H a, Baracos VE, Dhillon N, et al. Body composition, symptoms, and 
survival in advanced cancer patients referred to a phase I service. PLoS One. 
2012;7(1):e29330. doi:10.1371/journal.pone.0029330. 
49.  Cosquéric G, Sebag A, Ducolombier C, et al. Sarcopenia is predictive of 
nosocomial infection in care of the elderly. Br J Nutr. 2007;96(5):895–901. 
doi:10.1017/BJN20061943. 
102 
 
50.  Pichard C, Kyle UG, Morabia A, et al. Nutritional assessment: lean body mass 
depletion at hospital admission is associated with an increased length of stay. Am J 
Clin Nutr. 2004;79(4):613–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15051605. 
51.  Mourtzakis M, Wischmeyer P. Bedside ultrasound measurement of skeletal 
muscle. Curr Opin Clin Nutr Metab Care. 2014;17(5):389–95. 
doi:10.1097/MCO.0000000000000088. 
52.  Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) 
in older persons is associated with functional impairment and physical disability. J 
Am Geriatr Soc. 2002;50(5):889–896. doi:10.1046/j.1532-5415.2002.50216.x. 
53.  Detsky A, Mclaughlin JR, P.Baker J, et al. What is subjective global assessment of 
nutritional status? J Parenter Enter Nutr. 1987;11:8–13. 
54.  White J, Guenter P, Jensen G, et al. Consensus statement: Academy of Nutrition 
and Dietetics and American Society for Parenteral and Enteral Nutrition: 
characteristics recommended for the identification and documentation of adult 
malnutrition (undernutrition). J Parenter Enter Nutr. 2012;36(3):275–283. 
doi:10.1177/0148607112440285. 
55.  Ottery F. Definition of standardized nutritional assessment and interventional 
pathways in oncology. Nutrition. 1996;12(1):S15–S19. 
56.  Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective 
Global Assessment (PG-SGA) as a nutrition assessment tool in patients with 
cancer. Eur J Clin Nutr. 2002;56(8):779–785. doi:10.1038/sj.ejcn.1601412. 
57.  Sheean PM, Peterson SJ, Gomez Perez S, et al. The prevalence of sarcopenia in 
patients with respiratory failure classified as normally nourished using computed 
tomography and subjective global assessment. JPEN J Parenter Enteral Nutr. 
2014;38(7):873–9. doi:10.1177/0148607113500308. 
58.  Kelly TL, Slovik DM, Neer RM. Calibration and standardization of bone mineral 
densitometers. J Bone Miner Res. 1989;4(5):663–9. 
doi:10.1002/jbmr.5650040504. 
59.  Yang HR, Chang EJ. Insulin resistance, body composition, and fat distribution in 
obese children with nonalcoholic fatty liver disease. Asia Pac J Clin Nutr. 
2016;25(1):126–133. doi:10.6133/apjcn.2016.25.1.15. 
60.  Pelletier CA, Miyatani M, Giangregorio L, et al. Sarcopenic Obesity in Adults 
with Chronic Spinal Cord Injury: A Cross-Sectional Study. Arch Phys Med 
Rehabil. 2016. doi:10.1016/j.apmr.2016.04.026. 
61.  Orgel E, Mueske NM, Sposto R, et al. Limitations of body mass index to assess 
body composition due to sarcopenic obesity during leukemia therapy. Leuk 
Lymphoma. 2016;8194(June):1–8. doi:10.3109/10428194.2015.1136741. 
103 
 
62.  Barbour LA, Hernandez TL, Reynolds RM, et al. Striking differences in infant 
adiposity by new and old DXA software, PEA POD, and skinfolds at 2 weeks and 
1 year of life. Diabetes. 2015;64:A38–A39. doi:10.1111/ijpo.12055. 
63.  El Ghoch M, Pourhassan M, Milanese C, et al. Changes in lean and skeletal 
muscle body mass in adult females with anorexia nervosa before and after weight 
restoration. Clin Nutr. 2015:1–9. doi:10.1016/j.clnu.2015.10.006. 
64.  Verney J, Metz L, Chaplais E, et al. Bioelectrical impedance is an accurate method 
to assess body composition in obese but not severely obese adolescents. Nutr Res. 
2016;36(7):663–670. doi:10.1016/j.nutres.2016.04.003. 
65.  Charatsi AM, Dusser P, Freund R, et al. Bioelectrical impedance in young patients 
with cystic fibrosis: Validation of a specific equation and clinical relevance. J Cyst 
Fibros. 2016. doi:10.1016/j.jcf.2016.05.004. 
66.  Baranauskas MN, Johnson KE, Juvancic-Heltzel JA, et al. Seven-site versus three-
site method of body composition using BodyMetrix ultrasound compared to dual-
energy X-ray absorptiometry. Clin Physiol Funct Imaging. 2015:1–5. 
doi:10.1111/cpf.12307. 
67.  Beckman LM, Boullata JI, Fisher PL, et al. Evaluation of Lean Body Weight 
Equation by Dual-Energy X-Ray Absorptiometry Measures. JPEN J Parenter 
Enteral Nutr. 2015. doi:10.1177/0148607115595223. 
68.  Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to 
quantification of body composition in cancer patients using computed tomography 
images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–
1006. doi:10.1139/H08-075. 
69.  Pietrobelli A, Formica C, Wang Z, et al. Dual-energy X-ray absorptiometry body 
composition model: review of physical concepts. Am J Physiol. 1996;271(6 Pt 
1):E941-51. 
70.  Bazzocchi A, Ponti F, Albisinni U, et al. DXA: technical aspects and application. 
Eur J Radiol. 2016. doi:10.1016/j.ejrad.2016.04.004. 
71.  Norcross J, Van Loan MD. Validation of fan beam dual energy x ray 
absorptiometry for body composition assessment in adults aged 18-45 years. Br J 
Sports Med. 2004;38(4):472–476. doi:10.1136/bjsm.2003.005413. 
72.  Prado CMM, Heymsfield SB. Lean tissue imaging: a new era for nutritional 
assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940–53. 
doi:10.1177/0148607114550189. 
73.  Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-ray absorptiometry body 
composition reference values from NHANES. PLoS One. 2009;4(9):2–9. 
doi:10.1371/journal.pone.0007038. 
74.  Coin A, Giannini S, Minicuci N, et al. Limb fat-free mass and fat mass reference 
104 
 
values by dual-energy X-ray absorptiometry (DEXA) in a 20-80 year-old italian 
population. Clin Nutr. 2012;31(4):506–511. doi:10.1016/j.clnu.2012.01.012. 
75.  Guglielmi G, Ponti F, Agostini M, et al. The role of DXA in sarcopenia. Aging 
Clin Exp Res. 2016. doi:10.1007/s40520-016-0589-3. 
76.  Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia 
among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–763. 
77.  Santilli V, Bernetti A, Mangone M, et al. Clinical definition of sarcopenia 
2013.pdf. 2014;11(3):177–180. doi:1138/ccmbm/2014.11.3.177. 
78.  Kerr A, Slater GJ, Byrne N, et al. Reliability of 2 Different Positioning Protocols 
for Dual-Energy X-ray Absorptiometry Measurement of Body Composition in 
Healthy Adults. J Clin Densitom. 2015;(5). doi:10.1016/j.jocd.2015.08.002. 
79.  Van Loan MD, Keim NL, Berg K, et al. Evaluation of body composition by dual 
energy x-ray absorptiometry and two different software packages. Med Sci Sports 
Exerc. 1995;27(4):587–91. 
80.  Tothill P, Avenell A, Love J, et al. Comparisons between Hologic, Lunar and 
Norland dual-energy X-ray absorptiometers and other techniques used for whole-
body soft tissue measurements. Eur J Clin Nutr. 1994;48(11):781–94. 
81.  Soriano J-MP, Ioannidou E, Wang J, et al. Pencil-Beam vs Fan-Beam Dual-Energy 
X-Ray Absorptiometry Comparisons Across Four Systems. J Clin Densitom. 
2004;7(3):281–289. doi:10.1385/JCD:7:3:281. 
82.  Horber FF, Thomi F, Casez JP, et al. Impact of hydration status on body 
composition as measured by dual energy X-ray absorptiometry in normal 
volunteers and patients on haemodialysis. BrJ Radiol. 1992;65(0007–1285 
(Print)):895–900. 
83.  Nana A, Slater GJ, Hopkins WG, et al. Effects of daily activities on dual-energy 
X-ray absorptiometry measurements of body composition in active people. Med 
Sci Sports Exerc. 2012;44(1):180–189. doi:10.1249/MSS.0b013e318228b60e. 
84.  Kelly TL, Berger N, Richardson TL. DXA body composition: Theory and practice. 
Appl Radiat Isot. 1998;49(5–6):511–513. doi:10.1016/S0969-8043(97)00226-1. 
85.  Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, 
cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups 
(SIG) “ cachexia-anorexia in chronic wasting diseases” and “ nutrition in 
geriatrics.” Clin Nutr. 2010;29(2):154–159. doi:10.1016/j.clnu.2009.12.004. 
86.  Rothney MP, Brychta RJ, Schaefer E V., et al. Body Composition Measured by 
Dual-energy X-ray Absorptiometry Half-body Scans in Obese Adults. Obesity. 
2009;17(6):1281–1286. doi:10.1038/oby.2009.14. 
87.  Heymsfield SB, Noel R, Lynn M, et al. Accuracy of Soft Tissue Density Predicted 
105 
 
by CT. J Comput Assist Tomogr. 1979;3(6):859–860. 
88.  Kumar A, Moynagh MR, Multinu F, et al. Muscle composition measured by CT 
scan is a measurable predictor of overall survival in advanced ovarian cancer. 
Gynecol Oncol. 2016. doi:10.1016/j.ygyno.2016.05.027. 
89.  Sjøblom B, Grønberg BH, Wentzel-Larsen T, et al. Skeletal muscle radiodensity is 
prognostic for survival in patients with advanced non-small cell lung cancer. Clin 
Nutr. 2016. doi:10.1016/j.clnu.2016.03.010. 
90.  Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: 
Skeletal muscle depletion is a powerful prognostic factor, independent of body 
mass index. J Clin Oncol. 2013;31(12):1539–1547. 
doi:10.1200/JCO.2012.45.2722. 
91.  Huang DD, Wang SL, Zhuang CL, et al. Sarcopenia, as defined by low muscle 
mass, strength and physical performance, predicts complications after surgery for 
colorectal cancer. Color Dis. 2015;17(11):O256–O264. doi:10.1111/codi.13067. 
92.  Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with 
postoperative infection and delayed recovery from colorectal cancer resection 
surgery. Br J Cancer. 2012;107(6):931–6. doi:10.1038/bjc.2012.350. 
93.  Baracos V. Body composition in patients with non–small cell lung cancer: a 
contemporary view of cancer cachexia with the use of computed tomography 
image analysis. Am J Clin Nutr. 2010;91:1133–1137. 
doi:10.3945/ajcn.2010.28608C.INTRODUCTION. 
94.  Camus V, Lanic H, Kraut J, et al. Prognostic impact of fat tissue loss and cachexia 
assessed by computed tomography scan in elderly patients with diffuse large B-
cell lymphoma treated with immunochemotherapy. Eur J Haematol. 2014;93(1):9–
18. doi:10.1111/ejh.12285. 
95.  Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of 
sarcopenic obesity in patients with solid tumours of the respiratory and 
gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–
635. doi:10.1016/S1470-2045(08)70153-0. 
96.  Gakhar H, Dhillon A, Blackwell J, et al. Study investigating the role of skeletal 
muscle mass estimation in metastatic spinal cord compression. Eur spine J  Off 
Publ Eur Spine Soc  Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc. 
2015;24(10):2150–2155. doi:10.1007/s00586-015-4050-7. 
97.  Weijs PJM, Looijaard WGPM, Dekker IM, et al. Low skeletal muscle area is a risk 
factor for mortality in mechanically ventilated critically ill patients. Crit Care. 
2014;18(1):R12. doi:10.1186/cc13189. 
98.  Docimo S, Lamparello B, Cohen MF, et al. Utilizing quantitative measures of 
visceral adiposity in evaluating trauma patient outcomes. Int J Surg. 
106 
 
2015;21(2015):51–56. doi:10.1016/j.ijsu.2015.06.069. 
99.  Brewster DJ, Strauss BJG, Crozier TM. Measuring visceral fat, subcutaneous fat 
and skeletal muscle area changes by computed tomography in acute pancreatitis: A 
retrospective, single-centre study. Crit Care Resusc. 2014;16(1):42–47. 
100.  Wang CW, Feng S, Covinsky KE, et al. A Comparison of Muscle Function, Mass, 
and Quality in Liver Transplant Candidates. Transplantation. 2016;0(0):1. 
doi:10.1097/TP.0000000000001232. 
101.  Goldman LW. Principles of CT and CT technology. J Nucl Med Technol. 
2007;35(3):115-28-30. doi:10.2967/jnmt.107.042978. 
102.  Gomez-Perez SL, Haus JM, Sheean P, et al. Measuring Abdominal Circumference 
and Skeletal Muscle From a Single Cross-Sectional Computed Tomography 
Image: A Step-by-Step Guide for Clinicians Using National Institutes of Health 
ImageJ. JPEN J Parenter Enteral Nutr. 2016;40(3):308–18. 
doi:10.1177/0148607115604149. 
103.  Irving B a, Weltman JY, Brock DW, et al. NIH ImageJ and Slice-O-Matic 
computed tomography imaging software to quantify soft tissue. Obesity (Silver 
Spring). 2007;15(2):370–376. doi:10.1038/oby.2007.573. 
104.  Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated 
with computed tomography. Ann N Y Acad Sci. 2000;May(904):18–24. 
doi:10.1111/j.1749-6632.2000.tb06416.x. 
105.  Mazonakis M, Damilakis J. Computed tomography: What and how does it 
measure? Eur J Radiol. 2016:2–7. doi:10.1016/j.ejrad.2016.03.002. 
106.  Kim WH, Kim CG, Kim DW. Optimal CT number range for adipose tissue when 
determining lean body mass in whole-body F-18 FDG PET/CT studies. Nucl Med 
Mol Imaging (2010). 2012;46(4):294–299. doi:10.1007/s13139-012-0175-3. 
107.  Shen W, Punyanitya M, Wang Z, et al. Total Body Skeletal Muscle and Adipose 
Tissue Volumes: Estimation from a Single Abdominal Cross-Sectional Image. J 
Appl Physiol. 2004;97:2333–2338. doi:10.1152/japplphysiol.00744.2004. 
108.  Peng P, Hyder O, Firoozmand A, et al. Impact of Sarcopenia on Outcomes 
Following Resection of Pancreatic Adenocarcinoma. J Gastrointest Surg. 
2012;16(8):1478–1486. doi:10.1007/s11605-012-1923-5. 
109.  Veld J, Vossen JA, De Amorim Bernstein K, et al. Adipose tissue and muscle 
attenuation as novel biomarkers predicting mortality in patients with extremity 
sarcomas. Eur Radiol. 2016. doi:10.1007/s00330-016-4306-6. 
110.  Akahori T, Sho M, Kinoshita S, et al. Prognostic Significance of Muscle 
Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant 
Chemoradiotherapy. World J Surg. 2015;39(12):2975–2982. doi:10.1007/s00268-
015-3205-3. 
107 
 
111.  Voron T, Tselikas L, Pietrasz D, et al. Sarcopenia Impacts on Short- and Long-
term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg. 
2014;0(0):1–11. doi:10.1097/SLA.0000000000000743. 
112.  Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle 
radiation attenuation and basis of its biological variation. Acta Physiol. 
2014;210(3):489–497. doi:10.1111/apha.12224. 
113.  Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis 
in patients with metastatic renal cell carcinoma treated with targeted therapies. 
Cancer. 2013;119(18):3377–3384. doi:10.1002/cncr.28218. 
114.  Mategrano VC, Petasnick J, Clark J, et al. Attenuation values in computed 
tomography of the abdomen. Radiology. 1977;125(1):135–140. 
115.  McCullough EC, Morin RL. CT-number variability in thoracic geometry. Am J 
Roentgenol. 1983;141(1):135–140. doi:10.2214/ajr.141.1.135. 
116.  Tim B. DEPENDENCE OF SUBSTANCE CT NUMBER SCANNING 
TECHNIQUE AND POSITION WITHIN SCANNER. 1983;7(3):199–203. 
117.  Levi C, Gray JE, McCullough EC, et al. The unreliability of CT numbers as 
absolute values. Am J Roentgenol. 1982;139(3):443–447. 
doi:10.2214/ajr.139.3.443. 
118.  Groell R, Rienmueller R, Schaffler GJ, et al. CT number variations due to different 
image acquisition and reconstruction parameters: A thorax phantom study. Comput 
Med Imaging Graph. 2000;24(2):53–58. doi:10.1016/S0895-6111(99)00043-9. 
119.  Birnbaum B a, Hindman N, Lee J, et al. Multi-detector row CT attenuation 
measurements: assessment of intra- and interscanner variability with an 
anthropomorphic body CT phantom. Radiology. 2007;242(1):109–119. 
doi:10.1148/radiol.2421052066. 
120.  Paul J, Krauss B, Banckwitz R, et al. Relationships of clinical protocols and 
reconstruction kernels with image quality and radiation dose in a 128-slice CT 
scanner: Study with an anthropomorphic and water phantom. Eur J Radiol. 
2012;81(5):e699–e703. doi:10.1016/j.ejrad.2011.01.078. 
121.  Bryant JA, Drage NA, Richmond S. CT number definition. Radiat Phys Chem. 
2012;81(4):358–361. doi:10.1016/j.radphyschem.2011.12.026. 
122.  Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis-part 
II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–1453. 
doi:10.1016/j.clnu.2004.09.012. 
123.  Matthie JR. Bioimpedance measurements of human body composition: critical 
analysis and outlook. Expert Rev Med Devices. 2008;5(2):239–261. 
doi:10.1586/17434440.5.2.239. 
108 
 
124.  Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis - Part 
I: Review of principles and methods. Clin Nutr. 2004;23(5):1226–1243. 
doi:10.1016/j.clnu.2004.06.004. 
125.  Jaffrin MY, Morel H. Body fluid volumes measurements by impedance: A review 
of bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods. 
Med Eng Phys. 2008;30(10):1257–1269. doi:10.1016/j.medengphy.2008.06.009. 
126.  Mulasi U, Kuchnia AJ, Cole AJ, et al. Bioimpedance at the Bedside: Current 
Applications, Limitations, and Opportunities. Nutr Clin Pract. 2015. 
doi:10.1177/0884533614568155. 
127.  Lukaski HC. Evolution of bioimpedance: a circuitous journey from estimation of 
physiological function to assessment of body composition and a return to clinical 
research. Eur J Clin Nutr. 2013;67 Suppl 1(S1):S2-9. doi:10.1038/ejcn.2012.149. 
128.  Earthman C, Traughber D, Dobratz J, et al. Bioimpedance spectroscopy for 
clinical assessment of fluid distribution and body cell mass. Nutr Clin Pract. 
2007;22(4):389–405. doi:10.1177/0115426507022004389. 
129.  Cole KS, Cole RH. Dispersion and absorption in dielectrics I. Alternating current 
characteristics. J Chem Phys. 1941;9(4):341. doi:10.1063/1.1750906. 
130.  Marcelli D, Usvyat LA, Kotanko P, et al. Body composition and survival in 
dialysis patients: Results from an international cohort study. Clin J Am Soc 
Nephrol. 2015;10(7):1192–1200. doi:10.2215/CJN.08550814. 
131.  El-Kateb S, Davenport A. Changes in intracellular water following hemodialysis 
treatment lead to changes in estimates of lean tissue using bioimpedance 
spectroscopy. Nutr Clin Pract. 2016;31(3):375–377. 
doi:10.1177/0884533615621549. 
132.  Onofriescu M, Hogas S, Voroneanu L, et al. Bioimpedance-guided fluid 
management in maintenance hemodialysis: A pilot randomized controlled trial. Am 
J Kidney Dis. 2014;64(1):111–118. doi:10.1053/j.ajkd.2014.01.420. 
133.  O’lone EL, Visser A, Finney H, et al. Clinical significance of multi-frequency 
bioimpedance spectroscopy in peritoneal dialysis patients: Independent predictor 
of patient survival. Nephrol Dial Transplant. 2014;29(7):1430–1437. 
doi:10.1093/ndt/gfu049. 
134.  Dewitte A, Carles P, Joannès-Boyau O, et al. Bioelectrical impedance 
spectroscopy to estimate fluid balance in critically ill patients. J Clin Monit 
Comput. 2015:227–233. doi:10.1007/s10877-015-9706-7. 
135.  Ernstbrunner M, Kostner L, Kimberger O, et al. Bioimpedance spectroscopy for 
assessment of volume status in patients before and after general anaesthesia. PLoS 
One. 2014;9(10). doi:10.1371/journal.pone.0111139. 
136.  El-Kateb S, Davenport A. Changes in hydration following haemodialysis 
109 
 
estimated with bioimpedance spectroscopy. Nephrology. 2016;21(5):410–415. 
doi:10.1111/nep.12645. 
137.  Olde Rikkert MG, Deurenberg P, Jansen RW, et al. Validation of multi-frequency 
bioelectrical impedance analysis in detecting changes in fluid balance of geriatric 
patients. J Am Geriatr Soc. 1997;45(3):1345–1351. Available at: 
http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/134/CN-
00145134/frame.html. 
138.  Sun G, French C, Martin G, et al. Comparison of multifrequency bioelectrical 
impedance analysis with dual energy x-ray absorptiometry for assessment of 
percentage body fat in a large, health population. Am J Clin Nutr. 2005;81(10):74–
78. doi:81/1/74 [pii]. 
139.  Deurenberg P, Tagliabue  a, Schouten FJ. Multi-frequency impedance for the 
prediction of extracellular water and total body water. Br J Nutr. 1995;73(3):349–
358. 
140.  Earthman CP, Matthie JR, Reid PM, et al. A comparison of bioimpedance methods 
for detection of body cell mass change in HIV infection. J Appl Physiol. 
2000;88(43):944–956. 
141.  Donadio C, Consani C, Ardini M, et al. Estimate of body water compartments and 
of body composition in maintenance hemodialysis patients: Comparison of single 
and multifrequency bioimpedance analysis. J Ren Nutr. 2005;15(3):332–344. 
doi:10.1016/j.jrn.2005.04.001. 
142.  Hannan WJ, Cowen SJ, Plester CE, et al. Comparison of bio-impedance 
spectroscopy and multi-frequency bio-impedance analysis for the assessment of 
extracellular and total body water in surgical patients. Clin Sci (Lond). 
1995;89(6):651–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8549085. 
143.  Haverkort EB, Reijven PLM, Binnekade JM, et al. Bioelectrical impedance 
analysis to estimate body composition in surgical and oncological patients: a 
systematic review. Eur J Clin Nutr. 2014;69(1):3–13. doi:10.1038/ejcn.2014.203. 
144.  Gupta D, Lammersfeld CA, Vashi PG, et al. Bioelectrical impedance phase angle 
as a prognostic indicator in breast cancer. BMC Cancer. 2008;8:249. 
doi:10.1186/1471-2407-8-249. 
145.  Gupta D, Lammersfeld CA, Vashi PG, et al. Bioelectrical impedance phase angle 
in clinical practice: implications for prognosis in stage IIIB and IV non-small cell 
lung cancer. BMC Cancer. 2009;9:37. doi:10.1186/1471-2407-9-37. 
146.  Gupta D, Lis CG, Dahlk SL, et al. Bioelectrical impedance phase angle as a 
prognostic indicator in advanced pancreatic cancer. Br J Nutr. 2004;92(6):957–
962. doi:10.1079/BJN20041292. 
147.  Gupta D, Lis CG, Dahlk SL, et al. The relationship between bioelectrical 
110 
 
impedance phase angle and subjective global assessment in advanced colorectal 
cancer. Nutr J. 2008;7(1):7–19. doi:10.1186/1475-2891-7-19. 
148.  Ott M, Fischer H, Polat H, et al. Bioelectrical impedance analysis as a predictor of 
survival in patients with human immunodeficiency virus infection. J Acquir 
Immune Defic Syndr Hum Retrovirol. 1995;9(1):20–25. 
149.  Schwenk  a, Beisenherz  a, Römer K, et al. Phase angle from bioelectrical 
impedance analysis remains an independent predictive marker in HIV-infected 
patients in the era of highly active antiretroviral treatment. Am J Clin Nutr. 
2000;72(2):496–501. 
150.  Colín-Ramírez E, Castillo-Martínez L, Orea-Tejeda A, et al. Bioelectrical 
impedance phase angle as a prognostic marker in chronic heart failure. Nutrition. 
2012;28:901–5. doi:10.1016/j.nut.2011.11.033. 
151.  Selberg O, Selberg D. Norms and correlates of bioimpedance phase angle in 
healthy human subjects, hospitalized patients, and patients with liver cirrhosis. Eur 
J Appl Physiol. 2002;86:509–516. 
152.  Maggiore Q, Nigrelli S, Ciccarelli C, et al. Nutritional and prognostic correlates of 
bioimpedance indexes in hemodialysis patients. Kidney Int. 1996;50(6):2103–
2108. doi:10.1038/ki.1996.535. 
153.  Wirth R, Volkert D, Rösler A, et al. Bioelectric impedance phase angle is 
associated with hospital mortality of geriatric patients. Arch Gerontol Geriatr. 
2010;51:290–294. doi:10.1016/j.archger.2009.12.002. 
154.  Plank LD, Li A. Bioimpedance illness marker compared to phase angle as a 
predictor of malnutrition in hospitalised patients. Clin Nutr. 2013;32(Supplement 
1):S85. 
155.  Earthman CP, Kruizenga HM  and WP. Impedance ratio Z200/Z5 compared to 
phase angle at 50 kHz better predicts nutritional status and length of stay in 
hospitalized patients. Int J Obes. 2011;35(2):S58. 
156.  Itobi E, Stroud M, Elia M. Impact of oedema on recovery after major abdominal 
surgery and potential value of multifrequency bioimpedance measurements. Br J 
Surg. 2006;93(3):354–361. doi:10.1002/bjs.5259. 
157.  Valdespino-Trejo A, Orea-Tejeda A, Castillo-Martínez L, et al. Low albumin 
levels and high impedance ratio as risk factors for worsening kidney function 
during hospitalization of decompensated heart failure patients. Exp Clin Cardiol. 
2013;18(2):113–117. 
158.  Castillo Martínez L, Colín Ramírez E, Orea Tejeda A, et al. Bioelectrical 
impedance and strength measurements in patients with heart failure: comparison 
with functional class. Nutrition. 2007;23(5):412–418. 
doi:10.1016/j.nut.2007.02.005. 
111 
 
159.  Baracos V, Caserotti P, Earthman CP, et al. Advances in the Science and 
Application of Body Composition Measurement. JPEN J Parenter Enter Nutr. 
2012;36(1):96–107. doi:10.1177/0148607111417448.Advances. 
160.  Barbosa-Silva MCG, Barros AJD. Bioelectrical impedance analysis in clinical 
practice: a new perspective on its use beyond body composition equations. Curr 
Opin Clin Nutr Metab Care. 2005;8(3):311–317. doi:10.1016/j.yco.2004.09.001. 
161.  Kyle UG, Genton L, Pichard C. Low phase angle determined by bioelectrical 
impedance analysis is associated with malnutrition and nutritional risk at hospital 
admission. Clin Nutr. 2013;32(2):294–299. doi:10.1016/j.clnu.2012.08.001. 
162.  Kyle UG, Soundar EP, Genton L, et al. Can phase angle determined by 
bioelectrical impedance analysis assess nutritional risk? A comparison between 
healthy and hospitalized subjects. Clin Nutr. 2012;31(6):875–881. 
doi:10.1016/j.clnu.2012.04.002. 
163.  Barbosa-Silva MCG, Barros AJD. Bioelectric impedance and individual 
characteristics as prognostic factors for post-operative complications. Clin Nutr. 
2005;24(5):830–838. doi:10.1016/j.clnu.2005.05.005. 
164.  Barbosa-Silva MCG, Barros AJD, Post CL a, et al. Can bioelectrical impedance 
analysis identify malnutrition in preoperative nutrition assessment? Nutrition. 
2003;19(2):422–426. doi:10.1016/S0899-9007(02)00932-2. 
165.  Kim K, Wagner WR. Non-invasive and Non-destructive Characterization of 
Tissue Engineered Constructs Using Ultrasound Imaging Technologies: A Review. 
Ann Biomed Eng. 2015;44(3):621–635. doi:10.1007/s10439-015-1495-0. 
166.  Medical Imaging - Ultrasound Imaging. US Food Drug Adm. 2014. 
167.  Pillen S, van Alfen N. Skeletal muscle ultrasound. Neurol Res. 2011;33(10):1016–
24. doi:10.1179/1743132811Y.0000000010. 
168.  Paris M, Mourtzakis M, Day A, et al. VALIDation of bedside Ultrasound of 
Muscle layer thickness of the quadriceps in the critically ill patient (VALIDUM 
study): A prospective multicenter study [Epub ahead of print]. J Parenter Enter 
Nutr. 2016. 
169.  Parry SM, El-Ansary D, Cartwright MS, et al. Ultrasonography in the intensive 
care setting can be used to detect changes in the quality and quantity of muscle and 
is related to muscle strength and function. J Crit Care. 2015;30(5):1151.e9-
1151.e14. doi:10.1016/j.jcrc.2015.05.024. 
170.  Puthucheary ZA, Phadke R, Rawal J, et al. Qualitative Ultrasound in Acute 
Critical Illness Muscle Wasting. Crit Care Med. 2015;43(8):1603–1611. 
doi:10.1097/CCM.0000000000001016. 
171.  Abe T, Dabbs NC, Nahar VK, et al. Relationship between Dual-Energy X-Ray 
Absorptiometry-Derived Appendicular Lean Tissue Mass and Total Body Skeletal 
112 
 
Muscle Mass Estimated by Ultrasound. 2013;2013(June):283–286. 
172.  Arbeille P, Kerbeci P, Capri A, et al. Quantification of muscle volume by 
echography: comparison with MRI data on subjects in long-term bed rest. 
Ultrasound Med Biol. 2009;35(7):1092–7. 
doi:10.1016/j.ultrasmedbio.2009.01.004. 
173.  Abe T, Kondo M, Kawakami Y, et al. Prediction equations for body composition 
of Japanese adults by B-mode ultrasound. Am J Hum Biol. 1994;6(2):161–170. 
doi:10.1002/ajhb.1310060204. 
174.  Takai Y, Ohta M, Akagi R, et al. Applicability of ultrasound muscle thickness 
measurements for predicting fat-free mass in elderly population. J Nutr Health 
Aging. 2014;18(6):579–85. doi:10.1007/s12603-013-0419-7. 
175.  Connolly B, MacBean V, Crowley C, et al. Ultrasound for the assessment of 
peripheral skeletal muscle architecture in critical illness: A systematic review. Crit 
Care Med. 2015;(43):897–905. doi:10.1097/CCM.0000000000000821. 
176.  Paris M, Mourtzakis M. Assessment of skeletal muscle mass in critically ill 
patients. Curr Opin Clin Nutr Metab Care. 2016;19(2):125–130. 
doi:10.1097/MCO.0000000000000259. 
177.  Tillquist M, Kutsogiannis DJ, Wischmeyer PE, et al. Bedside ultrasound is a 
practical and reliable measurement tool for assessing quadriceps muscle layer 
thickness. JPEN J Parenter Enteral Nutr. 2014;38(7):886–90. 
doi:10.1177/0148607113501327. 
178.  Harris-Love MO, Monfaredi R, Ismail C, et al. Quantitative ultrasound: 
Measurement considerations for the assessment of muscular dystrophy and 
sarcopenia. Front Aging Neurosci. 2014;6(JUL). doi:10.3389/fnagi.2014.00172. 
179.  Ishida H, Watanabe S. Influence of Inward Pressure of the Transducer on Lateral 
Abdominal Muscle Thickness During Ultrasound Imaging. J Orthop Sports Phys 
Ther. 2012;42(9):815–818. doi:10.2519/jospt.2012.4064. 
180.  I T Campbell, Watt T, Withers D, et al. Muscle thickness, measured with 
ultrasound, may be an indicator of lean tissue wasting in multiple organ failure in 
the presence of edema. Am J Clin Nutr. 1995;62(3):533–539. 
181.  Harris-Love MO, Seamon BA, Teixeira C, et al. Ultrasound estimates of muscle 
quality in older adults: reliability and comparison of Photoshop and ImageJ for the 
grayscale analysis of muscle echogenicity. PeerJ. 2016;4:e1721. 
doi:10.7717/peerj.1721. 
182.  Cardenas-Garcia J, Mayo PH. Bedside ultrasonography for the intensivist. Crit 
Care Clin. 2015;31(1):43–66. doi:10.1016/j.ccc.2014.08.003. 
183.  Reimers CD, Fleckenstein JL, Witt TN, et al. Muscular ultrasound in idiopathic 
inflammatory myopathies of adults. J Neurol Sci. 1993;116(1):82–92. 
113 
 
doi:10.1016/0022-510X(93)90093-E. 
184.  Reimers K, Reimers CD, Wagner S, et al. Skeletal muscle sonography: a 
correlative study of echogenicity and morphology. J Ultrasound Med. 1993;12:73–
77. 
185.  Sarwal A, Parry SM, Berry MJ, et al. Interobserver Reliability of Quantitative 
Muscle Sonographic Analysis in the Critically Ill Population. J Ultrasound Med. 
2015;34(7):1191–200. doi:10.7863/ultra.34.7.1191. 
186.  Teigen LM, Kuchnia AJ, Mourtzakis M, et al. The Use of Technology for 
Estimating Body Composition: Strengths and Weaknesses of Common Modalities 
in a Clinical Setting. Nutr Clin Pract. 2017;32(1):20–27. 
doi:10.1177/0884533616676264. 
187.  Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin 
Nutr. 2006;84(3):475–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16960159. 
188.  Kuchnia A, Earthman C, Teigen L, et al. Evaluation of Bioelectrical Impedance 
Analysis in Critically Ill Patients: Results of a Multicenter Prospective Study 
[Epub ahead of print]. J Parenter Enter Nutr. 2016. 
doi:10.1177/0148607116651063. 
189.  Hoffer LJ, Bistrian BR. Why Critically Ill Patients Are Protein Deprived. J 
Parenter Enter Nutr. 2013;37(3):300–309. doi:10.1177/0148607113478192. 
190.  Daniel P. The Metabolic Homeostatic Role of Muscle and its Function as a Store 
of Protein. Lancet. 1977:446–448. 
191.  Wilkes EA, Selby AL, Atherton PJ, et al. Blunting of insulin inhibition of 
proteolysis in legs of older subjects may contribute to age-related sarcopenia. Am J 
Clin Nutr. 2009;90(5):1343–1350. doi:10.3945/ajcn.2009.27543. 
192.  Hegsted M. Assessment of nitrogen requirements. Am J Clin Nutr. 1978;31:1669–
1677. 
193.  Kopple JD. Uses and limitations of the balance technique. JPEN J Parenter 
Enteral Nutr. 1987;11(5 Suppl):79S–85S. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3312697. 
194.  Manatt M, Garcia P. Nitrogen Balance: Concepts and Techniques. In: Nissen S, 
ed. Modern Methods in Protein Nutrition and metabolism. Academic Press; 1992. 
195.  Waterlow JC. The mysteries of nitrogen balance. Nutr Res Rev. 1999;12(1):25–54. 
doi:10.1079/095442299108728857. 
196.  Rand WM, Scrimshaw NS, Young VR. Retrospective analysis of data from five 
long-term, metabolic balance studies: Implications for understanding dietary 
nitrogen and energy utilization. Am J Clin Nutr. 1985;42(6):1339–1350. 
114 
 
197.  Dickerson RN. Nitrogen balance and protein requirements for critically ill older 
patients. Nutrients. 2016;8(4). doi:10.3390/nu8040226. 
198.  Hegsted DM. Balance Studies. J Nutr. 1976;106:307–311. 
199.  Mackenzie TA, Clark NG, Bistrian BR, et al. A simple method for estimating 
nitrogen balance in hospitalized patients: a review and supporting data for a 
previously proposed technique. J Am Coll Nutr. 1985;4(5):575–581. 
200.  Mackenzie T, Clark N, Bistrian B, et al. A Simple Method for Estimating Nitrogen 
Balance in Hospitalized Patients: A Review and Supporting Data for a Previously 
Proposed Technique. J Am Coll Nutr. 1985;4(5):575–581. 
201.  Scrimshaw N. An Analysis of Past and Present Recommended Dietary Allowances 
for Protein in Health and Disease. N Engl J Med. 1976;294(4):198–203. 
doi:10.1056/NEJM197710132971510. 
202.  Arnal M, Obled C, Attaix D, et al. Dietary control of protein turnover. Diabetes 
Metab. 1987;13(6):630–42. 
203.  Elango R, Ball RO, Pencharz PB. Recent advances in determining protein and 
amino acid requirements in humans. Br J Nutr. 2012;108(S2):S22–S30. 
doi:10.1017/S0007114512002504. 
204.  Elango R, Humayun MA, Ball RO, et al. Evidence that protein requirements have 
been significantly underestimated. Curr Opin Clin Nutr Metab Care. 
2010;13(1):52–57. doi:10.1097/MCO.0b013e328332f9b7. 
205.  Report of a Joint WHO/FAO/UNU Expert Consultation. Protein and amino acid 
requirements in human nutrition.; 2007. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18330140. 
206.  Schaafsma G. The Protein Digestibility-Corrected Amino Acid Score (PDCAAS) - 
A concept for describing protein quality in foods and food ingredients: A critical 
review. J AOAC Int. 2005;88(3):988–994. 
207.  Weijs P, Calder A, Milne E, et al. Conversion of [15N]ammonia into urea and 
amino acids in humans and the effect of nutritional status. Br J Nutr. 1996;76(4). 
208.  World Health Organization. Energy and Protein Requirements. Report of a joint 
FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser. 
1985;724:1–206. 
209.  Waterlow J. Observations on the mechanism of adaptation to low protein intakes. 
Lancet. 1968;2(7578):1091–7. 
210.  Waterlow JC. Metabolic adaptation to low intakes of energy and protein. Annu Rev 
Nutr. 1986;6:495–526. doi:10.1146/annurev.nu.06.070186.002431. 
211.  Waterlow J. Nutrtitional adaptation in man : general introduction and concepts. Am 
115 
 
J Clin Nutr. 1990;51(2):259–263. 
212.  Das TK, Waterlow JC. The rate of adaptation of urea cycle enzymes, 
aminotransferases and glutamic dehydrogenase to changes in dietary protein 
intake. Br J Nutr. 1974;32(2):353. doi:10.1079/BJN19740088. 
213.  Winick M. Hunger disease. Studies by the Jewish Physicians in the Warsaw 
ghetto. New Yor: John Wiley & Sons, Inc.; 1979. 
214.  Rand WM, Young VR, Scrimshaw NS. Change of urinary nitrogen excretion in 
response to low-protein diets. Am J Clin Nutr. 1976;29(6):639–644. 
215.  Scrimshaw NS, Perera WD, Young VR. Protein requirements of man: obligatory 
urinary and fecal nitrogen losses in elderly women. J Nutr. 1976;106(April):665–
670. 
216.  Oddoye E a, Margen S. Nitrogen balance studies in humans: long-term effect of 
high nitrogen intake on nitrogen accretion. J Nutr. 1979;109(3):363–377. 
217.  Young VR. Nutritional balance studies: indicators of human requirements or of 
adaptive mechanisms? J Nutr. 1986;116(4):700–703. 
218.  Chiang A, Huang P. Excess energy and nitrogen balance at protein intakes above 
the requirement level in young men. Am J Clin Nutr. 1988;48(4):1015–22. 
Available at: http://ajcn.nutrition.org/content/48/4/1015.full.pdf. 
219.  Wolfe R, Volpi E. Insulin and Protein Metabolism. Comprehensive Physiology.; 
2011. Available at: papers3://publication/uuid/82D20102-6715-4711-B751-
841855519AD2. 
220.  Calloway DH. Nitrogen balance of men with marginal intakes of protein and 
energy. J Nutr. 1975;105(7):914–923. Available at: 
http://jn.nutrition.org/content/105/7/914.full.pdf. 
221.  Chow LS, Albright RC, Bigelow ML, et al. Mechanism of insulin’s anabolic effect 
on muscle: measurements of muscle protein synthesis and breakdown using 
aminoacyl-tRNA and other surrogate measures. Am J Physiol Endocrinol Metab. 
2006;291:E729–E736. doi:10.1152/ajpendo.00003.2006. 
222.  Fukagawa NK, Minaker KL, Rowe JW, et al. Insulin-mediated reduction of whole 
body protein breakdown. Dose-response effects on leucine metabolism in 
postabsorptive men. J Clin Invest. 1985;76(6):2306–2311. doi:10.1172/JCI112240. 
223.  Jeejeebhoy KN. Nutritional balance studies: indicators of human requirements or 
of adaptive mechanisms? J Nutr. 1986;116(4):700–703. 
224.  Waterlow J, Garlick P, Millward D. Protein turnover in mammalian tissues and in 
the whole-body. Amsterdam, The Netherlands: Elsevier/North-Holland Biomedical 
Press; 1978. 
116 
 
225.  Institute of Medicine of the National Academies. Dietary Reference Intakes for 
Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino 
Acids. Washington, D.C.; 2005. doi:10.1016/S0002-8223(02)90346-9. 
226.  Pencharz PB, Elango R, Wolfe RR. Recent developments in understanding protein 
needs - How much and what kind should we eat? Appl Physiol Nutr Metab. 
2016;580(March):1–19. doi:10.1139/apnm-2015-0549. 
227.  Earthman CP, Wolfe RR, Heymsfield SB. Dudrick Research Symposium 2015—
Lean Tissue and Protein in Health and Disease. J Parenter Enter Nutr. 
2015;41(2):226–237. doi:10.1177/0148607115619599. 
228.  Rand WM, Pellett PL, Young VR. Meta-analysis of nitrogen balance studies for 
estimating protein requirements in healthy adults. Am J Clin Nutr. 
2003;77(1):109–27. 
229.  Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr. 
2008;27(5):675–684. doi:10.1016/j.clnu.2008.06.008. 
230.  Stein J, Boehles HJ, Blumenstein I, et al. Amino acids - Guidelines on Parenteral 
Nutrition. Ger Med Sci. 2009;7:1–8. doi:10.3205/000083. 
231.  McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the Provision and 
Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: 
Society of Critical Care Medicine (SCCM) and American Society for Parenteral 
and Enteral Nutrition (A.S.P.E.N.). J Parenter Enter Nutr. 2016;40(2):159–211. 
doi:10.1177/0148607115621863. 
232.  Plank LD. Protein for the critically ill patient--what and when? Eur J Clin Nutr. 
2013;67(5):565–568. doi:10.1038/ejcn.2013.34. 
233.  Dickerson RN, Pitts SL, Maish GO, et al. A reappraisal of nitrogen requirements 
for patients with critical illness and trauma. J Trauma Acute Care Surg. 
2012;73(3):549–57. doi:10.1097/TA.0b013e318256de1b. 
234.  Verbruggen SCAT, Coss-Bu J, Wu M, et al. Current recommended parenteral 
protein intakes do not support protein synthesis in critically ill septic, insulin-
resistant adolescents with tight glucose control. Crit Care Med. 2011;39(11):2518–
2525. doi:10.1097/CCM.0b013e3182257410. 
235.  Weijs PJM, Stapel SN, de Groot SDW, et al. Optimal Protein and Energy Nutrition 
Decreases Mortality in Mechanically Ventilated, Critically Ill Patients. J Parenter 
Enter Nutr. 2012;36(1):60–68. doi:10.1177/0148607111415109. 
236.  Allingstrup MJ, Esmailzadeh N, Wilkens Knudsen A, et al. Provision of protein 
and energy in relation to measured requirements in intensive care patients. Clin 
Nutr. 2012;31(4):462–468. doi:10.1016/j.clnu.2011.12.006. 
237.  Weijs PJ, Cynober L, DeLegge M, et al. Proteins and amino acids are fundamental 
to optimal nutrition support in critically ill patients. Crit Care. 2014;18(6):591. 
117 
 
doi:10.1186/s13054-014-0591-0. 
238.  Ochoa Gautier JB, Martindale RG, Rugeles SJ, et al. How Much and What Type of 
Protein Should a Critically Ill Patient Receive? Nutr Clin Pract. 
2017;32(1_suppl):6S–14S. doi:10.1177/0884533617693609. 
239.  Jonker R, Engelen MPKJ, Deutz NEP. Role of specific dietary amino acids in 
clinical conditions. Br J Nutr. 2012;108(S2):S139–S148. 
doi:10.1017/S0007114512002358. 
240.  Dangin M, Boirie Y, Garcia-Rodenas C, et al. The digestion rate of protein is an 
independent regulating factor of postprandial protein retention. Am J Physiol 
Endocrinol Metab. 2001;280(2):E340–E348. 
241.  Martindale RG, Heyland DK, Rugeles SJ, et al. Protein Kinetics and Metabolic 
Effects Related to Disease States in the Intensive Care Unit. Nutr Clin Pract. 
2017;32(1_suppl):21S–29S. doi:10.1177/0884533617694612. 
242.  Weijs PJM, Dickerson RN, Heyland DK, et al. Experimental and Outcome-Based 
Approaches to Protein Requirements in the Intensive Care Unit. Nutr Clin Pract. 
2017:88453361769277. doi:10.1177/0884533617692774. 
243.  Volpi E, Kobayashi H, Sheffield-moore M, et al. Essential amino acids are 
primarily responsible for the amino acid stimulation of muscle protein anabolism 
in healthy elderly adults. Am J Clin Nutr. 2003;78(2):250–258. 
244.  Jonker R, Deutz NE, Erbland ML, et al. Effectiveness of essential amino acid 
supplementation in stimulating whole body net protein anabolism is comparable 
between COPD patients and healthy older adults. Metabolism. 2017;69:120–129. 
doi:10.1016/j.metabol.2016.12.010. 
245.  Drummond M, Rasmussen B. Leucine-enriched nutrients and the regulation of 
mTOR signalling and human skeletal muscle protein synthesis. Curr Opin Clin 
Nutr Metab Care. 2008;11(3):222–226. doi:10.1038/nbt.3121.ChIP-nexus. 
246.  Boirie Y, Dangin M, Gachon P, et al. Slow and fast dietary proteins differently 
modulate postprandial protein accretion. Proc Natl Acad Sci. 1997;94(26):14930–
14935. doi:10.1073/pnas.94.26.14930. 
247.  Wolfe RR. Effects of amino acid intake on anabolic processes. Can J Appl Physiol. 
2001;26 Suppl:S220-7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11897897. 
248.  Elwyn D. Nutritional requirements of adult surgical patients. Crit Care Med. 
1980;8(1). 
249.  Elwyn DH, Gump FE, Munro HN, et al. Changes in nitrogen balance of depleted 
patients with increasing infusions of glucose. Am J Clin Nutr. 1979;32(8):1597–
1611. 
118 
 
250.  Shaw S, Elwyn DH, Askanazi J, et al. Effects of increasing glucose intake on 
nitrogen balance and energy expenditure in malnourished adult patients receiving 
parenteral nutrition. Clin Sci. 1987;72(4):489–501. Available at: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&
D=med2&AN=3103972%5Cnhttp://lshtmsfx.hosted.exlibrisgroup.com/lshtm?sid=
OVID:medline&id=pmid:3103972&id=doi:&issn=0143-
5221&isbn=&volume=72&issue=4&spage=489&pages=489-
501&date=1987&title=. 
251.  Dickerson RN. Hypocaloric feeding of obese patients in the intensive care unit. 
Curr Opin Clin Nutr Metab Care. 2005;8(2):189–196. Available at: 
http://mcgill.on.worldcat.org/atoztitles/link ?sid=OVID:embase&id=pmid:&id=doi
:&issn=1363-1950&isbn=&volume=8&issue=2&spage=189&pages=189-
196&date=2005&title=Current+Opinion+in+Clinical+Nutrition+and+Metabolic+
Care&atitle=Hypocaloric+feeding+of+obese+pati. 
252.  Berg A, Rooyackers O, Bellander B-M, et al. Whole body protein kinetics during 
hypocaloric and normocaloric feeding in critically ill patients. Crit Care. 
2013;17(4):R158. doi:10.1186/cc12837. 
253.  Weijs PJ, Looijaard WG, Beishuizen A, et al. Early high protein intake is 
associated with low mortality and energy overfeeding with high mortality in non-
septic mechanically ventilated critically ill patients. Crit Care. 2014;18(6):701. 
doi:10.1186/s13054-014-0701-z. 
254.  Guadagni M, Biolo G. Effects of inflammation and/or inactivity on the need for 
dietary protein. Curr Opin Clin Nutr Metab Care. 2009;12(6):617–622. 
doi:10.1097/MCO.0b013e32833193bd. 
255.  Phillips SM, Dickerson RN, Moore FA, et al. Protein Turnover and Metabolism in 
the Elderly Intensive Care Unit Patient. Nutr Clin Pract. 2017:88453361668671. 
doi:10.1177/0884533616686719. 
256.  Wolfe RR, Chinkes DL. Isotope Tracers in Metabolic Research. Second Edi. John 
Wiley & Sons, Inc.; 2005. 
257.  Kim I-Y, Schutzler S, Schrader A, et al. The anabolic response to a meal 
containing different amounts of protein is not limited by the maximal stimulation 
of protein synthesis in healthy young adults. Am J Physiol Endocrinol Metab. 
2016;310(1):E73-80. doi:10.1152/ajpendo.00365.2015. 
258.  Deutz N, Ten Have G, Soeters P, et al. Increased intestinal amino-acid retention 
from the addition of carbohydrates to a meal. Clin Nutr. 1995;14(6):354–364. 
doi:10.1016/S0261-5614(95)80053-0. 
259.  Soeters PB, de Jong CH, Deutz NE. The protein sparing function of the gut and the 
quality of food protein. Clin Nutr. 2001;20(2):97–9. doi:10.1054/clnu.2000.0376. 
260.  Clarke JTR, Bier DM. The Conversion fo Phenylalanine to Tyrosine in Man. 
119 
 
Direct Measurement by Continuous Intravenous Tracer Infusions of L-[ring-
2H5]Phenylalanine and L-[1-13C]Tyrosine in the Postabsorptive State. 
Metabolism. 1982;31(10):999–1005. 
261.  Short K, Meek S, Moller N, et al. Whole body protein kinetics using Phe and Tyr 
tracers: an evaluation of the accuracy of approximated flux values. Methods. 
1999;276(6 pt 1):E1194-200. 
262.  Matthews DE. An overview of phenylalanine and tyrosine kinetics in humans. J 
Nutr. 2007;137(6 Suppl 1):1549S–1555S; discussion 1573S–1575S. 
doi:10.1016/j.bbi.2008.05.010. 
263.  Kim I-Y, Schutzler S, Schrader A, et al. Quantity of dietary protein intake, but not 
pattern of intake, affects net protein balance primarily through differences in 
protein synthesis in older adults. Am J Physiol Endocrinol Metab. 
2015;308(1):E21-8. doi:10.1152/ajpendo.00382.2014. 
264.  Jonker R, Deutz N, Erbland M, et al. Hydrolyzed casein and whey protein meals 
comparably stimulate net whole-body protein synthesis in COPD patients with 
nutritional depletion without an additional effect of leucine co-ingestion. J Clin 
Nutr. 2014;33(2):211–220. doi:10.1016/j.immuni.2010.12.017.Two-stage. 
265.  Engelen MPKJ, Safar AM, Bartter T, et al. High anabolic potential of essential 
amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol . 
2015;26(9):1960–1966. doi:10.1093/annonc/mdv271. 
266.  Deutz NEP, Safar A, Schutzler S, et al. Muscle protein synthesis in cancer patients 
can be stimulated with a specially formulated medical food. Clin Nutr. 
2011;30(6):759–68. doi:10.1016/j.clnu.2011.05.008. 
267.  Pencharz PB, Ball RO. DIFFERENT APPROACHES TO DEFINE INDIVIDUAL 
AMINO ACID REQUIREMENTS. Annu Rev Nutr. 2003;23(1):101–116. 
doi:10.1146/annurev.nutr.23.011702.073247. 
268.  Elango R, Ball RO, Pencharz PB. Indicator amino acid oxidation: concept and 
application. J Nutr. 2008;138(2):243–246. 
269.  Elango R, Humayun MA, Ball RO, et al. Protein requirement of healthy school-
age children determined by the indicator amino acid oxidation method. Am J Clin 
Nutr. 2011;94:1545–52. doi:10.3945/ajcn.111.012815.1. 
270.  Elango R, Humayun M a, Ball RO, et al. Lysine requirement of healthy school-age 
children determined by the indicator amino acid oxidation method. Am J Clin Nutr. 
2007;(2):360–365. doi:10.3945/ajcn.111.012815. 
271.  Bross R, Ball RO, Pencharz PB. Development of a minimally invasive protocol for 
the determination of phenylalanine and lysine kinetics in humans during the fed 
state. J Nutr. 1998;128(July):1913–1919. 
272.  Mager D, Wykes L, Roberts E, et al. Branched-Chain Amino Acid Needs in 
120 
 
Children with Mild-to-Moderate Chronic Cholestatic Liver Disease. J Nutr. 
2006;136(1):133–9. 
273.  Baum JI, Kim IY, Wolfe RR. Protein consumption and the elderly: What is the 
optimal level of intake? Nutrients. 2016;8(6):1–9. doi:10.3390/nu8060359. 
274.  Hoffer LJ. How much protein do parenteral amino acid mixtures provide? Am J 
Clin Nutr. 2011;94(6):1396–1398. doi:10.3945/ajcn.111.023390. 
275.  Hur E, Usta M, Toz H, et al. Effect of fluid management guided by bioimpedance 
spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized 
controlled trial. Am J Kidney Dis. 2013;61(6):957–65. 
doi:10.1053/j.ajkd.2012.12.017. 
276.  Tsai YC, Tsai JC, Chen SC, et al. Association of fluid overload with kidney 
disease progression in advanced CKD: A prospective cohort study. Am J Kidney 
Dis. 2014;63(1):68–75. doi:10.1053/j.ajkd.2013.06.011. 
277.  Bosy-Westphal A, Danielzik S, Dorhofer R-P, et al. Phase angle from bioelectrical 
impedance analysis: population reference values by age, sex, and body mass index. 
J Parenter Enter Nutr. 2006;30(4):309–316. doi:10.1177/0148607106030004309. 
278.  Mulasi U, Kuchnia AJ, Cole AJ, et al. Bioimpedance at the Bedside: Current 
Applications, Limitations, and Opportunities. Nutr Clin Pract. 2015;30(2):180–
193. doi:10.1177/0884533614568155. 
279.  Norman K, Stobäus N, Zocher D, et al. Cutoff percentiles of bioelectrical phase 
angle predict functionality, quality of life, and mortality in patients with cancer. 
Am J Clin Nutr. 2010;92(3):612–619. doi:10.3945/ajcn.2010.29215. 
280.  Dittmar M. Reliability and Variability of Bioimpedance Measures in Normal 
Adults: Effects of Age, Gender, and Body Mass. Am J Phys Anthropol. 
2003;122(4):361–370. doi:10.1002/ajpa.10301. 
281.  Bosy-Westphal A, Danielzik S, Dörhöfer R-P, et al. Phase angle from bioelectrical 
impedance analysis: population reference values by age, sex, and body mass index. 
J Parenter Enter Nutr. 2015;30(4):309–316. doi:10.1177/0148607106030004309. 
282.  Barbosa-Silva MCG, Barros AJD, Wang J, et al. Bioelectrical impedance analysis: 
population reference values for phase angle by age and sex. Am J Clin Nutr. 
2005;82(1):49–52. 
283.  Buchholz AC, Bartok C, Schoeller D a. The validity of bioelectrical impedance 
models in clinical populations. Nutr Clin Pract. 2004;19(5):433–446. 
doi:10.1177/0115426504019005433. 
284.  Kyle UG, Genton L, Slosman DO, et al. Fat-free and fat mass percentiles in 5225 
healthy subjects aged 15 to 98 years. Nutrition. 2001;17(7–8):534–541. 
285.  Norman K, Stobäus N, Pirlich M, et al. Bioelectrical phase angle and impedance 
121 
 
vector analysis - Clinical relevance and applicability of impedance parameters. 
Clin Nutr. 2012;31(6):854–861. doi:10.1016/j.clnu.2012.05.008. 
286.  Gonzalez MC, Barbosa-Silva TG, Bielemann RM, et al. Phase angle and its 
determinants in healthy subjects: influence of body composition. Am J Clin Nutr. 
2016;103(3):712–716. doi:10.3945/ajcn.115.116772. 
287.  Cardinal TR, Wazlawik E, Bastos JL, et al. Standardized phase angle indicates 
nutritional status in hospitalized preoperative patients. Nutr Res. 2010;30(9):594–
600. doi:10.1016/j.nutres.2010.08.009. 
288.  Paiva SI, Borges LR, Halpern-Silveira D, et al. Standardized phase angle from 
bioelectrical impedance analysis as prognostic factor for survival in patients with 
cancer. Support Care Cancer. 2011;19(2):187–192. doi:10.1007/s00520-009-
0798-9. 
289.  Reid C, Campbell I, Little R. Muscle wasting and energy balance in critical illness. 
Clin Nutr. 2004;23(2):273–280. doi:10.1016/S0261-5614(03)00129-8. 
290.  Visser M, van Venrooij LMW, Wanders DCM, et al. The bioelectrical impedance 
phase angle as an indicator of undernutrition and adverse clinical outcome in 
cardiac surgical patients. Clin Nutr. 2012;31(6):981–986. 
doi:10.1016/j.clnu.2012.05.002. 
291.  Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of 
skeletal muscle measurement by magnetic resonance imaging and computerized 
tomography. J Appl Physiol. 1998;85(1):115–122. 
292.  Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose 
tissue volumes : estimation from a single abdominal cross-sectional image. J Appl 
Physiol. 2004;97(6):2333–2338. doi:10.1152/japplphysiol.00744.2004. 
293.  Sekulic AD, Trpkovic S V., Pavlovic AP, et al. Scoring Systems in Assessing 
Survival of Critically Ill ICU Patients. Med Sci Monit. 2015;21:2621–2629. 
doi:10.12659/MSM.894153. 
294.  Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is 
adapted to predict costs of chronic disease in primary care patients. J Clin 
Epidemiol. 2008;61(12):1234–1240. doi:10.1016/j.jclinepi.2008.01.006. 
295.  Groll DL, To T, Bombardier C, et al. The development of a comorbidity index 
with physical function as the outcome. J Clin Epidemiol. 2005;58(6):595–602. 
doi:10.1016/j.jclinepi.2004.10.018. 
296.  Kuchnia A, Teigen L, Cole A, et al. Phase angle and impedance ratio: 
bioimpedance spectroscopy-generated reference cut points from National Health 
and Nutrition Examination Survey IV and V. J Parenter Enter Nutr. 
2016;40(1):125–127. 
297.  Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. 
122 
 
Annu Rev Nutr. 2006;26:435–461. doi:10.1146/annurev.nutr.26.061505.111151. 
298.  Wolfe RR. Perspective: optimal protein intake in the elderly. J Am Med Dir Assoc. 
2013;14(1):65–66. doi:10.1016/j.jamda.2012.09.017. 
299.  Richey LM, George JR, Couch ME, et al. Defining cancer cachexia in head and 
neck squamous cell carcinoma. Clin Cancer Res. 2007;13(22):6561–6567. 
doi:10.1158/1078-0432.CCR-07-0116. 
300.  Short K, Meek S, Moller N, et al. Whole body protein kinetics using Phe and Tyr 
tracers: an evaluation of the accuracy of approximated flux values. Am J Physiol 
Endocrinol Metab. 1999;276(6):E1194–E1200. 
301.  Jonker R, Deutz N, Erbland M, et al. Hydrolyzed casein and whey protein meals 
comparably stimulate net whole-body protein synthesis in COPD patients with 
nutritional depletion without an additional effect of leucine co-ingestion. Clin 
Nutr. 2014;33(2):211–220. doi:10.1016/j.biotechadv.2011.08.021.Secreted. 
302.  van Eijk HMH, Suylen DPL, Dejong CHC, et al. Measurement of amino acid 
isotope enrichment by liquid chromatography mass spectroscopy after 
derivatization with 9-fluorenylmethylchloroformate. J Chromatogr B Anal Technol 
Biomed Life Sci. 2007;856(1–2):48–56. doi:10.1016/j.jchromb.2007.05.020. 
303.  Meesters RJW, Wolfe RR, Deutz NEP. Application of liquid chromatography-
tandem mass spectrometry (LC-MS/MS) for the analysis of stable isotope 
enrichments of phenylalanine and tyrosine. J Chromatogr B Anal Technol Biomed 
Life Sci. 2009;877:43–49. doi:10.1016/j.jchromb.2008.11.018. 
304.  Hallemeesch MM, Soeters PB, Deutz NE. Tracer methodology in whole body and 
organ balance metabolic studies: plasma sampling is required. A study in post-
absorptive rats using isotopically labeled arginine, phenylalanine, valine and 
leucine. Clin Nutr. 2000;19(3):157–63. doi:10.1054/clnu.1999.0116. 
305.  Maastricht University. Stable Isotope Methodology - M3-Research. 2015. 
306.  Wagner DR. Ultrasound as a tool to assess body fat. J Obes. 2013. 
doi:10.1155/2013/280713. 
307.  Sanada K, Kearns CF, Midorikawa T, et al. Prediction and validation of total and 
regional skeletal muscle mass by ultrasound in Japanese adults. Eur J Appl 
Physiol. 2006;96(1):24–31. doi:10.1007/s00421-005-0061-0. 
308.  Iain T Campbell BF, Tracey Watt, David and Derrick F Martin Withers, Ruth 
England, Suthianandam Sukumar, Marie A Keegan, Brian Faragher  and DFM. 
Muscle thickness, measured with ultrasound, may be an indicator of lean tissue 
wasting in multiple organ failure in the presence of edema. Am J Clin Nutr. 
1995;62:533–539. 
309.  Gruther W, Benesch T, Zorn C, et al. Muscle wasting in intensive care patients: 
ultrasound observation of the M. quadriceps femoris muscle layer. J Rehabil Med. 
123 
 
2008;40(3):185–9. doi:10.2340/16501977-0139. 
310.  Abe T, Kawakami Y, Kondo M, et al. Comparison of ultrasound-measured age-
related, site-specific muscle loss between healthy Japanese and German men. Clin 
Physiol Funct Imaging. 2011;31(4):320–5. doi:10.1111/j.1475-
097X.2011.01021.x. 
311.  Abe T, Loenneke JP, Young KC, et al. Validity of Ultrasound Prediction 
Equations for Total and Regional Muscularity in Middle-aged and Older Men and 
Women. Ultrasound Med Biol. 2014:1–8. doi:10.1016/j.ultrasmedbio.2014.09.007. 
312.  Ligthart-Melis GC, Jonker R, Engelen M, et al. Individual protein requirements of 
older adults measured with a stable isotope multi-step feeding approach. 2015. 
313.  Skipper A, Ferguson M, Thompson K, et al. Nutrition screening tools: an analysis 
of the evidence. JPEN J Parenter Enteral Nutr. 2012;36(3):292–298. 
doi:10.1177/0148607111414023. 
314.  Seaquist ER. Comparison of arterialized venous sampling from the hand and foot 
in the assessment of in vivo glucose metabolism. Metabolism. 1997;46(11):1364–
1366. 
315.  Chan L-N, Compher C, DiBaise JK, et al. American Society for Parenteral and 
Enteral Nutrition research agenda. J Parenter Enter Nutr. 2014;38(1):13–8. 
doi:10.1177/0148607113508783. 
 
